Pathological role of double-stranded DNA antibodies in multiple sclerosis. by Rowton, Sharon
 University of Bradford eThesis 
This thesis is hosted in Bradford Scholars – The University of Bradford Open Access 
repository. Visit the repository for full metadata or to contact the repository team 
  
© University of Bradford. This work is licenced for reuse under a Creative Commons 
Licence. 
 
  
 
PATHOLOGICAL ROLE OF DOUBLE-STRANDED DNA ANTIBODIES 
IN MULTIPLE SCLEROSIS 
 
 
 
 
 
Sharon ROWTON, BSc (Hons) 
 
 
 
 
 
submitted for the degree of 
Doctor of Philosophy 
 
 
 
Division of Biomedical Sciences 
 
School of Life Sciences 
 
University of Bradford 
 
 
 
 
 
2009 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  ii 
ABSTRACT 
PATHOLOGICAL ROLE OF DOUBLE-STRANDED DNA ANTIBODIES 
IN MULTIPLE SCLEROSIS 
 
Sharon Rowton 
Keywords: EAE; dsDNA; antibodies; Alexa Fluor; DAPI, multiple sclerosis 
 
Multiple sclerosis is a complex disease and one for which the aetiology 
remains largely unanswered.  Anti-dsDNA antibodies have been found 
intrathecally and bordering lesions in multiple sclerosis patients and in 
view of their known pathogenity in lupus nephritis the aim of this project 
was to further investigate their role in multiple sclerosis.  Using the acute 
experimental allergic encephalomyelitis (EAE) model in the Lewis rat, the 
inflammatory phase of disease was profiled using immunohistological and 
ELISA methods and was related to clinical sign severity.  The parameters 
of interest were central nervous system deposits of IgM, IgG, B cells and 
C3 and anti-DNA antibodies in sera, cerebrospinal fluid and in situ.  In situ 
evaluation of anti-dsDNA antibodies was also performed in tissue taken 
from Biozzi (AH) mice (relapsing/remitting EAE model) and from a multiple 
sclerosis patient.  Inflammatory deposits specifically at sites of 
perivascular cuffing were found to increase with increasing clinical sign 
severity.  At the time clinical signs had plateaued in the Lewis rat, 
intrathecal anti-dsDNA antibodies were at their highest level and anti-
ssDNA antibodies at their lowest. The latter possibly due to their 
involvement in the ‘clearing-up’ process following tissue damage.  Using 
novel DNA probes fluorescence suggestive of the presence of anti-dsDNA 
  iii 
antibodies was seen in both animal and human tissue.  Within human 
tissue the antibodies appeared to accumulate around active lesions and 
within vessels, raising the question of these antibodies having differing 
location dependent functions. EAE models have the potential to 
investigate these findings further and to evaluate new therapies. 
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1 CHAPTER 1: INTRODUCTION 
Multiple sclerosis is a debilitating disease that affects young adults usually 
before the age of 40, with women being at greater risk than men [Homo-
Delarche et al. (1991)].  The progressive neurological impairment, which 
frequently develops during the course of the disease, is likely to be the 
result of irreversible tissue injury [Trapp et al. (1998)].  Although the 
disease pathology is thought to be due to an uncontrolled immune system 
creating an autoimmune state, leading to organ specific autoimmune 
destruction of CNS myelin [SØrensen & Ransohoff. (1998)], the aetiology 
remains largely unanswered.   
 
MS symptoms are far ranging and include visual disturbances, abnormal 
eye movements, facial weakness, impaired hearing and balance, cognitive 
disturbances, psychological problems such as depression, unpleasant 
sensations, paralysis/numbness and autonomic effects such as 
incontinence [www.patient.co.uk].  The severity and frequency of MS 
symptoms vary from patient to patient and have a variable and often 
unpredictable progression.  
 
The complexity of the disease and the possibility that MS itself may be a 
number of different diseases which are lumped together under the one 
umbrella, has meant that it remains largely incurable, with treatments 
concentrating on minimising pain and decreasing the duration and 
frequency of episodes [www.patient.co.uk].  Research using various 
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animal models has suggested that there are different pathological end-
points to MS and that the course of the disease may depend on the initial 
trigger and the individual’s genetic make-up [Prat & Martin (2002)].  The 
two most common types of MS are relapsing-remitting and chronic 
progressive. 
 
The relapsing-remitting type of MS is the most common type, affecting 
approximately 80% of patients and is the type that most people consider to 
be MS [Evans & Schriver (2002)].  This form of the disease is 
characterised by relatively mild, short-lived symptoms (flares) which 
disappear on their own accord, leaving the sufferer symptom free for 
varying lengths of time, weeks, months, or in some cases years [Evans & 
Schriver (2002)].  This type of the disease tends to affect people before 
the age of 40.  In contrast, the chronic-progressive type of MS tends to 
affect people over the age of 45.  This type of MS can be further split into 
two sub-types; primary-progressive and secondary-progressive [Evans & 
Schriver (2002)].  Primary-progressive MS affects about 10% of people 
with the disease and is characterised by the progression of symptoms 
without periods of remission.  Secondary-progressive MS affects about 
50% of people initially diagnosed with the relapsing-remitting form of the 
disease.  This sub-type of MS very rarely involves periods of remission 
[www.mult-sclerosis.org]. 
 
Symptoms expressed by MS patients are largely due to impaired neural 
transmission.  In MS the myelin sheath, which surrounds the nerve fibre 
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becomes damaged, this causes the nerve impulses to slow down to about 
1 m/s compared to up to 120 m/s for a myelinated fibre; speed being 
dependent on the total thickness of the fibre [Hess (1997)].  In severely 
demyelinated nerve fibres conduction is completely prevented.  This effect 
is resolved relatively quickly, after a few days, by the formation of sodium 
channels in demyelinated internodia [Hess (1997)]; this eventually results 
in the remission of clinical signs of the disease.  In addition to 
demyelination of the nerve fibres MS is characterised by the presence of 
plaques (lesions) in the CNS, of which there are four types.  Shadow 
plaques are plaques that have reduced myelin density resulting in thin 
myelin sheaths, which are undergoing remyelination.  They have dense 
astroglial scar formation and are typically found in the brains of patients 
with acute or chronic progressive MS [Kesselring (1997)].  Concentric 
plaques are rare and tend to be located around a central blood vessel.  
They are made up of alternating rings of myelinated and demyelinated 
tissue and are found in MS patients suffering from acute and subacute 
MS.  Destructive plaques are found in severe cases of acute and subacute 
MS.  These plaques may be characterised by loose tissue, dilated 
extracellular space and can lead to the degeneration of the CNS.  Plaques 
involving the destruction of astrocytes are rare and are only found in 
Caucasian MS patients with acute and progressive MS.  These plaques 
are found in the spinal cord and are devoid of astrocytes, myelin and 
oligodendrocytes.  Axon fibres are present and can be remyelinated 
[Lassmann (1997)]. 
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1.1 Aetiology 
MS is a T cell mediated autoimmune disease [Khoury et al. (1996)] for 
which the disease process is thought to comprise of an induction phase, 
followed by an effector phase involving the migration of activated T cells 
into the CNS.  The disease is characterised by perivascular T cells, 
particularly myelin epitope specific CD4+ T cells [Ota et al. (1990); Bernard 
& Kerlero de Rosbo (1991); Mendel et al. (1995); Kerlero de Rosbo et al. 
(1995); Zamvil & Steinman (1990)], B cells and macrophages infiltrating 
the blood brain barrier leading to demyelination within the CNS, resulting 
in impaired nerve conduction and paralysis [Alvord (1984); MacFarlin & 
MacFarland (1983); Yednock et al. (1992); Karin et al. (1993)].  It is 
thought that the overall phenotype of the immune response determines the 
expression pattern of clinical and pathological disease [Chitnis et al. 
(2001)]. 
 
Demyelination of the brain and spinal cord is characterised by plaques and 
an associated inflammatory response consisting of perivascular infiltrates 
of B cells, T cells and macrophages within the lesion and immediately 
surrounding its borders [McDonald & Ron (1999); Trapp et al. (1998)].  
Plaques result from the attempts made by oligodendrocytes and 
astrocytes to repair damaged myelin, which results in the production of 
scar tissue, known as gliotic plaques.  These plaques harden and become 
sclerotic and interfere with or obstruct the flow of nerve impulses that pass 
along the nerve cells.  Remyelination is partially possible if inflammation is 
quickly managed, for example by the administration of steroids.  If the 
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inflammatory process is left unmanaged, then the beneficial effect of 
remyelination is prevented by the gliotic plaque forming a barrier between 
myelin producing cells and axons.  The position of the plaque within the 
CNS determines the symptom, if several plaques are active at the same 
time they will produce multiple disturbances. 
 
Analysis of cerebrospinal fluid samples has indicated that MS is typified by 
intrathecal IgG synthesis, with high affinity anti-DNA antibodies being a 
major component of this response [Owens et al. (1998)].  B cell 
populations in CSF and brain plaques have been found to be of restricted 
diversity suggesting that those mediating the response in MS are seen to 
be compartmentalised within the CNS and are not well represented in 
peripheral circulation [Owens et al. (1998); Colombo et al. (2000); Qin et 
al. (1998); Baranzini et al. (1999)].  Active demyelinating MS plaques have 
an increased B cell content [Esiri (1977)] with IgG deposition, including 
anti-dsDNA antibodies around the borders which correlate with the 
presence of activated complement fragments and complexes, compared 
to that found in older inactive lesions [Woyciechowska & Brzosko (1977); 
Lumsden (1971); Storch et al. (1998)].  This association of antibodies and 
active lesions has led to the hypothesis that the surrounding antibodies 
may be responsible for plaque formation [Archelos et al. (2000)].  It is 
possible that anti-dsDNA antibodies may be involved in increasing the size 
of the plaque from the border region by increasing the rate of localised 
apoptosis.  Studies in vitro have shown that anti-dsDNA antibodies from 
patients with SLE significantly increase neutrophilia apoptosis, compared 
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to the rate of neutrophil apoptosis in controls [Armstrong et al. (2006)].  If 
anti-dsDNA antibodies can have this effect in SLE it is possible that they 
may influence the apoptosis rate of other cell types and this may happen 
in MS.  Alternatively, apoptosis could be responsible for the induction of 
anti-dsDNA antibodies.  It has been hypothesised that in diseases, such 
as SLE, the clearance of apoptotic cells may be much slower than that in 
healthy people and this may result in lingering nucleoproteins inducing an 
autoimmune response [Herrmann et al. (1996)].  The importance of anti-
dsDNA antibodies in the MS autoimmune repertoire has not yet been fully 
investigated and they are not considered to be a reliable clinical 
biomarker.  This is in contrast to SLE for which these antibodies have 
been found to be a relatively robust predictor of the disease [Kumar et al. 
(2009)]. In the past MS research has focused on other autoantibodies 
thought to be linked to MS such as myelin oligodendrocyte glycoprotein 
and 2′,3′-cyclic nucleotide 3′-phosphodiesterase [Williamson et al. (2001)].   
1.1.1 Familial Genetics 
Considerable research has been performed with regard to MS.  Such 
research has used a number of animal models and various induction 
agents; myelin peptides [Asensio et al. (1999)] and viruses [Miller et al. 
(1997)] being frequently employed to induce the disease-state.  The 
results from such studies have been convincing in many cases, conflicting 
in others, but overall demonstrate the complexity of the disease, or 
possibly diseases and the elusiveness of the pathogenic agent.  The 
following discusses genetic links that may make some people more 
susceptible to MS than others. 
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Prevalence of MS globally was estimated to be 0.1% in 2006 
[www.mssociety.org.uk].  Although MS is not strictly an inherited disease, 
there does appear to be a genetic link, with children of one parent with MS 
having a 2% chance of developing the disease, compared to 0.1% for the 
general population who have no known relatives with the disease 
[www.mssociety.org.uk].  This risk is further reduced to levels comparable 
with those seen in the general population if the child is male, as females 
are twice as likely to contract MS [www.mssociety.org.uk].  The risk of 
developing MS appears to be the same regardless of whether the mother 
or father is affected [Multiple Sclerosis Genetics group (1998)] and is more 
frequent among direct relatives of probands, becoming less frequent as 
the relationship to the proband becomes more remote [MacKay & 
Myrianthopoulos (1966)]. If both parents have MS, then the chance of their 
offspring developing MS increases to 20-30%.  Studies have found 
concordance to be higher for sister pairs than for brother pairs [Multiple 
Sclerosis Genetics group (1998)] and comparisons of MS development 
between step-brothers and sisters (half siblings) compared to siblings from 
the same mother and father (full siblings) show that full siblings are nearly 
three times as likely to show concordance for MS that that for half siblings 
[Sadovnick et al. (1996)]. 
 
Twin studies have been extensively used to further support the familial link 
to MS, but are not without limitations.  Twins are difficult to study in any 
large number and some of the studies which have been performed 
suggest that concordance of MS in twins is extremely rare and as such 
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point to another trigger factor independent of the genetic make-up, e.g. 
infection in childhood [James (1996); Bobowick et al. (1978)].  In contrast, 
other researchers have found there to be a strong case for a genetic link 
by examining twins, in particular monozygotic twins for which a 25% 
concordance rate has been found compared to 3.79% for dizygotic twins 
[Hawkes (1997)].  A Canadian study [Ebers et al. (1986)] which looked at 
the concordance of MS in monozygotic and dizygotic twins also found 
concordance of 26 and 2%, respectively.  
 
Population genetics has found that there are some communities that are 
more susceptive to developing MS than others.  One such community can 
be found in the south-western part of the Sassari province of Sardinia.  
This particular area comprises the Common Logudorese Linguistic 
domain, which is known to be genetically stable population with high 
inbreeding rates compared to other areas.  In comparison, the 
neighbouring Catalan area, which is linguistically and genetically distant 
from other Sardinian domains, MS susceptibility is no higher than would 
be expected for this latitude [Pugliatti et al. (2002)]. 
 
Despite a considerable amount of research focusing on finding a specific 
genetic link for MS, no one underlying risk gene has been identified and 
proven to be fully responsible for MS pathology.  However, results from 
familial studies do undoubtedly show that a genetic link exists and that this 
link becomes stronger the closer the relationship to the proband.  What is 
also clear is that MS shows some characteristics that are consistent with a 
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polygenic model.  A polygenic model of inheritance is one for which each 
contributing gene has small and relatively equal effects, the effects of each 
allele are additive and there is no dominance.  MS however contradicts 
this model in that it is thought to depend upon epistasic effects, i.e. the 
modification of one gene by others and this certainly appears to be the 
case with regards to the regulation and severity of the disease [Vyse & 
Todd (1996)].  Secondly, MS is not entirely dependent on genetics.  This is 
supported by most monozygotic twins being discordant for MS, which 
implies that non-genetic risk factors e.g. environmental factors play a 
significant role in MS.  
 
So, although a familial genetic link exists, this link on its own is not strong 
enough to be considered reliable for use in clinical diagnosis of MS or in 
the prediction of developing the disease.  
1.1.2 The human leukocyte antigen  
MS genetics focuses on the major histocompatibility complex whose 
molecules present antigens to T cells.  The MHC in humans is known as 
the human leukocyte antigen system.  In MS, susceptibility is linked to 
class II MHC genes with the HLA type often being associated with 
ethnicity.  For Caucasians the strongest genetic link in MS is the HLA-DR2 
haplotype; individuals having this haplotype are four times more likely to 
develop the disease compared to HLA-DR2 negative people [Fierz 
(1997)].  Familial studies [Francis et al. (1987)] have confirmed there to be 
a linkage with the HLA-DR2 allele and suggest that this linkage is 
responsible for the genetic aetiology in 16 - 62% of MS cases.  However, 
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the absence of this link in other MS cases supports the heterogeneous 
nature of this disease and the possibility of external triggers or the 
presence of a predisposing haplotype. 
 
Links to the MHC have been found in studies of Canadian and Finnish MS 
populations [Lincoln et al. (2005)].  Strong associations were found for 
blocks in the HLA class II region, these being the cell surface glycopeptide 
antigens of the HLADP, DQ and DR loci.  The strongest associations were 
however found for HLA-DRB1.  The results show that the MHC-associated 
susceptibility of MS is determined by HLA class II alleles, allelic 
interactions and closely neighbouring variants.  This is supported by Chao 
et al. (2008) who concluded that HLA-DRB1*15 allele is only partly 
responsible for MS susceptibility and in addition requires either epistatic 
interactions, epigenetic modifications of some haplotypes or neighbouring 
structural variation. 
 
It has been reported that the frequency of specific T cells to the amino 
acids 95-116 in the proteolipid protein (PLP95-116) is significantly 
elevated in MS patients who carry class II major histocompatibility type 
HLA-DR2+, compared with those who are HLA-DR2- [Ohashi et al. (1995)].  
However, it remains unclear whether HLA-DR2 restricted T cells alone can 
induce MS, or if other cell types such as B cells are necessary [Kawamura 
et al. (2000)].  
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Studies [Zipp et al. (1995)] have found that T cells from people positive for 
HLA-DR2 produce more TNFβ and TNFα than those taken from people 
negative for HLA-DR2 which increases their risk of inflammatory disorders.  
The reason for this may be due to the presence of a polymorphic gene in 
this region.  A TNFα-376 promoter polymorphism association has been 
found in Spanish populations of MS which appears to be independent of 
MHC class II.  This risk is synergistically increased in the presence of 
HLA-DRB1*1501 which appears to be linked to TNFα polymorphism 
[Fernandez-Arquero et al. (1999)].  This finding however was not found to 
be the case in Northern European populations [Weinshenker et al. (2001)] 
and was further dismissed as being the sole MHC determinant in northern 
European populations by Ligers et al. (2001).   
 
Further studies [Francis et al. (1987)] support the association of a MS 
susceptibility gene residing within the HLA-D region and others [Barcellos 
et al. (2003)] have found HLA-DR2 to have a dose-response effect on MS 
susceptibility, with two copies of this haplotype increasing the risk of 
disease susceptibility and severity.  
 
The HLA-DR13 haplotype has been found not only to be associated with 
an increased susceptibility to MS, but also with disease progression.  It 
was found that in a population of Italians residing in the north-east of the 
country that the HLA-DR13 haplotype was found in 40% of patients with 
relapsing-remitting MS and in just 4% of those with secondary progressive 
MS.  The haplotype was also found in 16% of the population studied who 
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did not exhibit MS [Perini et al. (2001)].  These findings suggest that HLA-
DR13 may have a protective effect against the more severe form of the 
disease or is associated with a milder version. 
 
Evidence that the MHC class I HLA-C gene influences susceptibility to MS 
was found by the International Multiple Sclerosis Genetics Consortium 
(2007).  The results showed there not only to be a significant link with the 
HLA-C locus, but also that the allele HLA-C*05 potentially had a protective 
effect against MS due it being under represented in the MS patients on the 
study when compared to the control group. 
 
In addition to HLA-DR2, studies have found MS associations with other 
HLA types such as HLA-A3, HLA-B7 and HLA-Dw2, the latter showing a 
strong association with MS [Terasaki et al. (1976)].  Support for the HLA-
Dw2 allele has come from epidemiology studies [Kutzke and Hyllested 
(1979); Shermata et al. (1985)] which have found that in general, MS is 
linked to latitude and the exceptions to this e.g. Japan, can be explained 
by a lack of the Dw2 allele.  
 
Studies [DeLuca et al. (2007)] have suggested that the DRB1*01 allele 
has a protective effect against MS.  It was also shown to modify disease 
progression as seen in Sardinian MS patients in which nineteen patients 
exhibiting relapsing-remitting MS had the DRB1*01 allele, in contrast to 
patients with the progressive form of MS for whom this allele was absent. 
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From the vast number of investigations into finding a gene responsible for 
MS susceptibility within the MHC two main points can be concluded.  The 
first being that there does appear to be a genetic association with MS 
susceptibility which resides within the HLA and secondly it is apparent that 
multiple alleles are involved, some of which e.g. HLA-C*05, can be seen to 
have a protective effect against the disease. 
1.1.3 Other genes 
With the advancement of technology it has become apparent that the 
genetic risk of MS is due to numerous genetic variants.  More recently 
(2005), a high power admixture mapping scan has found a locus on 
chromosome 1 that is significantly associated with multiple sclerosis 
[Reich et al. (2005)].  Admixture mapping is method where by the genome 
can be scanned for gene variants that are potentially pathogenic in 
complex diseases such as MS.  A genomewide association study [The 
International Multiple Sclerosis Genetics Consortium (2007)] found that 
single-nucleotide polymorphisms in genes encoding for IL2Rα and IL7Rα 
chains are associated with MS.  IL2Rα has also been associated with 
type 1 diabetes and Graves disease and goes some way in supporting MS 
as being an autoimmune inflammatory disease, with the presence of 
IL2Rα being an indication of susceptibility.   
 
IL7R is another gene, which has been found to have an association with 
MS susceptibility.  The association between the SNPs in this gene and 
multiple sclerosis has been supported by a number of studies.  One study 
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[Gregory et al. (2007)] found that the SNP rs6897932 had a significant 
association with MS in European and Nordic populations.  Whereas 
another study [O’Doherty et al. (2008)] found that such an association was 
dependent on geographical location, with a positive association being 
found for patients from Olmsted County, Minnesota, but not for those in 
Belfast, Northern Ireland.   
 
T cell receptor genes have been shown to increase susceptibility to MS.  
Studies [Utz et al. (1993)] in which monozygotic twins concordant or 
discordant in response to self and foreign antigens were exposed to 
myelin basic protein or tetanus toxoid.  Researchers found that the 
controls and concordant twins selected similar V-alpha chains, whereas 
those discordant for MS selected a different set of T cell receptors.  It is 
thought that the T cell repertoire of a person dictates their susceptibility to 
disease and that this in turn may be affected by environmental factors.   
 
Studies have found that a diverse T cell repertoire increases the risk of 
MOG-induced EAE relapse.  Terminal deoxynucleotidyl transferase (TdT) 
is a specialised DNA polymerase which is expressed in immature pre-B 
and T cells; it aids T cell diversity by catalysing the random insertion of 
non-template nucleotides.  A lack of TdT leads to low T cell diversity.  
Using TdT-/- (low diversity) and TdT+/+ (high diversity) mice it was found 
that TdT-/- mice immunised with MOG did not relapse following a single 
episode of EAE, TdT+/+ mice on the other hand displayed successive EAE 
episodes.  In this study there was no evidence of epitope spreading and 
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the relapse was suggested to be due to the highly diversified T cell 
repertoire of TdT+/+ mice which resulted from the initial MOG-specific 
T cells.  It was proposed that during the first episode of EAE the T cell 
response is down regulated in some individuals.  However, in individuals 
with a highly diverse T cell repertoire, as seen in TdT+/+ mice another 
subset of specific T cells expands which leads to relapse in the absence of 
epitope spreading  [Fazilleau et al. (2007)]. 
 
It has been proposed that the MBP gene is genetically linked to and/or 
associated with MS.  A study [Tienari et al. (1992)], using a population in 
Finland for which there was a hotspot of familial clustering, found that the 
allele frequencies significantly differed between individuals with MS and 
the negative controls.  In particular this difference related to a 1.27-kb 
allele, which was seen to occur at a higher incidence in MS patients.  A 
genetic linkage was found between MS susceptibility, MBP and HLA.  
Other studies [Rose et al. (1993); Eoli et al. (1994)] found there to be no 
such linkage or association.  It was hypothesised by Tienari et al. (1992) 
that the role of the MBP gene in MS may be due to a functional defect, 
possibly producing low levels of MBP expression and thus impairing the 
ability of the nerves to remyelinate. 
 
Studies have also found there to be associations with an increased 
frequency (28%) of the K469 allele of the intercellular adhesion molecule-1 
[Mycko et al. (1998)] and the presence of the interferon-gamma gene on 
chromosome 12q14 [Vandenbroeck et al. (1998)].  
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Other genetic studies have suggested that a point mutation in the gene 
encoding protein-tyrosine phosphatase, receptor-type C (PTPRC also 
known as CD45) may be involved in disease development.  The mutation 
lies within exon 4 of the gene and interferes with mRNA splicing, resulting 
in altered expression of CD45 isoforms on immune cells.  Jacobsen et al. 
(2000) found that, in three out of four independent case-controlled studies, 
the frequency of this point mutation was higher in MS patients than in 
people without MS.  This mutated gene is thought to alter the expression 
of CD45 proteins on lymphocytes and may increase susceptibility to the 
disease possibly by affecting activation, adhesion or migration of immune 
cells.  These findings are far from conclusive, with the results being 
positive for German based studies, but not so for studies using patients 
from the United States.  Jacobsen suggests that environmental factors 
may partially explain this finding. 
 
The genes mentioned in this section are just a handful that have shown 
some association or linkage with MS, many more have been implicated in 
this way.  It is clear that genetics does have a role to play in MS 
susceptibility and disease progression and that multiple genes are 
involved in this process.  However, with continual contradictory findings it 
is unlikely that any one set of genes is exclusively responsible for the 
development of MS. 
1.1.4 Genetic modifiers 
Not only are genetics involved in an individual’s susceptibility to MS, they 
are also thought to influence the severity of the disease.  Studies have 
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used MRI technology to investigate disease severity between familial MS 
and non-familial MS.  They found that familial MS individuals had 
significantly more destructive lesions, lower volume of whole brain, white 
matter and grey matter and other indications of greater brain degradation.  
This study found that the closer the family relationship the greater the 
damage to the grey matter, suggesting that there is not only an increase in 
MS susceptibility risk associated with genetics, but also a link with severity 
[Zivadinov (2007)]. 
 
A genetic link with disease severity is supported by a study in which early 
death in MS was found to be linked with the CCR5delta 32 deletion allele.  
It was found that MS patients with this deletion were twice as likely to die 
compared to individuals without it.  In addition, in female patients this risk 
was more pronounced [Gade-Andavolu et al. (2004)]. 
 
The apolipoprotein E (APOE) gene has been implicated in the severity of 
MS by a number of researchers.  Studies have found an association 
between the APOE4 allele and an increase in disease severity and faster 
progression.  One study [Chapman et al. (2001)] found that the presence 
of the APOE4 allele was associated with a faster progression of MS but 
had little involvement with regards to age of onset.  It was hypothesised 
that APOE4 affects the efficiency of neuronal maintenance and repair 
mechanisms, which in turn results in the disease state.  Studies [Schmidt 
et al. (2002)] conducted to further investigate the role of APOE looked at 
its functional alleles and seven SNPs which are within 13 kb of the APOE 
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gene.  Using familial association analysis, one of the seven SNPs was 
found to increase MS susceptibility and that people carrying the APOE4 
allele were prone to a greater severity of MS.  It was also found that 
women with the APOE2 allele developed MS of less severity.  Another 
study [Enzinger et al. (2003)] found that the APOE4 allele was linked to a 
decrease in N-acetylaspartate (NAA):creatine ratio compared to controls 
without this allele.  NAA is found in mature neurones, a decrease in this is 
associated with neuronal and axonal loss resulting in neuronal 
dysfunction.  It was found that the lower the NAA:creatine ratio the higher 
number of relapses and the faster the disease progressed. 
 
Studies [Schrijver et al. (1999)] have found there to be a higher rate of 
disease progression in patients who have the IL1TN*2 allele and lack the 
IL1B*2 allele, compared to those not having this allele combination. 
1.1.5 Epidemiology 
Although genetic make-up may influence an individuals susceptibility to 
MS and disease progression, it is widely accepted that genetic make-up 
alone is not sufficient to induce MS and that an external trigger is also 
required.  
 
Environmental factors, in particular geographical location have been 
recognised to increase a person’s susceptibility to MS.  Prevalence of MS 
at the equator is extremely low, whereas the further away from the 
equator, in particular at latitudes higher than 40°, an increased rate of the 
disease is observed.  Twin studies [Islam & Mack (2007)] suggest that 
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exposure to sunlight in childhood has a protective effect against MS.   It is 
possible that vitamin D synthesised in response to ultraviolet radiation 
from the sun has the ability to inhibit an inappropriate immune attack.  
Other possibilities as suggested in migration patterns and epidemiological 
studies have shown that people who are born in an area of the world with 
a high risk of MS and then move to a low risk area acquire the risk of their 
new home if the move occurs before the age of 15 [NMSS Information 
Resource Center and Library (1997)].  This supports the theory that the 
trigger factor in MS occurs early on in life, with a viral component e.g. 
measles being a likely candidate.  Alternatively it could be the way the 
T cell repertoire is developed. 
 
The measles virus has been identified as a potential MS trigger due to 
high measles virus antibody titres found in MS patients.  In addition there 
is an increased incidence of MS in people who have contracted measles 
late in life compared to those who contracted the virus in early childhood.  
This is supported by the observation that geographical areas where MS is 
rare also have a high incidence of childhood measles, i.e. the late onset of 
measles is low.  It is possible that susceptibility to MS is due to the 
difference in the person's immune response to measles due to their age at 
the time of infection [Alter (1977)].  The vaccine against measles became 
available in 1968, however it was not until the introduction of the MMR 
vaccination in 1988 that routine immunisation took place in the UK.  As the 
onset of MS is typically between 20 – 40 years of age it is still too early to 
assess the potential beneficial impact of vaccination on this disease.   
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One disease, although rare in occurrence (1 in 8000 for the people who 
contract measles before they are 2 years of age), for which a decline in 
incidence has been observed since the introduction of the measles 
vaccine is subacute sclerosing panencephalitis.  This disease causes 
brain degeneration and ultimately death.  It is linked to exposure to the 
natural measles virus early on in life (under 2 years of age), with 
symptoms typically appearing before the age of 20.  The measles vaccine 
appears to prevent this in some way, which is not fully understood [Miller 
et al. (1992)].   
 
If early contact with the measles virus has a protective effect against MS, 
then we can expect to see a gradual decrease in the prevalence of the 
disease in developed countries due to the introduction of the measles 
vaccine.  At present there appears to be little sign of this, in fact over the 
past 10 years or so MS has increased this however may be due in part to 
improved diagnostic skills and improved life expectancy for those with the 
disease.   
 
Diet is another factor that may be linked to MS susceptibility.  One theory 
for this is based on the observation that areas in the world with increased 
MS have an incidence that is closely related to the consumption of 
saturated fats.  Studies have shown that levels of essential fatty acids in 
the blood tend to be low in some people with long standing MS [Marshall 
(1991)]  Studies which have investigated the effect of lipids on the immune 
system and autoimmune disease have found that in general, n-3 fatty 
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acids and essential fatty acid deficient diets worsen T-cell mediated 
diseases such as MS and n-6 fatty acids have the ability to prevent or 
decrease the severity of such diseases.  It is thought that the modifying 
effect of essential fatty acids on immunoregulation and inflammation is due 
to their effect on cytokines through the production of eicosanoids, although 
they also have a role with the regulation of gene expression and signal 
transduction pathways [Harbige (1998)].  Support for the preventative 
effects of a diet high in essential fatty acids is found in communities living 
along the coastlines of counties such as Japan and Norway.  In these 
areas the typical diet is fish and as such is high in essential fatty acids, 
here the incidence of MS has been found to be much lower than would be 
expected in the general population at these latitudes [Challem (1994)].  
 
Other dietary components that have been linked to the 
development/disease progression of MS are B12 deficiency, excess sugar 
intake and folic acid deficiency [Challem (1994)].  Recently (2008) it has 
been proposed that vitamin B12 deficiency may exacerbate symptoms of 
MS.  It has been reported that a patient suffering from MS whose 
symptoms had rendered her wheelchair bound was treated for vitamin B12 
deficiency following which there was a 60% improvement in symptoms 
within 2 days of treatment [Kayalackakom (2009)].  This finding is unlikely 
to be of benefit to the majority of MS sufferers, but for some, in particular 
those with chronic MS symptoms it is possible that effects due to vitamin 
B12 deficiency may be overlooked.  Treatments with vitamin B12 
supplements may appear to have the effect of alleviating the MS 
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symptoms, but this may be alleviating the vitamin deficiency symptoms 
sometimes associated with MS, rather than the actual MS symptoms. 
 
There is no doubt that external factors play an important role in MS.  
Geographical location pre-disposes an individual to MS, whether this is 
due to the presence of a viral/bacterial component in that region or local 
dietary habits.  What is also clear is that the timing of exposure to 
environmental factors is important, whether it is the proposed protective 
effect of UV light in early childhood or the timing of exposure to a 
childhood disease.   
1.2 Pathological triggers 
The most likely trigger for MS and one for which epidemiological studies 
have provided strong evidence, is that of a viral or bacterial infection 
[Kurtzke (1993)].  No specific virus or bacterium has been conclusively 
identified in this role, but a number of mechanisms of how such an 
encounter may result in autoimmunity have been postulated, these being 
molecular mimicry and epitope spreading.  
1.2.1 Epitope spreading 
Epitope spreading is the development of an immune response to epitopes, 
which are distinct from and non-cross-reactive with the disease causing 
epitope.  Epitope spreading may be more relevant in diseases that are 
caused by chronic infection of the target organ and in the chronic stage of 
an autoimmune process.  In MS, antibodies may initially target myelin 
basic protein, however with the destruction of the myelin sheath other 
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antigens are released e.g. myelin oligodendrocyte glycoprotein, resulting 
in additional antibody types becoming involved in the disease process 
(spreading), which may be far removed from the initial trigger.  This is 
known as intermolecular epitope spread.  Intramolecular epitope spread 
occurs when antibodies are directed against a particular amino acid 
sequence of an antigen e.g. an initial response against MPB amino acid 
sequence 82-99 spreads to a different epitope such as MBP 102-118.  
The initial antibody response results in the destruction of myelin, exposing 
‘hidden’ antigenic sequences, which then come under attack and lead to 
an acceleration of organ specific destruction [Coyle (2003)].   
 
Epitope spreading has been demonstrated in a number of animal models, 
in particular murine EAE models.  Such research has supported the role of 
epitope spreading in autoimmune disease and also that epitope spreading 
can be T cell mediated.  Research has found that with regards to the EAE 
model, myelin damage is necessary for the initiation of epitope spreading 
and also that epitope spreading is required for relapse to occur in the EAE 
model [Powell & Black (2001)]. 
 
In an EAE model using PL/J mice immunised with MBP, it was 
hypothesised that reactivation of EAE by the superantigen staphylococcal 
enterotoxin causes the intramolecular spread of T cell specificities for 
other MPB epitopes [Torres et al. (2001)]. 
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1.2.2 Molecular mimicry 
Molecular mimicry is the activation of autoreactive T cells following an 
encounter of a pathogen with epitopes that are shared or cross-reactive 
with self-antigens [Fujinami & Oldstone (1985); Oldstone (1987)].  It is 
possible that molecular mimicry could trigger the initial activation of 
autoreactive T cells and/or induce the expansion of a memory T cell 
population, while superantigens could reactivate autoreactive T cells and 
induce relapses.  Superantigens are immunostimulatory bacterial or viral 
toxins that bind to MHC class II molecules and T cell receptors.  They are 
active at very low concentrations and are able to interact with MHC class II 
molecules outside the binding groove without compromising their 
stimulatory effect on T cells.  There are three main classes of 
superantigens.  The first are endogenous superantigens, which are 
encoded by viruses and are integrated into the genome e.g. Epstein-Barr 
virus.  The second are exogenous superantigens, which are secreted by 
bacteria e.g. staphylococcal pyrogenic exotoxins.  The third class are the 
B cell superantigens, which mainly stimulate B cells e.g. staphyloccal 
protein A [Solanki et al. (2008)].  Superantigens have a role in molecular 
mimicry and MS when their antigens are similar to that of self-antigens. 
 
Molecular mimicry has been demonstrated in a number of murine models, 
in which mice, expressing virus proteins as transgenes, develop 
autoimmune disease following viral infection [Ohashi et al. (1991); 
Oldstone et al. (1991)].  Theiler’s murine encephalomyelitis virus [Miller et 
al. (1997)] is a naturally occurring mouse pathogen that induces chronic 
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CD4+ T cell mediated demyelinating disease.  This virus remains within the 
CNS causing virus specific CD4+ T cells to initiate the demyelination 
process.  This EAE model not only provides an example of how a chronic 
CNS infection can result in the priming of self-reactive antigens that initiate 
demyelination, but also demonstrates that myelin specific T cells are not 
essential in the pathogenesis of the disease [Miller et al. (1997)].  Such 
studies show that immunisation using CNS material is not exclusive in 
producing EAE signs and that infection by some bacteria or viruses can 
also initiate the disease process.  This supports the hypothesis that myelin 
antibodies are produced in response to demyelination initiated by an 
alternative mechanism or by antibodies other than those targeted towards 
myelin peptides, this may also be true in the case of anti-dsDNA antibody 
induction. 
 
The presence of anti-dsDNA antibodies in MS patients may also be 
explained using the molecular mimicry hypothesis.  It would be reasonable 
to assume that anti-DNA antibodies are produced following inflammation, 
during which cells are destroyed releasing large amounts of DNA.  
However, studies have shown that mammalian DNA, even in the presence 
of an adjuvant has an extremely low antigenic potential [Gilkeson et al. 
(1991)].  Based on this assumption it is quite possible that anti-dsDNA 
antibodies may be the result of bacterial infection. 
 
It has been demonstrated that bacterial proteins and bacterial 
polysaccharides can induce anti-dsDNA antibodies in a number of 
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experimental models [Madaio et al. (1984); Gilkeson et al. (1989); Desai et 
al. (1993); Rekvig et al. (1995); Ray et al. (1996)] and that these peptides 
can be molecular mimics of dsDNA.  A study whereby pre-autoimmune 
NZB/W mice (mice which spontaneously produce anti-DNA antibodies as 
they age) immunised with Escherichia coli dsDNA subsequently produced 
antibodies resembling spontaneous autoantibodies that bind to 
mammalian dsDNA [Wloch et al. (1997)].  The same study when 
performed using normal mice found that the induced antibodies only 
bound to bacterial dsDNA, suggesting that a genetic component is 
important in disease initiation.  In studies investigating SLE using 
MRL/MpJ mice, it has been found that repeated administration of bacterial 
plasmids containing eukaryotic promoter elements may induce immune 
responses with the generation of antibodies cross-reacting not only with 
the mammalian DNA, but also more significantly with nuclear antigens 
[Radic et al. 1993]].  Gilkeson et al. (1989, 1991) proposed that bacterial 
DNA could be the immunogen that induces the production of antibodies 
that are reactive to DNA in patients with SLE, this also being a possibility 
in MS. 
 
Although studies have found a restricted antibody presence in the CSF of 
MS patients, to-date none of these antibodies have been shown to be 
solely responsible for the disease state.  Myelin antibodies have been well 
documented and studies [Tuohy et al. (1997)] investigating these 
antibodies have shown that epitope spreading occurs during MS, thus 
changing the target slightly during the course of the disease.  However, 
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although anti-myelin antibodies are found in MS patients and are 
considered by many to play an important role in the pathology of MS, a 
number of these antibodies have also been found in normal individuals  
and in diseases where demyelination is not seen [Rauer et al. (2006)].  In 
the Lewis rat model of EAE, although a single injection of myelin or 
complete spinal cord, in the presence of an adjuvant, produces marked 
clinical signs of EAE and a myelin antibody response, demyelination is not 
observed [Linington et al. (1993)].  This would suggest that although 
myelin antibodies may have a place in MS, they are unlikely to be entirely 
responsible for the pathogenesis of the disease.   
 
Controversially, it has been proposed that variant Creutztfeldt Jakob 
disease (vCJD) is an extreme progressive form of MS [Hughes et al. 
(2001); Ebringer et al. (2005); Wilson et al. (2004)].  The symptoms (visual 
disturbances, impaired motor co-ordination) certainly have many 
similarities with MS and in the early stages of vCJD, sufferers are often 
mis-diagnosed as having MS.  Interestingly, studies have found that 
antibodies to a common soil bacterium (Acinetobacter) and to a lesser 
extent to the microbe Pseudomonas, are frequently found in significantly 
higher titres in people with MS than in people without the disease.  The 
same has been found to be true of cows with bovine spongiform 
encephalopy.  It is hypothesised that molecular mimicry is responsible, as 
Acinetobacter have epitopes similar to those found in nervous tissue and 
there are similarities in the amino acid sequence of the bovine prion 
sequence (RPVDQ) and an Acinetobacter molecule.  It is suggested that 
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antibodies formed in response to the Acinetobacter antigen could lead to 
the activation of auto-reactive cells and hence the production of 
autoantibodies, in particular those which target the CNS, resulting in 
disease development [Hughes et al. (2001); Ebringer et al. (2005); Wilson 
et al. (2004)].  In support of this theory it has been found that 50% of MS 
patients suffer from sinusitis which could be the result of acinetobacter 
infection [Gay et al. (1986)].  Such research provides a convincing case for 
the role of molecular mimicry between Acinetobacter and brain antigens 
and this may also have a role in CJD and MS.  Although this is an 
interesting theory and one that provides a possible pathogenic link 
between MS and CJD, the prion hypothesis remains the most widely 
accepted pathogenic factor in the overall pathology of CJD.   
1.2.3 Hormones 
Hormones have been implicated in the control of MS due to the disease 
predominating in young women.  During pregnancy, clinical signs of MS 
are seen to subside, this is in contrast to postpartum when sex hormones 
are reduced and an increase in the frequency of exacerbations is often 
observed [Korn-Lubetzki et al. (1984); Confavreux et al. (1998); Ostensen 
& Husby (1983)].  These findings have led to the hypothesis that 
hormones, in particular oestrogen may affect regulatory T cells [Offner et 
al. (2000)].  Studies have shown oestrogen can bind to and regulate CD4+ 
T cells and decrease inflammation by inhibiting Th1 cells or by promoting 
regulatory Th2 [Wegmann et al. (1993)] or CD8+ cells [Stimson (1998)].  
Support for this theory comes from studies in which castrated female mice 
have been found to show acceleration in the onset of EAE.   
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Testosterone has been implicated in MS severity.  It has been found that 
women with MS tend to have abnormally low testosterone levels 
compared to disease-free women [Tomassini et al. (2005)].   In addition, 
women with low testosterone levels suffered a greater degree of brain 
inflammation than those with normal hormone levels.  However, women 
suffering from MS who had abnormally high levels of testosterone were 
more likely to have a higher incidence of irreversible brain tissue damage 
[Tomassini et al. (2005)].  
1.2.4 NOTCH1 pathway 
Studies have been performed to investigate the potential reinstatement of 
the NOTCH1 pathway in MS.  During development of the nervous system 
NOTCH1 is activated by the ligand Jagged1 which in turn activates HES5 
resulting in the inhibition of the maturation of oligodendrocytes.  John et al. 
(2002) found that in vitro, TGFβ1 which is up-regulated in MS has the 
ability to reintroduce Jagged1 in human astrocytes.  It was also found that 
around MS lesions in which there was little or no remyelination there were 
high levels of jagged1 and in lesions in which there was remyelination 
there were very low levels of jagged1.  These findings implement the 
NOTCH1 pathway in the remyelination process in MS and offer a potential 
for new therapies. 
1.3 Pathological mechanisms 
Triggers thought to be involved in MS are relatively well defined compared 
to the understanding of what happens following disease initiation.  The 
control of the disease state, in particular the mechanisms involved in 
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relapse and remission are far from clear and once again contradictory 
results have hindered progress. 
1.3.1 Adhesion molecules and chemoattractants 
There are two categories of molecules that direct leukocyte migration into 
inflammatory sites; adhesion molecules and chemoattractants.  Among 
chemoattractants, chemokines have been of particular interest, due to 
their potential role in inflammation [Luster (1998); Rollins (1997); 
Baggiolini (1998)].  Chemokines selectively attract leukocyte subsets; 
some chemokines act specifically on neutrophils, others on monocytes, 
dendritic cells or T cells [Rollins (1997)].  Chemokines appear to act in at 
least two ways, firstly through direct chemoattraction and secondly by 
activating leukocyte integrins to bind their adhesion receptors on 
endothelial cells [Baggiolini (1998); Campbell et al. (1998)].   
 
The adhesion molecules P and E selectin are essential for the localisation 
of T cells to other tissues [Springer (1994)], however they are not required 
for the development of EAE in animal models [Engelhardt et al. (1997)].  
This research has been supported by Döring et al. (2007) who found by 
using E/P selectin double-deficient knockout SJL mice that E and P 
selectins were not required for the recruitment of inflammatory cells into 
the CNS and for the development of EAE.  The knockout mice displayed 
comparable EAE to that of the wild-type mice.  Although these findings 
would suggest that E and P selectin are not critical for blood brain barrier 
inflammatory infiltration other studies have found E and P selectin to be 
expressed in the superficial blood vessels in the brain during EAE which 
  31 
mediate leuckocyte recruitment [Piccio et al. (2002)].  It has been 
suggested that the role of E and P selectins is species/strain dependent 
[Carrithers et al. (2002)].  Due to the presence of E and P selectin 
expression in EAE it can not be ruled out that these molecules do not have 
some role in the development of this disease. 
 
Studies using transgenic mice that over-express chemokines under the 
control of tissue-specific promotors, indicate that chemokines are sufficient 
to direct the migration of target leukocytes into the CNS [Tani and 
Ransohoft (1994); Bell et al. (1996); Fuentes et al. (1995)], and that 
vigorous CNS chemokine expression during EAE has a consistent 
relationship to clinical disease activity [Karpus et al. (1995); Karpu & 
Kennedy (1997); Berman et al. (1996); Godiska et al. (1995); Glabinski et 
al. (1996, 1997); Hulkower et al. (1993); Miyagishi et al. (1997); Tani and 
Ransohoft (1994)]. 
 
Production of chemokines by leukocytes and resident CNS cells near 
inflamed vessels (perivascular cuffing) has been previously described in 
EAE and reported in MS [Glabinski et al. (1997); Miyagishi et al. (1997); 
Hvas et al. (1997); McManus et al. (1998); Simpson et al. (1998)].  It was 
found that the CXCR3 IP-10Mig receptor, a selective attractant for 
activated memory T cells, was the predominant chemokine receptor on 
lymphocytic cells in both CSF and parenchymal compartments, where it 
was found on 80% of CD4+ cells [Anderson et al. (2000)].  CXCR3 positive 
cells have also been found in perivascular cuffs in MS brain sections 
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[Sørensen et al. (1999)].  It was proposed that activated T cells expressing 
CXCR3 are preferentially able to gain access to CNS tissue and initiate an 
autoimmune response [Torben et al. (1999); Williams et al. (1994)] and 
thus are likely to have a pathogenic role.   
1.3.2 Cytokines  
Cytokines are also thought to play a pro-inflammatory and regulatory role 
in MS [Lin et al. (1995); Chitnis et al. (2001)] and studies investigating their 
role may be interpreted in such a way that some cytokines are considered 
to be the primary pathogenic agents in MS, leaving little place for the 
antibody theories, unless of course the antibodies themselves act as 
stimulators of cytokines.   
 
In mammals, Th1 cells secrete IL-12 and IFN-γ and mediate delayed type 
hypersensitivity, whereas Th2 cells secrete predominantly IL-4, IL-5 and 
IL-10 and mediate humoral immunity [Mosmann et al. (1986)].  Cells that 
secrete predominantly TGF-β have been termed Th3 cells [Chen et al. 
(1994); Weiner (1997)].  In the EAE model in the mouse, T cells producing 
Th1 cytokines can transfer disease [Ando et al. (1989); Racke et al. 
(1994); Powell et al. (1990); Begolka et al. (1998)], while spontaneous 
recovery from EAE correlates with a switch to TGF-β and Th2 cytokines 
[Khoury et al. (1992); Kennedy et al. (1992); Issazadeh et al. (1995, 1998); 
Chen et al. (1998)].  Other studies have found that Th2-like cells are not 
always efficient in regulating the effector activity of differentiated 
autoimmune Th1 effector cells and in some cases may themselves be 
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capable of causing CNS pathology [Khortus et al. (1995); Lafaille et al. 
(1997)].  Despite such contradictions, it has been postulated that a 
cytokine switch from a pro-inflammatory Th1 to an anti-inflammatory Th2 
environment in the CNS immediately precedes or coincides with remission 
from an acute episode of disease.  This is supported by studies that have 
shown a cyclical expression of mRNA in the CNS encoding Th1 and Th2 
cytokines during relapsing-remitting disease [Kennedy et al. (1992); 
Tanuma et al. (1997); Racke et al. (1991, 1992); Rott et al. (1994); Johns 
et al. (1991)].  Recovery from disease in acute self-limiting EAE in Lewis 
rats and PL/J mice depends on the presence of regulatory T cells that are 
apparently able to down-regulate ongoing inflammatory autoimmune 
responses [Sun et al. (1988); Lider et al. (1989)].  CD4+ regulatory T cells 
from Lewis rats recovered from acute EAE produce TGF-β to inhibit IFN-γ 
and TNF-β production [Karpus & Swanborg (1991); Stevens et al. (1994)].  
 
IL-12 is produced mainly by monocytes/macrophages in response to 
bacterial products and intracellular parasites, some B cells and murine 
dendritic cells also produce IL-12.  IL-12 in MS is considered to have a 
detrimental role, with elevated serum levels and an increase in T cell 
receptor mediated IL-12 secretion found in the chronic progressive form of 
MS [Balashov et al. (1997); Nicoletti et al. (1996)].  Elevated levels of IL-12 
p40 mRNA has also been found in the brain and the lymphoid organs of 
animals in the acute phase of the disease [Issazadeh et al. (1995)].  Other 
studies [Yoshimoto et al. (1998)] have found that IL-12 p40 has an 
antagonist effect on IL-12 and has a possible therapeutic effect by altering 
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the Th1 environment.  IL-18 works in synergy with IL-12 [Ahn et al. (1997)] 
and in humans it can enhance Th1 differentiation [Micalef et al. (1996)].  
TNF-α also plays a pivotal role in the initiation and progression of the 
autoimmune inflammatory process [Wildbaum et al. (2000)]. 
 
Activated T cells, B cells, macrophages, endothelial cells and fibroblasts 
produce IL-6 [Taga & Kishimoto (1997)].  An elevation of IL-6 gene 
expression in the brain appears to correlate with the severity of disease 
[Diab et al. (1997); Kennedy et al. (1992); Okuda et al. (1995)].  It is 
suggested that IL-6 is important in the induction of disease and/or as a 
factor necessary for pathogenic T cells to survive. 
 
IL-3 is released from activated T cells, but functions mainly as a growth 
factor for hematopoietic stem cells.  When over expressed in the brains of 
mice by transgenic technology using the GFAP promotor [Chiang et al. 
(1996); Powell et al. (1999)], macrophage/microglial mediated primary 
demyelination occurs, thus demonstrating the potential toxicity of this 
cytokine within the CNS, which may arise in the vicinity of active 
inflammation.  In these mice the disease is manifested as chronic 
progressive rather than relapsing/remitting. 
 
IL-15 has been associated with Th1 and Th2 differentiation with IL-15 
causing chronic stimulation of Th1 leading to an autoimmune state.  In 
MS, IL-15 mRNA expression has been correlated with the manifestations 
of clinical disease in the CNS of patients [Kivisakk et al. (1998)]. 
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In rats IL-1 and IL-1Ra (interleukin 1 receptor antagonist), respectively 
exacerbate and ameliorate clinical disease scores [Jacobs et al. (1991)].  
This is also true in multiple sclerosis patients where disease progression is 
controlled in part by the regulation of IL-1 by the IL-1 receptor antagonists 
(type I and II) and IL-1 accessory protein [Libra et al. (2006)].  De Jong et 
al. (2002) found that families having a high IL-1β production compared to 
IL-Ra production were 2.2 times more likely to have a patient relative with 
relapsing MS than those families with a low IL-1β:IL-1Ra ratio.  
Oligodendrocyte destruction in MS may be due in part to interleukin1β (a 
microglia-derived cytokine), due to its ability to impair the uptake and 
metabolism of glutamate by astrocytes.  A similar effect was seen for 
TNFα [Takahashi et al. (2003)].  
 
IFN-γ is secreted by activated T cells and macrophages.  It promotes T cell 
growth and inhibits IL-4 mediated B cell growth and murine IgG1 and IgE 
secretion.  In humans, systemic IFN-γ exacerbates MS [Panitch & Bever 
(1993)].  It is possible that secretion of IFN-γ is necessary to establish the 
conditions, which subsequently regulate the progress of inflammation and 
in its absence more tissue damage results, because the inflammatory 
process continues for longer [Bettelli & Nicholson (2000)]. 
 
IL-4 is produced by the Th2 subset of activated T cells, mast cells, NK 
cells and basophils.  It regulates immunoglobulin isotype switching in 
B cells, stimulating IgG1 and IgE production [Kuhn et al. (1991)].  It drives 
T cells to differentiate towards the Th2 phenotype [Seder et al. (1992); 
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Swain et al. (1990)] and has been shown to reduce the severity of EAE 
[Racke et al. (1994)], especially during the disease induction phase.  
 
IL-10 is produced by Th2 and Th0 CD4+ T cells clones, but not by Th1 or 
CD8+ T cells, although it has been reported that some CD8+ T cells can 
secrete IL-10 [Racke et al. (1994)].  T cells following stimulation with 
antigen or polyclonal activators, mouse B cells (especially the Ly1 B cell 
subset) and CNS resident astrocytes and microglia produce IL-10.  The 
major source of IL-10 is from activated macrophages.  IL-10 appears to 
have a protective role in MS.  It has been shown to inhibit the expression 
of MHC class II antigens and prolonged treatment with IL-10 has been 
found to inhibit EAE development in SJL mice.  SLJ mice are a strain of 
mouse that are immunocompetent, but have elevated levels of circulating 
T cells and are frequently used as an EAE model.  Studies have also 
reported IL-10 mRNA peaks before, or during remission in EAE 
[Issazadeh et al. (1995); Kennedy et al. (1992)], although other studies 
have shown an almost constant expression of IL-10 mRNA in the brains of 
animals with EAE [Begolka et al. (1998)]. 
 
Many different cell types including lymphocytes and macrophages produce 
TGF-β. TGF-β has been shown to inhibit proliferation of T and 
B lymphocytes [Kehrl et al. (1986)] and inhibit the effect or production of 
IFN-γ, TNF-α, TNF-β and IL-2 [Espevik et al. (1987)].  TGF-β has a 
chemotactic effect and induces expression of inflammatory mediators such 
as IL-1 and TNF-α by monocytes.  TGF-β mRNA in the CNS has been 
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reported to correlate with remission of EAE in the rat model [Issazedeh et 
al. (1996); Tanuma et al. (1997)].   
 
A study found that cDNA transcripts for the gene osteopontin were found 
in MS lesions compared to their complete absence in control brains 
[Chabas et al. (2001)].  In addition to the role of osteopontin in bone 
maintenance, it also has an immunological role and is found to be 
expressed in macrophages, neutrophils, dendritic cells, and T and B cells.  
Osteopontin promotes cell recruitment to sites of inflammation, acts as an 
adhesion protein in wound healing, mediates cell activation and cytokine 
production and regulates apoptosis.  In MS the presence of osteopontin 
within plaques may be due to the body trying to repair itself following 
inflammatory attack. 
1.3.3 Complement 
The complement system circulates in the blood and is composed of 
approximately 30 proteins [Mayer (2009)].  The most abundant of the 
proteins in this system is C3.  It is activated via the classical pathway, in 
that it can be activated in response to antigen-antibody binding or undergo 
self-activation.  The ability to self-activate creates a magnified 
inflammatory response.  Once activated, C3 is cleaved by C3 convertase 
(C4b2a) into two fragments, C3a and C3b [Mayer (2009)].  C3b acts as an 
opsonin, increasing phagocytic efficiency and C3a binds to basophils and 
mast cells resulting in the release of vasoactive substances such as 
histamine.  In the body C3b is quickly inactivated by sialic acid which is 
found on the surface of cells.  Some foreign cells such as bacteria cells 
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have little or no sialic acid which can cause the complement system to 
escalate resulting in a prolonged inflammatory attack.  In such cases, C3b 
binds to the Factor B protein forming C3b•Bb, this in turn activates more 
C3 forming C3b•Bb•C3b, a C5 convertase which initiates the membrane 
attack complex producing more C3b [Mayer (2009)].  
 
Complement deficiency can lead to infection and autoimmunity.  In 
individuals with SLE, the early complement components such as C2, C3 
are often found in low levels and this can have a significant effect on the 
immune system [Sturfelt & Truedsson (2005)].  Similarly low levels of early 
complement components are found in other immune complex disorders, 
including MS [Sturfelt & Truedsson (2005)].  In addition complement has a 
role in lupus nephritis in which it is fixed by anti-dsDNA antibodies and 
deposited in the glomeruli causing vasculitis, which damages the blood 
vessels and leads to impaired renal function.   
 
Complement has been implicated in MS pathology, but whether it is 
essential for disease development is not yet known.  Complement may 
increase damage to myelin due to its ability to enhance phagocytosis.  It 
may enhance antibody dependent cell-mediated cytotoxicity, mediated by 
macrophages as seen in EAE models.  Complement activation may lead 
to the release of anaphylatoxins such as histamine, which further 
increases the inflammatory effect.  Complement may shape the adaptive 
immune response in some way that increases the neuroantigen-specific 
immune response, this has been demonstrated in EAE models [Dempsy et 
  39 
al. (1996)].  A MOG peptide-induced mouse EAE study found that none of 
these mechanisms were absolutely required for EAE development 
[Dempsy et al. (1996)].   
 
Studies have found C3 levels to be decreased within the CSF during 
relapses in MS, but this may be a result of low serum levels which are also 
associated with MS [Gaillard et al. (1993)].  An EAE study in mice [Calida 
et al. (2001)] found that inactivation of complement did not prevent EAE 
signs and that the severity of the disease was greatest in animals negative 
for C3.  If was also observed that in this particular model (MOG-induced) 
of EAE inflammatory demyelination was not always associated with local 
complement deposition. 
1.3.4 Antibodies and antigens 
Antibodies linked to MS are autoantibodies reactive with myelin basic 
protein, myelin oligodendrocyte glycoprotein and 2′,3′ -cyclic nucleotide 3′ -
phosphodiesterase [Williamson et al. (2001)].  However, anti-MBP and 
anti-MOG antibodies are frequently found in people with other diseases of 
the nervous system for which demyelination is not a characteristic, this has 
led to a questioning of the relevance of using these antibodies as 
biomarkers for MS [Pittock et al. (2007)].  With regards to possible 
antigens triggering the disease state, animal EAE models have used many 
different CNS associated antigens.  Whole CNS material as used in the 
Lewis rat model in this project induces an acute disease state with no 
relapse, and negligible demyelination, whereas PLP, MOG and lipoprotein 
induce a disease state characterised by inflammation and demyelination.  
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Other encephalitogenic epitopes are thought to be MAG, GFAP, S-100, 
and possibly stress proteins [Kojima et al. (1994)].  Antigens that have the 
potential to induce a demyelinating immune response are 
galactocerebroside [Dubois-Dalq et al. (1970)] which is found in nervous 
tissue components (e.g. myelin), gangliosides GM1 and GM4 [Roth et al. 
(1985); Schwerer et al. (1986)] which are found on the cell surface of 
neural cells (e.g. astrocytes) and sulfatide which is synthesised by 
oligondendrocytes.   
 
Research has been carried out into finding out if it is the location of a 
particular antigen that increases the potential to induce MS.  One such 
study [van Noort et al. (1995)] investigated the potential of an antigen 
specific to the white matter in the brains of MS patients to activate T cells.  
Using reverse phase HPLC it was found that a protein fraction of MBP in 
the brains of MS patients stimulated the proliferation of T cells taken from 
MS patients and healthy controls, this was not the case in protein fraction 
samples taken from the control group.  It was found that the heat shock 
protein alpha-crystallin (CRYAB) was expressed in glial cells of MS 
lesions.  This protein has neuroprotective properties and is a CD4+ T cell 
target in the myelin sheath of patients with MS.  Studies [Ousman et al. 
(2007)] have shown CRYAB to slow down or stop inflammatory pathways.  
Animal studies using CRYAB knockout mice found that these animals 
exhibited a more severe type of EAE with higher Th1 and Th17 cytokine 
secretion from T cells and macrophages than mice positive for CRYAB.  
The protective effect in the CNS appears in part to be due to the anti-
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apoptotic properties of CRYAB.  This finding led to the suggestion that by 
preventing an immune response to CRYAB, i.e. the development of anti-
CRYAB antibodies, or by treating with CRYAB itself, symptoms could be 
prevented or halted. 
1.3.5 Anti-double-stranded DNA antibodies 
In view of the elusive pathogenic agent in MS, this project has turned the 
attention on anti-dsDNA antibodies, for which very little research in this 
area has been reported.  As these antibodies are strictly regulated in 
normal individuals, their presence is often associated with a dysfunctional 
autoimmune state [Hahn (1998)] and as such potentially of significant 
pathological importance.   
 
Although antibodies themselves are thought to play a key role in MS 
pathogenicity they are also part of a vicious circle of escalating immune 
responses [Hahn (1998)].  A T cell-mediated inflammatory response 
stimulates apoptosis which is cleaned up by low affinity natural antibodies, 
typically of the IgM class [Hahn (1998)].  In some cases, the lack of B cell 
regulation allows these low affinity antibodies to switch into high affinity 
IgG antibodies that bind to DNA and other autoantigens, resulting in the 
fixation of complement and an enhanced inflammatory response [Hahn 
(1998)].  
 
It is suggested that even a single autoreactive H (heavy) Ig chain that 
escapes tolerance may be enough to induce features of autoimmune 
disease [Radic et al. (1995)]. A tight correlation between lack of allelic 
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exclusion (where the protein from only one allele is expressed, leading to 
high affinity antigen-specific antibodies and B cell survival) and anti-
dsDNA antibody specificity, is thought to prevent the maintenance of a 
pool of potentially activatable autoreactive cells [Iliev et al. (1994)].  In 
SLE, it is well recognised that anti-dsDNA antibodies are primarily 
responsible for the pathogenesis of the disease, with circulating immune 
complexes depositing in the renal glomeruli, which eventually leads to 
renal failure.  If such antibodies are responsible for damage in SLE then it 
can be assumed that their presence in cerebrospinal fluid and their 
increased incidence surrounding plaque formations within the spinal cord 
of MS patients is not likely to be beneficial.  
 
In addition to SLE, other diseases have shown an association with anti-
dsDNA antibodies, although in general to a much lesser extent.  One 
study [Alnaqdy et al. (2007)] which used an ELISA, found raised sera 
levels of anti-dsDNA antibodies in 17% of people with rheumatoid arthritis, 
23% of people with mixed connective tissue diseases and in 60% in 
people with SLE, this was compared to 3% in healthy controls.  It is 
possible that for some diseases anti-dsDNA antibodies may be 
compartmentalised in the parenchyma or CSF as found in MS [Williamson 
et al. (2001)], away from the circulating blood and as such its association 
with the disease may be overlooked.  
 
The mechanism behind the pathological role of anti-dsDNA antibodies 
may not be the same for all diseases and may not be responsible for all 
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aspects of the disease, particularly in those where multiple organs are 
affected.  In SLE, anti-dsDNA antibodies are primarily responsible for renal 
disease due to the formation and accumulation of immune complexes in 
the glomeruli which induce an inflammatory response, leading to tissue 
scarring and ultimately a loss of renal function [Pisetsky (1998)]. 
 
Considerable work has been carried out on anti-dsDNA antibodies in 
relation to their pathological role in SLE, this is in contrast to the limited 
amount of published information associated with their suggested role in 
MS.  Much of the information regarding the properties, in particular the 
pathogenic role of anti-dsDNA antibodies has been obtained from studies 
using animal models of SLE.  Although the actual pathological mechanism 
may be different in MS, much of the following may apply to their role in MS 
and if nothing else provides a useful starting point. 
 
Splenic anti-ssDNA B cells are short lived, they exhibit an immature, 
antigen experienced phenotype and localise to the T/B interface of the 
splenic follicle [Noorchashm et al. (1999)].  They are functionally 
unresponsive to anti-IgM and LPS stimulation and do not phosphorylate 
intracellular proteins upon mIgM (membrane IgM) cross-linking 
[Noorchashm et al. (1999)].  Anti-dsDNA B cells however phosphorylate 
intracellular proteins, including Syk upon mIg stimulation and anergy is 
maintained in the absence of T cells.  In response to these signals, anti-
dsDNA B cells remain viable, up-regulate cell surface expression of B7.2 
(CD86, which has been implicated in allergic inflammation) and IgM and 
  44 
restore their ability to proliferate and phosphorylate Syk upon mIg cross-
linking [Noorchashm et al. (1999)]. 
 
In SLE, anti-DNA antibodies arise as a result of an antigen driven 
response [Shlomchik et al. (1990); Diamond et al. (1992); Radic & Weigert 
(1994); Tillman et al. (1990)] e.g. by bacterial proteins or polysaccharides 
and peptides that can be molecular mimics of dsDNA.  A model for the 
progression of the anti-DNA antibody response in murine models of SLE 
suggests that clonal expansion and selection of non-mutated IgM anti-
dsDNA antibodies is followed by somatic mutation, which begins before 
isotype switching to IgG.  Further accumulation of mutations has the effect 
of increasing the affinity for DNA.  However, studies in autoimmune 
MRL/lpr mice have found that such antibodies lacked evidence of somatic 
mutation, suggesting that affinity maturation via somatic mutation is not 
essential for dsDNA reactivity [Radic et al. (1993)].  A general picture of 
the pathogenic autoantibody that emerges is one of high affinity cationic 
IgG molecules that bind dsDNA and fix complement resulting in activation 
leading to an inflammatory response.  A study performed by Sontheimer & 
Gilliam (1978) found that complement fixation by anti-dsDNA antibodies 
was primarily seen in SLE patients with lupus nephritis and did not occur 
in those patients for whom nephritis was absent.  This finding suggests 
that the anti-DNA antibodies found in the latter group of patients differed in 
some way compared to the complement fixing antibodies found in the 
presence of lupus nephritis.   
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Ohnishi et al. (1994) found that autoantibodies with pathogenic properties 
had a greater number of positively and negatively charged residues than 
did the non-pathogenic group of antibodies.  In other studies, it has been 
suggested that pathogenicity might not be related to the charge and 
affinity of an antibody, but to its fine binding specificity [Putterman et al. 
(1996)].  Some authors have reported the greater potency of anti-
nucleosome antibodies as mediators of tissue damage compared with 
anti-DNA antibodies [Burlingame et al. (1994)] and other studies have 
found that anti-ssDNA antibodies can occasionally be more damaging 
than antibodies that bind to dsDNA [Swanson et al. (1996)].  The 
relationship between specificity of binding and the degree of mutation 
does not apply to all anti-DNA antibodies.  It is quite possible for a natural 
polyreactive IgM antibody, to contain many somatic mutations or a specific 
IgG and dsDNA antibody to contain few mutations [Rahman et al. (1998)]. 
 
Identification of the antigen responsible for raising pathogenic DNA 
antibodies has proved to be less obvious than one would think.  DNA, 
even in the presence of an adjuvant, is not immunogenic in vivo, 
supporting the theory that DNA complexed to histones in the form of 
nucleosomes is the key immunogenic particle responsible for the 
production of anti-DNA antibodies [Moens et al. (1995)].  Nucleosomes are 
the fundamental repeating units of chromatin and are released from the 
nucleus during apoptosis by inter-nucleosomal cleavage of the chromatin 
[Schwartz & Osborne (1993)].  Apoptosis leads to the development of 
blebs that contain nuclear material on the cell surface, suggesting that 
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under some circumstances apoptosis could be an essential step in the 
development of anti-dsDNA antibodies [Rose et al. (1997)].  This implies 
that interference with apoptosis may be important in the pathogenesis of 
autoimmune disease. 
 
In non-SLE susceptible mice, bacterial DNA complexed to methylated 
bovine serum albumin in a suitable adjuvant can induce the production of 
high titres of IgG anti-DNA antibodies [Gilkeson et al. (1991)].  Anti-DNA 
antibodies induced in this way do not bind to mammalian dsDNA, they do 
however, react with mammalian histone proteins complexed with 
mammalian RNA.  This provides evidence for the potential induction of 
autoimmune anti-dsDNA antibodies following bacterial infection.  There 
are several mammalian histone peptides and other components that are 
common target antigens in autoimmune disease (typically mixed 
connective tissue diseases), for example Sm-D antigens (e.g. SLE), 
ubiquitinated histone H2A antigen (e.g. SLE) and poly (ADP-ribose) 
antigens (e.g. rheumatoid arthritis) [Atanassov et al. (1991)].  Protein 
antigens may also be responsible for loss of tolerance to dsDNA in 
systemic disease [Putterman et al. (2000)]. 
 
In SLE mouse models, the onset of the autoimmune response is 
characterised by the early emergence of antibodies that recognise 
conformational epitopes of the nucleosome particles [Burlingame et al. 
(1993); Amoura et al. (1994)].  As the immune response progresses, 
autoantibodies that react to dsDNA or histones become apparent.  
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Nucleosomes have been found to be a major immunogen for inducing 
Th cells that are able to stimulate pathogenic autoantibodies in mice with 
lupus [Mohan et al. (1993)].  In a study where human hybridoma-derived 
monoclonal anti-DNA antibodies were produced (IgG and IgM), two of the 
IgG antibodies bound both to dsDNA and histones, whereas none of the 
IgM antibodies did.  The binding of these human monoclonal antibodies to 
histones was enhanced by the presence of DNA [Ehrenstein et al. (1993)]. 
 
Epitope spreading may be a mechanism by which anti-DNA antibodies are 
generated [James. (1991)].  Activated phagocytic cells such as 
polymorphonuclear leukocytes and macrophages are capable of releasing 
highly reactive oxygen species which may be able to penetrate cell 
membranes and interact with and damage nuclear DNA.  Subsequent 
release of the altered DNA may then stimulate the production of anti-DNA 
antibodies by B cells.  
 
Studies have found that in SLE, anti-DNA antibodies can induce IFN-α 
production when combined with the appropriate kind of DNA.  It was 
suggested that the various immunomodulatory actions of type 1 IFN 
(IFNα/β), including the promotion of expression of the IL-12 receptor and 
survival of activated T cells, could counteract the maintenance of self-
tolerance [De Maeyer & De Maeyer-Guignard (1988); Belardelli (1995); 
Rogge et al. (1997, 1998); Marrack et al. (1999); Tough & Sprent (1998)].  
An increased rate of apoptosis caused in T cells by IL-10 for example 
[Georgescu et al. (1997)] and in virus infected cells by type 1 IFN [Tanaka 
  48 
et al. (1998)] may generate relevant nuclear autoantigens and possibly 
endogenous dsDNA, the latter forming IFN-α inducing complexes with 
anti-DNA antibodies.  A mechanism resembling a vicious cycle may 
sustain the disease process by means of continuous IFN-α production, 
occasionally boosted by infections or other processes that generate more 
autoantibodies, costimulatory cytokines and DNA [Vallin et al. (1999)]. 
 
It has been demonstrated that native mammalian DNA complexed with an 
immunogenic DNA binding peptide Fus1 from Tyrpanosoma cruzi can 
induce anti-DNA antibodies in mice not genetically prone to autoimmune 
disease.  Although of a lower titre, the induced anti-DNA antibodies were 
found to be of similar specificity, structure and immunopathological 
function as that seen for autoimmune anti-DNA antibodies and resulted in 
the development of lupus nephritis [Desai & Marion (2000)].  Further more 
it was found that DNA-Fus1-induced anti-DNA and anti-Fus1 antibodies 
levels were dependent on the presence of the H-2 haplotype.  Animals 
with the H-2z haplotype had the highest titres, which was to be expected in 
light of the link found between H-2z and autoimmune anti-DNA antibody 
production [Desai & Marion (2000)].  In a different study, pre-autoimmune 
NZB/W mice (a strain of mouse known to produce high affinity anti-dsDNA 
antibodies and glomerulonephritis) immunised with Escherichia coli 
dsDNA produced antibodies that resemble spontaneous autoantibodies 
that bind to mammalian dsDNA.  However, when normal mice were 
similarly immunised, they produce antibodies that only bind to bacterial 
dsDNA [Wloch et al. (1997)].  These findings are also of relevance to anti-
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dsDNA antibody production in MS, in particular with regards to the 
association with genetic make-up, with the presence of the MHC 
haplotype being important in MS susceptibility. 
 
Proposed mechanisms of T cell help for anti-dsDNA antibody secretion 
include T cell recognition of DNA associated protein antigens such as 
histones and recognition of anti-DNA antibody-derived peptides in the 
context of class II MHC [Hardin & Thomas (1983); Mohan et al. (1993); 
Ebing et al. (1993); Singh et al. (1995)].  The presentation of such 
antigens could initiate T cell activation to these self components which in 
turn would help B cells to secrete antibodies specific to histones of dsDNA 
for example, thus producing an autoimmune response.  It has been 
suggested that DNA alone is unlikely to be a T cell epitope and that carrier 
proteins e.g. histones, bound to DNA may be involved in creating its 
antigenicity [Lu et al. (2003)].  If this was to be the case then auto-reactive 
T cells that recognise these carrier proteins would provide help to anti-
dsDNA antibody secreting B cells.  B cells have the ability to recognise 
haptens, which in this example is dsDNA, as well as carrier proteins.  With 
the loss of tolerance, B cells would secrete anti-dsDNA antibodies and 
antibodies to the carrier proteins [Lu et al. (2003)]. 
 
The potential for anti-dsDNA antibodies to be pathological is supported by 
a significant amount of research.  In general, anti-dsDNA antibodies are 
not found in healthy individuals, but are often seen in individuals with 
automimmune diseases [Hahn (1998)].  They have been proven to have a 
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pathological role in SLE, in particular in relation to lupus nephritis [Pisetsky 
(1998)].  The existence of anti-dsDNA antibodies fits into the molecular 
mimicry and/or epitope spreading theories.  
 
Anti-ds-DNA antibodies have been found to have a number of pathogenic 
features such as their potential to induce IFNα and affect apoptosis.  With 
regards to MS, evidence of anti-dsDNA antibodies being a major 
component of CSF and their presence on the outer edge of active lesions 
[Williamson et al. (2001)] makes them prime suspects in the disease 
process.  Williamson et al proposed that these antibodies are associated 
with an autoimmune state resulting from impaired B cell regulation leading 
to the generation of anti-dsDNA antibodies, which precede disease 
development.  This has been found to be the case in a Russian study 
[Ershova et al. (2003)] of MS patients where an association between 
increased anti-dsDNA antibody titre and the level of disability was 
observed. 
1.4 Animal models 
Animal models of MS are important for the understanding of the pathology 
and pathogenesis of the disease in humans and as such for the 
development of new therapies to control disease progression.  Animal 
models are vital in MS research due to the target organ being the CNS, 
which makes research on human tissue from patients living with MS 
extremely difficult, if at all possible.  However, due to the complexity of MS 
and the different progressions it can take, there is no one animal model 
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that mimics the disease in its entirety and as such researchers select the 
model most appropriate to the question they are trying to answer. 
 
Animal models of MS are typically known as experimental allergic (or 
autoimmune) encephalomyelitis models and depending on the 
immunisation agent, dosing regime and species/strain of animal used can 
be used to investigate the mechanisms involved in causing inflammation 
and/or demyelination/remyelination and also the efficacy of new 
treatments.   
1.4.1 Models of demyelination 
Demyelination/remyelination processes can be studied in a number of 
different animals, for example MAG knockout mice [Lunn et al. (2002)] or 
myelin mutant animals such as the myelin basic protein mutant Taiep rat 
[Foote & Blakemore (2005)] or PLP mutant Rumpshaker and Jimpy mice 
[Yool et al. (2000)].   
 
The Taiep rat develops chronic demyelination with age and by the time it 
is one year old, demyelination in this rat is considered to have many 
similarities to that observed in MS patients [Foote & Blakemore (2005)].  In 
this model demyelination occurs in the absence of inflammation [Foote & 
Blakemore (2005)].   
 
The Jimpy mouse displays severe neurological dysfunction due to the 
reduced ability of the CNS to form myelin.  These animals display clinical 
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signs of neurodegeneration such as tremor and convulsion, often resulting 
in a premature death [Yool et al. (2000)].   
 
The Rumpshaker mouse has a less severe phenotype compared to the 
Jimpy mouse and in general can survive into adulthood [Yool et al. 
(2000)]. 
1.4.2 Viral models 
Viral EAE models involve the immunisation of an animal with a virus that is 
known to target the CNS.  One such virus is Theiler’s murine 
encephalitomyelitis virus which is considered by some researchers to 
result in one of the best animal models of MS presently available [Dal 
Canto et al. (1995)].  Using genetically susceptible mice such as SJL mice, 
this virus can induce paralysis, CNS inflammation and demyelination [Dal 
Canto et al. (1995)].  Research with this particular model has shown how 
viral and bacterial infection can induce demyelinating disease by 
molecular mimicry [Miller et al. (1997)]. 
1.4.3 CNS material-induced EAE 
This model is frequently used by researchers.  The methodology is 
relatively straight forward and in the right hands is reproducible. 
 
EAE in this model has been induced by whole spinal cord homogenate 
[Levine and Sowinski (1980 &1989)], MBP [Asensio et al. (1999)], MOG 
[Reynolds et al. (2002)] and PLP [Chalk et al. (1994)] to name a few 
agents.  Typically the encephalitogenic agent is combined with an 
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adjuvant e.g. carbonyl iron [Levine and Sowinski (1980 &1989)] or 
Freund's complete adjuvant [Asensio et al. (1999)].  Immunisation regimes 
such as a single intraperitoneal injection [Levine and Sowinski (1980 
&1989)] or by injection into the base of the tail [Heremans et al. (1999)], 
subcutaneous injection into the flank [Liblau et al. (1997)] or into the foot 
pad [Delarasse et al. (2003)] followed approximately a week later by a 
booster injection have been used to induce EAE. 
 
In the majority of cases, for EAE induction to be successful autoimmune 
susceptible animals, in particularly those that display a strong Th1 
response to immunisation are required.  Strains found to be susceptible to 
EAE are the Lewis rat, Biozzi (antibody high) mouse, the SJL mouse and 
the C57BL/6 mouse.  The progression of EAE depends on the 
encephalitogenic agent and the strain of animal used.  For example, Biozzi 
(ABH) and SJL mice develop a relapsing/remitting disease when 
immunised with whole myelin [Lavi & Constantinescu (2005)].  C57BL/6 
mice on the other hand are EAE resistant when immunised with whole 
myelin [Lavi & Constantinescu (2005)], but when immunised with MOG 
these mice develop a chronic progress type of EAE.  The Lewis rat 
develops acute EAE following immunisation with guinea-pig whole spinal 
cord [Levine and Sowinski (1980 &1989)].   
 
Following immunisation with the encephalitogenic agent the animals 
develop a limp tail and in some cases paralysis of the hind limbs [Beeton 
et al. (2007)].  In the case of a relapsing/remitting or acute model signs are 
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first apparent approximately 9 - 14 days following immunisation and 
disappear within approximately 5 days of the emergence of the first signs.  
In acute models no further signs are seen.  In relapsing/remitting models 
approximately 2 weeks later signs reappear.  With each episode the 
severity of signs may increase and remission may not be complete 
[Beeton et al. (2007)].  In the chronic progressive model the animals enter 
a continuous decline leading to paralysis and death within a few weeks 
[Lavi & Constantinescu (2005)].  The actual disease profile depends upon 
the species and encephalitogenic agent used.   
 
Histopathologically inflammatory infiltrates are present within the CNS and 
in some models, in particular the relapsing/remitting models of EAE 
demyelination is present. 
 
In this project the acute EAE Lewis rat and the relapsing/remitting Biozzi 
(ABH) mouse EAE models were selected.  The Lewis rat was selected as 
this model is good for investigating the inflammatory aspects of the 
disease.  The Biozzi (ABH) mouse was used as this mouse exhibits a 
relapsing/remitting form of the disease with increasing levels of 
autoantibodies with each subsequent EAE episode. 
1.4.4 Spontaneous EAE models 
There are no known spontaneous animal models of MS.  However, 
transgenic mice which have myelin-specific T cell receptors in all of their 
T cells spontaneously develop an autoimmune state as a result of the 
slightest antigenic trigger [Lavi & Constantinescu (2005)].  The problem 
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with this particular model is that the C57BL/6 mouse which is often used 
for this purpose exhibits a rapid and chronic progression of EAE, which 
may make research using these particular animals difficult [Lavi & 
Constantinescu (2005)].  Transgenic animal models have helped 
researchers understand the role of the MHC [Friese et al. (2006)].   
1.4.5 Non-human primates in MS research 
There are instances in drug development when rodents are not an 
appropriate species for the testing of a new drug.  Such instances may 
arise if the drug is a human monoclonal antibody with high receptor 
specificity which would be ineffective in rodents.  In these instances the 
use of a higher species such as a non-human primate for research 
purposes may be justified.   
 
For MS research the non-human primate used is the common marmoset 
[Hart et al. (2005)].  The marmoset has many immunological similarities 
with humans and is highly susceptible to developing EAE.  In contrast to 
the rodent models of EAE, where the animals are frequently killed and 
examined histologically for EAE effects, the disease process (CNS 
lesions) is often visualised in the primate using non-invasive magnetic 
resonance imaging techniques [Hart et al. (2005)].  In the study performed 
by Hart et al., EAE was induced by a single immunization with 
recombinant human myelin/oligodendrocyte glycoprotein.  Active CNS 
lesions in this model remain active for a prolonged time [Hart et al. (2005)]. 
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1.5 Project overview  
The aim of this project was to investigate the potential pathogenic role of 
anti-dsDNA antibodies in multiple sclerosis.  In order to do this the project 
set out to: 
 
• Clinically and histopathologically profile the EAE model in the Lewis 
rat. 
• Using the profile information determine the most likely time-point during 
the disease progression when anti-dsDNA antibodies would most likely 
be present. 
• Develop a novel technique for the visualisation of anti-dsDNA 
antibodies in situ. 
• Investigate structure function relationships in these antibodies. 
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2 CHAPTER 2: METHODS 
2.1 The Profiling of Parameters of Interest in Experimental Allergic 
Encephalomyelitis in the Female Lewis Rat; an Acute Model of 
EAE - in vivo phase 
2.1.1 Introduction 
This chapter details the methodology used to obtain sera, cerebrospinal 
fluid, spinal cord and brain samples from rats which had been subjected to 
experimental allergic encephalomyelitis.  Samples obtained in this test 
were used to validate methods for the detection of anti-ssDNA and anti-
dsDNA antibodies in sera and cerebrospinal fluid using an enzyme-linked 
immunosorbant assay and immuno-staining techniques for the detection of 
deposits of IgG, IgM, complement (C3) and B cells in spinal cord and brain 
sections.  In addition, these techniques were used to profile acute 
experimental allergic encephalomyelitis progression in the female Lewis 
rat. 
 
Acute EAE in the Lewis rat has been previously described by Levine and 
Sowinski (1980 &1989). 
2.1.2 Materials 
Sixty-eight female Lewis rats from different litters were obtained from 
Charles River (UK) Ltd., Kent, for use in this study.  The rats weighed 
between 101 and 139 g on their respective day of dosing (Day 1), and 
were approximately 6 weeks of age.  Six male Dunkin-Hartley guinea pigs 
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(weighing approximately 600 g) were supplied by David Hall, Staffordshire, 
UK for the extraction of central nervous system material which was used 
for the induction of EAE.  The adjuvant and vehicle control was carbonyl 
iron (batch 79H1139), supplied by Sigma, UK which was formulated in 
sodium chloride (saline: batch 6230), supplied by Fresenius Ltd., UK. 
2.1.3 Preparation of materials 
The encephalitogenic agent (whole spinal cord) was obtained from six 
healthy male guinea pigs that had been previously shaved in order to 
minimise contamination of the spinal cord with fur.  Following euthanasia 
by an intraperitoneal overdose of sodium pentobarbitone, the entire spinal 
column was removed (from the pelvic region to the high cervic) and cut 
into three pieces.  Each section of spinal cord was exposed by carefully 
cutting away the vertebrae from the inner aspect of the spinal column.  
Once exposed, the spinal cord, complete with myelin sheath was teased 
out and placed in a petri dish.  A total of 4.5 g of spinal cord was used in 
this part of the project. 
 
The encephalitogenic agent was prepared by homogenising 4.5 g of spinal 
cord with 4.5 g of carbonyl iron in 45 mL of 0.9% (w/v) saline to give a final 
concentration of 100 mg/mL (CNS material):100 mg/mL (adjuvant). 
 
The vehicle control (carbonyl iron) was formulated in 0.9% (w/v) saline at a 
concentration of 100 mg/mL.   
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All formulations were stored at room temperature (nominally 15 to 25°C) in 
sealed containers and protected from light prior to dosing. 
2.1.4 Environment 
The rats were housed in groups of four in polypropylene cages 
(approximately 45 x 28 x 20 cm) with solid floors and Grade 
10 woodflakes, supplied by Datesand Ltd., UK as bedding.  The cages 
were cleaned and dried before use.  Aspen chew blocks, supplied by 
Datesand Ltd., UK were placed within the cages as a form of 
environmental enrichment. 
 
Holding rooms were maintained within acceptable limits for temperature 
and relative humidity (19 to 25°C and 40 to 70 %, respectively).  The room 
was illuminated by fluorescent light for 12 hours (6am – 6pm) out of each 
24 hour cycle and designed to receive at least 15 fresh air changes per 
hour. 
2.1.5 Diet and water 
Diet (RM1.(E).SQC., Special Diets Services Ltd., UK) and water from the 
mains tap supply were provided ad libitum.  These are routinely analysed 
for specific constituents and are not known to contain any biological or 
chemical entity, which might interfere with the test system. 
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2.1.6 Animal health and welfare 
All procedures to be carried out on live animals as part of this study were 
subject to the provisions of United Kingdom Law, in particular the Animals 
(Scientific Procedures) Act, 1986. 
2.1.7 Acclimatisation and health procedures 
On arrival, all animals were examined for ill-health.  Animals were 
acclimatised for a period of at least 3 days.  
2.1.8 Random allocation to treatment groups 
Prior to the start of the study, animals were allocated randomly to 
treatment groups as they came to hand (Tables 1 and 2) and individually 
tail-marked with a number using an indelible pen.  
2.1.9 Experimental design 
2.1.9.1 Part I 
Food and water were available at all times, except when the animals were 
removed from their home cage for the study procedures. 
 
On Day 1, animals in Group 2 (a-d) received a single 1 mL intraperitoneal 
injection of CNS material (100 mg):carbonyl iron (100 mg).  Animals in 
Group 3 (a-d) received a single 1 mL intraperitoneal injection of carbonyl 
iron (100 mg/mL) and served as a control group.  Animals in Group 1 
remained untreated. 
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Treatment groups (2a-d) for which signs of EAE were expected, consisted 
of eight rats per group.  A total of eight rats per group was considered to 
be a sufficiently high enough number to allow for the presence of non-
responders and at the same time keeping animal usage to a minimum.  
For the control groups (1, 3a-d) for which no signs were expected, group 
sizes of four were used, thus minimising animal usage, without 
compromising the objective of this study.  This rationale was based on 
previous experience with this model. 
 
Group Treatment Point of sampling Number of 
animals 
1 Untreated Beginning and end of observation 
period 
4 
2a CNS:carbonyl iron  
(100 mg/mL:100 mg/mL) 
Onset of EAE 8 
2b CNS:carbonyl iron  
(100 mg/mL:100 mg/mL) 
Plateau of EAE 8 
2c CNS:carbonyl iron  
(100 mg/mL:100 mg/mL) 
Remission of EAE 8 
2d CNS:carbonyl iron  
(100 mg/mL:100 mg/mL) 
Day 34 (‘relapse’) 8 
3a Carbonyl iron 
(100 mg/mL) 
For every 2 Group 2a animals 1 
animal from this group was sampled 
4 
3b Carbonyl iron 
(100 mg/mL) 
For every 2 Group 2b animals 1 
animal from this group was sampled 
4 
3c Carbonyl iron 
(100 mg/mL) 
For every 2 Group 2c animals 1 
animal from this group was sampled 
4 
3d Carbonyl iron 
(100 mg/mL) 
Day 34 (‘relapse’) 4 
Table 1  Treatment groups for Part I of the Lewis EAE in vivo phase 
 
The rats were observed daily from Day 1 to Day 34 (as appropriate) and 
scored for signs of EAE as follows:  
 
 
 
  62 
0 Normal 
1 Slight limpness of tail (distal half) 
2 Moderate limpness of the tail 
3 Substantial limpness of tail (entire tail) 
4 Ataxia/hind limb weakness 
5 Extreme weakness of hind limbs, but not paralysis (response to toe 
 pinch) 
6 Hind limb paralysis (dragging hind limbs behind when moving) 
 
It is possible for any one animal to have more than one of the scores 
shown above and in such instances the scores are added together.  For 
example, an animal displaying a substantially limp tail and an ataxic gait 
would have a total score of 7. 
 
The scoring system used was developed on the basis of previous 
experience with this model. 
 
Bodyweights were recorded twice weekly from Day 1 to Day 34, as 
appropriate. 
2.1.9.2 Part II 
Food and water were available at all times, except when the animals were 
removed from their home cage for study procedures 
 
On Day 1, animals in Group 5 received a single 1 mL intraperitoneal 
injection of CNS material:carbonyl iron (1:1 ratio).  Animals in Group 6 
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received a single 1 mL intraperitoneal injection of carbonyl iron 
(100 mg/mL).   
 
Animals in Group 4 remained untreated. 
 
Rationale for group sizes was the same as stated previously.  
 
Group Treatment Point of sampling Number of 
animals 
4 Untreated Pre-dose 4 
5 CNS:carbonyl iron  
(100 mg/mL:100 mg/mL) 
Peak EAE 8 
6 Carbonyl iron 
(100 mg/mL) 
For every 2 Group 5 animals 1 animal 
from this group was sampled 
4 
Table 2  Treatment groups for Part II of the Lewis EAE in vivo phase 
 
Rats in Groups 5 and 6 were observed daily from Day 1 until they were 
sampled at the time of peak EAE signs for Group 5, or as appropriate for 
Group 6.  EAE was scored as detailed previously.   
 
Bodyweights were recorded on Day 1, 5, 8, 12 and 15, as appropriate. 
2.1.9.3 Sampling time criteria 
Blood, cerebrospinal fluid, spinal cord and brain were collected from each 
animal at the appropriate time, as shown in Tables 1 and 2.  Two 
untreated animals from Group 1 were sampled on Day 4, with the 
remaining two rats sampled on Day 34.  In Part II, two untreated animals 
from Group 4 were sampled on Day 4, with the remaining two rats 
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sampled on Day 15.  This was done to allow for age differences between 
the animals from the start to the end of the study. 
 
Using a self-set criterion, onset was taken as the time at which the first 
detectable signs of EAE were observed, this being a slight limpness of the 
distal part of the tail.  Peak was taken as the time at which the first marked 
signs of EAE were observed, this being at least a substantially limp tail.  
Plateau was taken as the time at which the same signs of comparable 
severity had been observed on at least two consecutive days.  Remission 
was taken as the first day that the animals appeared normal.  Relapse was 
not seen in this study, the animals were therefore killed and sampled on 
Day 34 in order to see if there had been any histological relapse. 
2.1.9.4 Sampling procedures 
Terminal blood samples (approximately 2 mL) were taken from 
anaesthetised (sodium pentobarbitone administered intraperitoneally) 
animals via cardiac puncture and collected in plain tubes.  Blood samples 
were allowed to clot for 2–4 hours at room temperature (nominally 15 to 
25°C) and then overnight in the refrigerator (nominally 2 to 8°C).  The 
blood was centrifuged at approximately 3000 rpm for 10 minutes at 4°C 
and the serum harvested and divided into two aliquots.  Sera was stored 
frozen (nominally –70°C) prior to antibody analysis. 
 
Immediately following blood sampling, the rats were killed by an 
intravenous overdose of sodium pentobarbitone and approximately 0.1 mL 
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of CSF was collected into plain tubes.  CSF samples were collected by 
inserting a butterfly needle (23 gauge, 0.75 inch, supplied by BD Infusion 
Therapy, Sweden) into the cerebellomedullary cistern.  Correct insertion of 
the needle was confirmed by the presence of straw coloured CSF flowing 
into the cannula.  Care was taken not to contaminate the CSF with blood.  
CSF was stored frozen (nominally -70°C) prior to antibody analysis. 
 
The brain was removed and cut into three sections (cerebellum, parietal 
lobe and frontal lobe) and flash frozen in iso-pentane cooled in liquid 
nitrogen.  Brain samples were stored at -70°C. 
 
The entire spinal cord was removed from the inner aspect, by carefully 
cutting away the vertebrae.  The cord was teased from the cavity and cut 
transversally in half.  Both sections were flash frozen in iso-pentane 
cooled in liquid nitrogen.  Spinal cord samples were stored at -70°C prior 
to analysis. 
2.2 Method Validation of Experimental Allergic Encephalomyelitis in 
the Biozzi (ABH) Mouse; a Relapsing/Remitting Model of EAE 
 - in vivo phase 
2.2.1 Introduction 
Due to the limited success in detecting anti-dsDNA antibodies in the rat, 
an attempt was made to validate an EAE model, which was expected to 
have a relapsing/remitting profile and a model in which, unlike acute EAE 
in the rat features demyelination, which is particularly evident in relapse.  
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By using a relapsing/remitting model it was hoped that with each episode 
continuing damage would lead to an increase in anti-dsDNA antibody 
levels, thus increasing the chance of detection.   
 
The Biozzi (ABH) mouse is a well-documented strain of mouse used in the 
study of immunological diseases and shows high susceptibility in models 
of EAE [Liblau et al. (1997) and Heremans et al. (1999)].   
 
The duration of each validation study in general decreased with each 
attempt.  This was due to awareness that if initial signs had not developed 
within three weeks they were not likely to do so.  The same was true for 
signs of relapse. 
2.2.2 Materials 
Sixty-six female and thirty male Biozzi (ABH) mice weighing between 13 
and 37 g and approximately 6 to 12 weeks old on their respective Day 1, 
were obtained from Harlan (UK), Bicester.  Male Dunkin-Hartley guinea 
pigs (approximately 600 g) were supplied by David Hall, Staffordshire, UK 
for central nervous system harvesting.  Biozzi (ABH) mice were supplied 
by Harlan (UK) for spinal cord donation.  CD-1 mice were supplied by 
Charles River (UK) Ltd., Kent for spinal cord donation.  The adjuvants 
were identified as carbonyl iron (batch 79H1139), Freund's complete 
adjuvant (batch 11K8928) and Freund’s incomplete adjuvant (batch 
111K8926) and were supplied by Sigma, UK.  Mycobacterium butyricum 
(heat killed), batch not supplied, was supplied by DSMZ, Braunschweig, 
Germany.  Sodium chloride (saline: batch 03K24BD, 03E30BR) was 
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supplied by Baxter Healthcare Ltd., Norfolk, UK.  Bovine myelin basic 
protein (batch 011K7045) and murine myelin basic protein (batch 
014K1341) were supplied by Sigma, UK. 
2.2.3 Preparation of materials  
Five different encephalitogenic agents were used: Whole spinal cord from 
healthy untreated guinea-pigs, whole spinal cord from Biozzi (ABH) and 
CD-1 mice, murine MBP and bovine MBP.   
 
The encephalitogenic agent (whole spinal cord) had been previously 
obtained from healthy male guinea pigs.  Spinal cord from Biozzi (ABH) 
and CD-1 mice was collected following euthanasia by an intraperitoneal 
overdose of anaesthetic (sodium pentobarbitone).  The entire spinal 
column was removed (from the pelvic region to the high cervic) and cut 
into three pieces.  A 5 mL syringe was filled with air and held at one end of 
the spinal column in such a way that a good seal was formed.  The syringe 
plunger was rapidly depressed causing air to blow the spinal cord out of 
the spinal column. 
 
For Part I, finely chopped Biozzi (ABH) mouse spinal cord was formulated 
in saline and FCA or FIA at the required concentration of 10 mg/mL.  For 
Part II and IV, homogenised Biozzi (ABH) mouse spinal cord was 
formulated in saline and FCA or FIA at the required concentration of 
10 mg/mL.  For Part V, homogenised guinea-pig or CD-1 mouse spinal 
cord was formulated in saline and FCA or FIA at the required 
concentration of 10 mg/mL.  For Part III, homogenised Biozzi (ABH) 
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mouse spinal cord was formulated in carbonyl iron at the required 
concentration of 100 mg/mL CNS material:100 mg/mL carbonyl iron.  
Bovine and murine MBP were formulated in saline and FCA or FIA at the 
required concentration of 1 mg/mL.  For Part VII and VIII, freeze-dried  
CD-1 mouse spinal cord was formulated in saline and FCA or FIA at the 
required concentration of 10 mg/mL and 3 mg/mL of Mycobacterium 
butyricum was added.  
 
All formulations were stored at room temperature (nominally 15 to 25°C) in 
sealed containers and protected from light prior to dosing. 
2.2.4 Environment 
The mice were housed in groups of no more than five in polypropylene 
cages (approximately 33 x 15 x 13 cm) with solid floors and Aspen wood 
chips, supplied by Datesand Ltd., UK) as bedding.  The cages were 
cleaned and dried before use.  Aspen chew blocks, supplied by Datesand 
Ltd, UK were placed within the cages as a form of environmental 
enrichment. 
 
Holding rooms were maintained within acceptable limits for temperature 
and relative humidity (19 to 25°C and 40 to 70 %, respectively).  The room 
was illuminated by fluorescent light for 12 hours (6am – 6pm) out of each 
24 hour cycle and designed to receive at least 15 fresh air changes per 
hour. 
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2.2.5 Diet and water 
Diet (supplied by RM1.(E).SQC., Special Diets Services Ltd., UK) and 
water from the mains tap supply were provided ad libitum.  These are 
routinely analysed for specific constituents and are not known to contain 
any biological or chemical entity which might interfere with the test system. 
2.2.6 Animal health and welfare 
All procedures to be carried out on live animals as part of this study were 
subject to the provisions of United Kingdom Law, in particular the Animals 
(Scientific Procedures) Act, 1986. 
2.2.7 Acclimatisation and health procedures 
On arrival, all animals were examined for ill-health.  Animals were 
acclimatised for a period of at least 3 days.  
2.2.8 Random allocation to treatment groups 
Prior to the start of the study, animals were allocated randomly to 
treatment groups as they came to hand (Table 3) and individually tail-
marked with a number using an indelible pen. 
2.2.9 Experimental design 
Numerous attempts, over a period of 21 months, using various study 
designs were used to validate the EAE relapsing/remitting EAE model in 
the Biozzi (ABH) mouse.  Table 3 summarises the number of animals 
allocated to the treatments groups. 
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Part Treatment Route Day of 
Dosing 
Number of 
animals 
I Chopped Biozzi (ABH) mouse 
spinal cord in FCA / FIA 
Intradermal (base of tail) 1 + 8 8 females 
II Homogenised Biozzi (ABH) mouse 
spinal cord in FCA / FIA 
Intradermal (base of tail) 1 + 8 8 females 
III Homogenised Biozzi (ABH) mouse 
spinal cord in carbonyl iron 
Intraperitoneal 1 6 females 
Bovine MBP in FCA / FIA Intradermal (base of tail) 1 + 8 6 females 
Murine MBP in FCA / FIA Intradermal (base of tail) 1 + 8 6 females 
Untreated - - 2 females 
IV Homogenised Biozzi (ABH) mouse 
spinal cord in FCA / FIA 
Intradermal (base of tail) 1 + 8 10 females 
 Untreated - - 5 females 
V Homogenised CD-1 mouse spinal 
cord in FCA / FIA 
Intradermal (base of tail) 1 + 8 5 females 
 Homogenised guinea-pig spinal 
cord in FCA / FIA 
Intradermal (base of tail) 1 + 8 5 females 
 Untreated - - 5 females 
VI Homogenised CD-1 mouse spinal 
cord in FCA/ FIA 
Intradermal (base of tail) 1 + 8 8 males 
VII Freeze dried CD-1 mouse spinal 
cord in FCA/FIA, plus 
mycobacterium butyricum (heat 
killed) 
Subcutaneous (flank) 1 + 8 8 males 
 Untreated - - 4 males 
VIII Freeze dried CD-1 mouse spinal 
cord in FCA / FIA plus 
mycobacterium butyricum (heat 
killed) 
Intradermal (base of tail) 1 + 8 8 males 
 Untreated - - 2 males 
Table 3  Treatment groups for Biozzi (ABH) mouse EAE in vivo phase (summary table) 
 
If any of the treatments above had shown a potential to reliably induce 
relapsing/remitting EAE, a more in depth validation would have taken 
place and the animals would have been profiled as per the Lewis rats as 
previously described.   
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2.2.9.1 Part I - Encephalitogenic agent = finely chopped Biozzi (ABH) 
mouse spinal cord plus FCA or FIA (10 mg/mL) 
Although there are numerous methods for inducing EAE in the Biozzi 
(ABH) mouse this method, based on published information [Liblau et al. 
(1997) and Heremans et al. (1999)] and modified based on previous 
experience with other immunological animal models (e.g. collagen type II 
arthritis in the rat), was selected for this project. 
 
Food and water were available ad libitum, except when the animals were 
removed from their home cage for the study procedures.   
 
A total of eight female Biozzi (ABH) mice (approximately 6 weeks old and 
21-25 g on Day 1), housed four per cage was used for this phase of the 
validation. 
 
On Day 1, eight female Biozzi (ABH) mice received a single 0.1 mL 
injection of finely chopped Biozzi (ABH) mouse spinal cord in FCA 
(10 mg/mL) intradermally into the base of the tail.  On Day 8, the mice 
received a booster injection into the base of the tail of 0.1 mL of finely 
chopped Biozzi (ABH) mouse spinal cord in FIA (10 mg/mL). 
 
The mice were observed daily from Day 1 and scored for signs of EAE as 
follows: 
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0 Normal 
1 Slight limpness of tail (distal half) 
2 Moderate limpness of the tail 
3 Substantial limpness of tail (entire tail) 
4 Ataxia/hind limb weakness 
5 Extreme weakness of hind limbs, but not paralysis (response to toe 
 pinch) 
6 Hind limb paralysis (dragging hind limbs behind when moving). 
 
It is possible for any one animal to have more than one of the scores 
shown above and in such instances the scores are added together.  For 
example, an animal displaying a substantially limp tail and an ataxic gait 
would have a total score of 7. 
 
The scoring system used was developed on the basis of previous 
experience with this model. 
 
Bodyweights were recorded twice weekly.   
 
Animals were killed on Day 73. 
2.2.9.2 Part II - Encephalitogenic agent = homogenised Biozzi (ABH) 
mouse spinal cord plus FCA or FIA (10 mg/mL) 
Due to a lack of EAE signs in Part I, it was thought that this might have 
been due to poor preparation of the spinal cord.  For this phase of the 
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validation spinal cord was homogenised, rather than finely chopped, to 
form a uniform and fine suspension. 
 
A total of eight female Biozzi (ABH) mice (approximately 6 weeks old and 
13-24 g on Day 1), housed four per cage was used for this phase of the 
validation. 
 
Food and water were available at all times, except when the animals were 
removed from their home cage for study procedures. 
 
On Day 1, eight female Biozzi (ABH) mice received a single 0.1 mL 
injection of homogenised Biozzi (ABH) mouse spinal cord in FCA 
(10 mg/mL) intradermally into the base of the tail.  On Day 8, the mice 
received a booster injection into the base of the tail of 0.1 mL of 
homogenised Biozzi (ABH) mouse spinal cord in FIA (10 mg/mL). 
 
The mice were observed daily from Day 1 and scored for signs of EAE as 
previously described. 
 
Bodyweights were record twice daily.   
 
Four animals were killed on Day 87 and four on Day 89. 
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2.2.9.3 Part III - Encephalitogenic agents = homogenised Biozzi (ABH) 
mouse spinal in carbonyl iron or bovine MBP in FCA / FIA or 
murine MBP in FCA / FIA. 
Due to limited success in Part II of the validation, it was considered 
necessary to change the EAE induction protocol.  Three different methods 
of induction were examined.  Spinal cord homogenised with carbonyl iron 
dosed intraperitoneally was assessed; this being the method of induction 
in the rat EAE model which was found to be successful.  The use of 
bovine and murine myelin basic protein have been documented in 
published literature [Asensio et al. (1999)] and as such were also 
considered worthy of investigation. 
 
A total of 20 female Biozzi (ABH) mice (approximately 6 weeks old and 19-
24 g on Day 1), housed up to three per cage was used for this phase of 
the validation. 
 
Food and water were available at all times, except when the animals were 
removed from their home cage for study procedures. 
 
On Day 1, female Biozzi (ABH) mice received a single 0.2 mL 
intraperitoneal injection of homogenised Biozzi (ABH) mouse spinal cord 
(100 mg/mL) in carbonyl iron (100 mg/mL), bovine MBP (1 mg/mL) in FCA 
intradermally into the base of the tail, or murine MBP (1 mg/mL) in FCA 
intradermally into the base of the tail.  
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On Day 8, the mice dosed with bovine or murine MBP received a booster 
injection of bovine MBP (1 mg/mL) in FIA or murine MBP (1 mg/mL) in 
FIA, respectively, intradermally into the base of the tail.   
 
Two mice remained untreated and acted as negative controls. 
The mice were observed daily from Day 1 and scored for signs of EAE as 
previously described. 
 
Bodyweights were record daily from Day 11 to Day 56.   
 
Animals were killed on Day 62. 
2.2.9.4 Part IV - Encephalitogenic agent = homogenised Biozzi (ABH) 
mouse spinal cord plus FCA / FIA (10 mg/mL) 
Due to limited success it was considered appropriate to return to the 
original induction protocol using female mice.  However, in this phase of 
the study animals were weighed daily to see if a cyclic decrease in 
bodyweight was present, even in the absence of EAE specific signs. 
 
A total of 15 female Biozzi (ABH) mice (approximately 5 weeks old and 19-
23 g on Day 1), housed five per cage was used for this phase of the 
validation. 
 
Food and water were available at all times, except when the animals were 
removed from their home cage for study procedures. 
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On Day 1, ten female Biozzi (ABH) mice received a single 0.1 mL injection 
of homogenised Biozzi (ABH) mouse spinal cord in FCA (10 mg/mL) 
intradermally into the base of the tail.  On Day 8, the mice received a 
booster injection intradermally into the base of the tail of 0.1 mL of 
homogenised Biozzi (ABH) mouse spinal cord in FIA (10 mg/mL). 
 
Five mice remained untreated and acted as negative controls. 
 
The mice were observed daily from Day 1 and scored for signs of EAE as 
previously described. 
 
Bodyweights were record daily. 
 
Three animals were killed on Day 84, one animal on Day 91, two animals 
on Day 93 and the remainder on Day 109.  
 
From Day 78 onwards, encephalitogenic-treated mice exhibited hair loss 
around the whisker area.  
2.2.9.5 Part V - Encephalitogenic agent = homogenised CD-1 mouse or 
guinea-pig spinal cord plus FCA / FIA (10 mg/mL) 
A possible cause of the lack of anticipated response in the previous 
validation attempts was thought possibly to be due to the encephalitogenic 
agent being too similar to ‘self’, i.e. Biozzi (ABH) spinal cord.  For the 
acute EAE study, rats are injected with guinea-pig spinal cord and 
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successfully develop EAE signs.  In order to investigate this further, for 
this phase of the study CD-1 mouse and guinea-pig spinal cord was used.  
 
A total of 15 female Biozzi (ABH) mice (approximately 6 weeks old and 20-
25 g on Day 1), housed five per cage was used for this phase of the 
validation. 
 
Food and water were available at all times, except when the animals were 
removed from their home cage for study procedures. 
 
On Day 1, female Biozzi (ABH) mice received a single 0.1 mL injection of 
homogenised CD-1 mouse or guinea-pig spinal cord in FCA (10 mg/mL) 
intradermally into the base of the tail.  On Day 8, the mice received a 
booster injection intradermally into the base of the tail of 0.1 mL of 
homogenised CD-1 mouse or guinea-pig spinal cord in FIA (10 mg/mL).   
 
Five mice remained untreated and acted as controls. 
 
The mice were observed daily from Day 1 and scored for signs of EAE as 
previously described. 
 
Bodyweights were record daily.   
 
Animals were killed on Day 51. 
  78 
2.2.9.6 Part VI - Encephalitogenic agent = homogenised CD-1 mouse 
spinal cord plus FCA / FIA (10 mg/mL) 
Following advice from a contact at St Bartholomew's Hospital Medical 
College, London, validation was attempted using male Biozzi (ABH) mice.  
Although female mice are in general more susceptible, success of 
inducing EAE in females can be variable due to fluctuating hormone 
levels.  The mice were housed individually to prevent in-house fighting, 
thus minimising the potential to increase stress hormone levels such as 
corticosteroids, which have the affect of inhibiting the required 
autoimmune response.  The animals used were considerably older than 
previously tested and were considered to be an optimum age for EAE 
induction.   
 
A total of eight male Biozzi (ABH) mice (approximately 10 weeks old and 
29-33 g on Day 1) was used for this phase of the validation.   
 
Food and water were available at all times, except when the animals were 
removed from their home cage for study procedures. 
 
On Day 1, male Biozzi (ABH) mice received a single 0.1 mL injection of 
homogenised CD-1 mouse spinal cord in FCA (10 mg/mL) intradermally 
into the base of the tail.  On Day 8, the mice received a booster injection 
intradermally into the base of the tail of 0.1 mL of CD-1 mouse spinal cord 
in FIA (10 mg/mL).  
 
  79 
The mice were observed daily from Day 1 and scored for signs of EAE as 
previously described. 
 
Bodyweights were record daily. 
 
Animals were killed on Day 23. 
2.2.9.7 Part VII - Encephalitogenic agent = Freeze dried CD-1 mouse 
spinal cord plus FCA / FIA (10 mg/mL), plus 3 mg/mL 
Mycobacterium butyricum (heat killed) 
Due to a failure of EAE induction, further advice was received which 
indicated that freeze dried spinal cord was preferable to homogenised 
material.  Also Freund’s adjuvant should be supplemented with 
Mycobacterium.  Immunisation by subcutaneous administration into each 
flank was suggested [Liblau et al. (1997) and Heremans et al. (1999)]. 
 
A total of 12 male Biozzi (ABH) mice (approximately 12 weeks old and 27-
35 g on Day 1), housed individually was used for this phase of the 
validation.   
 
Food and water were available at all times, except when the animals were 
removed from their home cage for study procedures. 
 
On Day 1, male Biozzi (ABH) mice received a single 0.1 mL injection of 
freeze dried CD-1 mouse spinal cord in FCA (10 mg/mL), plus 3 mg/mL 
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mycobacterium butyricum (heat killed) subcutaneously into both the 
shaved flanks.   
 
On Day 8, the mice received a booster injection subcutaneously into both 
the shaved flanks of 0.1 mL of freeze dried CD-1 mouse spinal cord in FIA 
(10 mg/mL), plus 3 mg/mL Mycobacterium butyricum (heat killed).   
 
Four mice remained untreated and acted as negative controls. 
 
The mice were observed daily from Day 1 and scored for signs of EAE as 
previously described. 
 
Bodyweights were record daily. 
 
Animals were killed on Day 27. 
2.2.9.8 Part VIII - Encephalitogenic agent = freeze dried CD-1 mouse 
spinal cord plus FCA / FIA (10 mg/mL) 3 mg/mL Mycobacterium 
butyricum (heat killed) 
A lack of EAE signs in mice in Part VII led to a final attempt at inducing 
EAE in the Biozzi (ABH) mouse.  For this phase, intradermal injection into 
the base of the tail was used as before, but this time Mycobacterium was 
added to the Freund’s adjuvant at a concentration of 3 mg/mL. 
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A total of 10 male Biozzi (ABH) mice (approximately 10 weeks old and 30-
37 g on Day 1), housed individually was used for this phase of the 
validation.   
 
Food and water were available at all times, except when the animals were 
removed from their home cage for study procedures. 
 
On Day 1, eight male Biozzi (ABH) mice received a single 0.1 mL injection 
of freeze dried CD-1 mouse spinal cord in FCA (10 mg/mL) plus 3 mg/mL 
Mycobacterium butyricum (heat killed) intradermally into the base of the 
tail.  On Day 8, the mice received a booster injection into the base of the 
tail of 0.1 mL of freeze-dried CD-1 mouse spinal cord in FIA (10 mg/mL) 
plus 3 mg/mL Mycobacterium butyricum (heat killed).   
 
Two mice remained untreated and acted as controls. 
 
The mice were observed daily from Day 1 and scored for signs of EAE as 
previously described. 
 
Bodyweights were record daily. 
 
Two animals were killed on Day 18 and the remainder on Day 25. 
2.2.10 Source of spinal cord and brains from Biozzi (ABH) mice 
Due to a lack of success in validating the EAE model in the Biozzi (ABH) 
mouse.  The spinal cords and brains of two Biozzi (ABH) mice which 
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exhibited peak EAE signs during a second EAE episode (relapse) were 
donated by Chris Bolton at John Vane Science Centre, William Harvey 
Research Institute, St Bartholomew’s Hospital Medical College, London.  
Spinal cord and brains were also supplied from control (untreated) Biozzi 
(ABH) mice.  
2.3 Method Validation of Anti-ss and –dsDNA Antibodies in Rat Sera 
and CSF using an ELISA Method 
2.3.1 Materials 
Plasmid dsDNA, 1 mg/mL (lot 5) and plasmid ssDNA, 0.5 mg/mL (lot 6) 
were supplied by Bayou Biolabs, USA.  Plasmid DNA was produced from 
E coli. 
 
Linearisation of dsDNA: Restriction endonuclease Bam H1 
(batch 41K1292) and Solubilisation/Denaturation (SD) buffer 
(batch 107H0592) were supplied by Sigma, UK. 
 
Electrophoresis: Agarose (batch 3060113, supplied by Life 
Technologies), Tris-borate-EDTA (batch 3066660, Invitrogen–Life 
Technologies), ethidium bromide (batch 1113071, Invitrogen–Life 
Technologies), λDNA/HIND III fragments (batch D-9780, Sigma, UK), 
DNase-, RNase-free 0.2 µm filtered water (batch 91K2328, Sigma, UK), 
gel loading solution (batch 02411, Biotech) and non-sterile reverse 
osmosis high purity (ROHP) water for gel preparation (batch 1284, 
Covance, UK). 
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Photobiotinylation of dsDNA: Photobiotin (batch 60K5004), butanol 
(batch U01195), ethanol (batch 111K3657) and Tris EDTA 
(batch 21K8933) were supplied by Sigma, UK. 
 
ELISA assay: Streptavidin (batch 118H8660), gelatin (batch 50K0124), 
phosphate buffered saline (batch 71K8201), Tween 20 (batch 81K8201), 
o-phenylenediamine (batch 11K5312), citrate phosphate buffer (batch 
99H8203), H2SO4 (batch 071K3251) and Tris EDTA (batch 21K8933) were 
supplied by Sigma, UK.  HCl (batch K28735352103) was supplied by BDH 
Laboratory supplies, UK.  Horseradish peroxidase conjugate IgG (Lot 128 
(902)), IgA (Lot 055 (602)) and IgM (Lot 080 (501)) were supplied by 
Dako, Denmark.  Plasmid ds and ssDNA was obtained from Bayou 
Biolabs, USA.  Anti-dsDNA antibody (batch 454920) was supplied by The 
Binding Site, UK.  Anti-ssDNA antibody (batch 1678) was supplied by 
Immunovision, Inc, USA. 
2.3.2 Linearisation of plasmid dsDNA 
Fresh uncut plasmid dsDNA preparation can be present in a number of 
forms; nicked, closed circular, linear, covalently bonded, supercoiled or 
circular single-stranded.  Nicked or opened DNA occurs when there is a 
break in one or more strands which causes the DNA to unwind.  Closed 
circular DNA is formed by two strands of the double helix linking to form a 
circle.  Supercoiled DNA occurs when the double helix becomes twisted 
around itself in a high-energy state.  Covalently bonded DNA is when DNA 
becomes strongly linked with RNA or protein.  Circular single-stranded is 
when a single strand links together to form a circle and linear DNA is a 
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straight piece of DNA.  When uncut plasmid dsDNA is run on a gel in 
electrophoresis, multiple bands relating to these different DNA forms can 
often be seen, as shown in figure 1.   
 
A linear form of plasmid was needed for photobiotinylation, so the plasmid 
dsDNA was cut to a linear form with the restriction endonuclease Bam H1.  
Restriction endonuclease Bam H1 (from Bacillus amyloli) works by 
recognising short sections (6 base pairs) of DNA and cleaving them at the 
target site.  The resulting preparation formed a single band on the gel 
when run following digestion as shown in figure 2 (original photographs 
unavailable).   
 
Linear DNA was prepared by dividing 200 µL of dsDNA (1 mg/mL) equally 
into four tubes.  To each tube, 20 µL (200 units) of restriction 
endonuclease Bam H1, 32.5 µL water and 97.5 µl of SD buffer was added.  
Although 1 unit of Bam H1 cleaves 1 µg of DNA, a higher concentration 
was recommended.  Care was taken to ensure that the amount of enzyme 
added was no more that 10% of the total volume, as exceeding this 
amount could inhibit the reaction due to the glycerol present in the storage 
buffer.  The digestion process was performed by placing the tubes 
containing the mixture in an incubation cabinet at 37°C overnight.  The 
following day the reaction was inactivated by placing the tubes in a water-
bath (Techne) at 65°C for 20 minutes.  The mixture was stored frozen at  
-70°C prior to electrophoresis. 
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2.3.3 Electrophoresis - linearisation check 
Linearisation of plasmid dsDNA was examined using agarose gel 
electrophoresis.  The gel consisted of 0.8% agarose in 0.5 x Tris-borate-
EDTA pH 8.0 and was heated until it was dissolved.  The agarose was 
poured into a gel tray with an appropriate comb in the presence of 
0.5 µg/mL of ethidium bromide and allowed to set. 
 
10 µL of DNA sample was mixed with 2 µL gel loading buffer which 
consisted of 0.25% bromophenol, 0.25% xylene cyanol and 15% Ficoll 
type 400 in water. 6 µL of mixture were added to a slot of the gel. 
 
λDNA/HIND III fragments were used as standard molecular weight 
markers and 0.1 µg/mL of the fragments were mixed with gel loading 
buffer and loaded onto the gel. 
 
The electrophoresis was carried out until the bromophenol blue had 
migrated to the opposite end of the gel.  A constant voltage of 100 volts 
was applied for a period of 1 hour using a wide-mini sub cell gel tank (Bio-
Rad). 
 
The gel was viewed was under short-wavelength ultraviolet irradiation and 
a photograph was taken using a Polaroid CU-5 camera (actual 
photographs inadvertently misplaced). 
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- 
   
      Figure 1  A diagram showing the appearance of uncut plasmid DNA.  Fresh uncut plasmid 
dsDNA preparation can be nicked, circular, linear, covalently closed supercoiled or 
circular single stranded and when run on agarose gel in electrophoresis, multiple bands 
can often be seen. 
 
 
   
       
   
Linear----------------------- 
   
    
    
    
 
   
      Figure 2  A diagram showing the appearance of cut plasmid DNA.  Following linearisation 
of dsDNA using restriction endonuclease Bam H1, a single band is formed when run on 
agarose gel. 
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2.3.4 Photobiotinylation of plasmid DNA 
Plasmid ds and ssDNA was previously prepared at a concentration of 
0.5 mg/mL. Each was mixed with an equal volume of photobiotin, at a 
concentration of 1 mg/mL, without exposure to light.  The mixture was 
placed on ice and irradiated with a 250W light source through glass to 
exclude UVB, at a distance of 10 cm for 20 minutes. 
 
An equal volume of butanol was added to extract the DNA and to remove 
the unbound photobiotin.  This was repeated a further two times.  The 
plasmid DNA was then ethanol precipitated by incubation at 4°C for 
1 hour, followed by centrifugation at 12000 g for 30 minutes at 4°C.  After 
rinsing with 70% ethanol and another centrifugation at 12000 g for 
10 minutes at 4°C, the plasmid DNA was re-suspended in Tris-EDTA, 
pH 8.0 and its concentration determined by measuring the absorbance at 
260 nm. 
 
The concentration of plasmid DNA was measured by reading the 
absorbance at 260 nm using a spectrophotometer (Pharmacia).  50 µg/mL 
of dsDNA is known to have an absorbance of 1 at 260 nm wavelength and 
40 µg/mL of ssDNA is known to have an absorbance of 1 at the same 
wavelength. 
 
Photobiotinylated DNA was stored frozen at -70°C prior to use in the 
ELISA. 
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2.3.5 ELISA validation 
The ELISA used was based on the method detailed by Emlen et al. 
(1990). 
 
For the validation of the ELISA, the procedure detailed above was 
followed.  Response curves were produced using various dilutions (in 
duplicate) of anti-dsDNA antibodies and anti-ssDNA antibodies as follows: 
 
dsDNA ELISA reciprocal dilutions: 1, 2, 4, 8, 16, 32, 64, 128, 256, 512, 
1024, 2048, 4096, 8192, 16384 and 32768. 
 
ssDNA ELISA reciprocal dilutions: 1, 2, 4, 8, 16, 32, 64, 128, 256, 512, 
1024, 2048, 4096, 8192, 16384, 32768, 65536, 131072. 
 
The response curves obtained in the ELISA validation (figure 3) were as 
expected with the anti-dsDNA antibodies exhibiting a slightly higher affinity 
for the antigen (dsDNA), compared to the affinity demonstrated by the 
anti-ssDNA antibodies for their associated antigen (ssDNA).  This effect 
was particularly apparent at reciprocal dilutions of 100 – 10,000. 
 
In general, the data showed little variability, the exception being for anti-
ssDNA at a reciprocal dilution of 8.  The individual OD values of the 
duplicates were 1.090 and 1.510, with the 1.090 OD value appearing to be 
erroneous.  This variation may have been due to an insufficient sample 
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being added to the well during pipetting or perhaps poor coating of this 
particular well with antigen, thus providing limiting binding sites. 
 
Due to limited volumes available, all samples were analysed in duplicate 
rather than triplicate. 
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Figure 3  Anti-dsDNA and anti-ssDNA antibody ELISA validation curves.  Response 
curves were produced using various dilutions of anti-dsDNA antibodies (reciprocal 
dilutions: 1, 2, 4, 8, 16, 32, 64, 128, 256, 512, 1024, 2048, 4096, 8192, 16384 and 32768) 
and anti-ssDNA antibodies (reciprocal dilutions: 1, 2, 4, 8, 16, 32, 64, 128, 256, 512, 
1024, 2048, 4096, 8192, 16384, 32768, 65536, 131072.).  The response curves indicate 
that anti-dsDNA antibody has a higher affinity for the antigen, compared to the anti-
ssDNA antibody.  Each dilution sample was analysed in duplicate. 
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In addition, the potential of cross-reaction between ss and dsDNA ELISA 
plates were examined.  This was done by adding reciprocal dilutions (1, 2, 
4, 8, 16, 32, 64, 128, 256, 512, 1024, 2048, 4096, 8192, 16384, 32768, 
65536, 131072) of anti-dsDNA antibodies to ssDNA coated plates and 
reciprocal dilutions (1, 2, 4, 8, 16, 32, 64, 128, 256, 512, 1024, 2048, 
4096, 8192, 16384, 32768, 65536, 131072) of anti-ssDNA antibodies to 
dsDNA coated plates. 
 
Cross reactivity investigation showed there to be minimal cross-reaction 
when dsDNA antibodies were added to ssDNA coated plates (figure 4).  
However, when ssDNA antibodies were examined for cross-reactivity, a 
similar curve was obtained to that when dsDNA antibodies are added at 
the same concentrations to a plate coated with dsDNA. 
 
In general, the data showed little variability, the exception being for ssDNA 
versus dsDNA antibody at a reciprocal dilution of 64, and dsDNA versus 
ssDNA antibody at reciprocal dilutions of 128, 2048 and 4096.  The 
individual OD values of the duplicates for ssDNA versus dsDNA antibody 
at a reciprocal dilution of 64 were 0.430 and 0.943, with both values being 
markedly higher than expected.  This variation between the duplicates 
may have been due to inaccurate pipetting.   
 
The individual OD values of the duplicate samples for ssDNA versus 
dsDNA antibody at a reciprocal dilution of 128 were 0.901 and 1.140, and 
at reciprocal dilutions of 2048 and 4096 were comparable to each other 
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with OD values of 0.450, 0.610 and 0.609, 0.451, respectively.  Pipetting 
technique is a probable cause of the variability in all cases. 
 
In addition to the variability seen for a minority of duplicates, the response 
curve for ssDNA versus dsDNA antibody had two outliers, one at a 
reciprocal dilution of 64 and the other at 16384.  The mean of the 
duplicates at each dilution and the OD values of each individual sample 
was much higher that anticipated.  These results suggest that the error did 
not occur during the well preparation or during pipetting, but more likely 
occurred at the dilution stage.  
 
All samples were analysed in duplicate. 
 
The results suggest that if both anti-ss and –dsDNA antibodies were 
present in a sample, it would not be possible to detect anti-ssDNA 
antibody alone using this method.  However, using an anti-dsDNA plate 
the presence of anti-dsDNA antibodies could be reliably detected using 
this method. 
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Figure 4  Anti-dsDNA and anti-ssDNA antibody cross-reactivity ELISA response curves.  
Response curves were produced by adding reciprocal dilutions (1, 2, 4, 8, 16, 32, 64, 
128, 256, 512, 1024, 2048, 4096, 8192, 16384, 32768, 65536, 131072) of anti-dsDNA 
antibodies to ssDNA coated plates and reciprocal dilutions (1, 2, 4, 8, 16, 32, 64, 128, 
256, 512, 1024, 2048, 4096, 8192, 16384, 32768, 65536, 131072) of anti-ssDNA 
antibodies to dsDNA coated plates.  Minimal cross-reaction occurred when dsDNA 
antibodies were added to ssDNA coated plates, whereas a high level of cross-reactivity 
occurred when ssDNA antibodies were added to dsDNA coated plates.  Each dilution 
sample was analysed in duplicate. 
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2.3.6 Detection of anti-DNA antibody by ELISA using 
photobiotinylated DNA as the antigen 
Streptavidin (to which biotinylated DNA forms non-covalent bonds, thus 
attaching the DNA to a streptavidin coated surface) was diluted with 
distilled water to a concentration of 1 µg/mL.  150 µL/well of streptavidin 
was added to Maxisorp 96-well plates (Nunc) which were then incubated 
at 4°C overnight.  After four washes with PBS/0.05% Tween 20, 
200 µL/well of 0.2% gelatin in PBS was added to the plates as a blocking 
reagent, this was to prevent any other reagents from attaching to the 
surface not occupied by streptavidin, which could lead to erroneous 
readings.  After four washes with PBS/0.05% Tween 20, 150 µL/well of a 
1 µg/mL solution of photobiotinylated DNA was added to each well of a 
Maxisorp plate and incubated at 4°C overnight.  After another four washes 
with PBS/Tween 20, 50 µL of supernatant (CSF or sera) was added to the 
wells and incubated at room temperature for 2 hours.  After four washes 
with PBS/Tween 20, 50 µL/well of horseradish peroxide conjugated human 
IgG, A, M diluted to 1:1000 with blocking buffer was added and the plates 
were incubated for 1 hour at room temperature.  After four washes, 
50 µL/well of 1 mg/mL OPD in 0.5M of citrate phosphate buffer (pH 5.0) in 
the presence of 0.003% H202 (prepared immediately before use) was 
added to the plates and incubated for 15 minutes at room temperature in 
the dark.  25 µL/well of 1M HCl was added to stop the reaction and the 
plates were read at 492 nm wavelength. 
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Sera and CSF samples were initially examined at 1:50 dilution in 
duplicate.  Undiluted sera and CSF, where possible were subsequently 
assayed.  Each run included duplicate blank wells and seven dilutions of 
the appropriate reference (anti-dsDNA or anti-ssDNA antibodies).  For 
ssDNA plates the following reciprocal dilutions were used for the response 
curve; 10, 100, 500, 1000, 4000, 8000 and 40000. For dsDNA plates the 
following reciprocal dilutions were used: 100, 500, 1000, 4000, 8000, 
15000 and 50000.  Three dilutions of the reference standards were 
positioned in duplicate at the beginning and at the end of each run.  For 
the ssDNA plates these were 250, 2000 and 10000 reciprocal dilutions 
and 750, 5000 and 10000 reciprocal dilutions for the dsDNA plates. 
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2.4 Method Validation of Immuno-histopathology Techniques  
in Rat CNS Tissue 
2.4.1 Materials 
3,3-diaminobenzidine (DAB, batch 32K1582 and 71K1383, Sigma, UK), 
Dulbecco's phosphate buffer saline (batch 80K83031, Sigma, UK), 
hydrogen peroxide (batch 052K3250, Sigma, UK), methanol (batch 
3F26MA, 2J30HA, 2K01HA and 2G11SA, Rathburn Chemicals Ltd., UK), 
acetone (batch 2E29EB, 2J19MB and 2G09HB, Rathburn Chemicals Ltd., 
UK), rabbit anti-mouse Igs-biotin, code E0464 (batch 079(201) and 
059/601 Dako), StreptABComplex/HRP (batch 100(101), Dako), mouse 
anti-rat B cells (batch MCA1432 and 041102, Serotec), normal rabbit 
serum (batch M1128 and N0404, Vector Laboratories Inc. USA), donkey 
anti-sheep Igs (batch 050385, Binding Site, UK), sheep anti-rat 
complement C3 (batch 046536, Binding Site, UK), normal donkey serum 
(batch 080202, Serotec), avidin/biotin (batch N0503, Vector Laboratories 
Inc, USA), sheep anti-rat IgG:HRP (batch AAR10P, Serotec), normal 
sheep serum (batch 250401, Serotec), mouse anti-rat IgM:HRP 
(batch MCA189P and 220502, Serotec), mouse serum (batch 011(102), 
041(101) and 062(101), Dako, Denmark). 3-aminopropyl triethoxysilane 
(APES: batch 91K1271, Sigma), DPX (batch 140398, Surgipath Europe 
Ltd, UK), 4’,6-diamidino-2-phenylindole (DAPI: batch 12K4067, Sigma), 
Dako fluorescent mounting medium (batch 06260, Dako). 
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Copper sulphate, Scott’s tap water, haematoxylin and eosin were 
formulated in bulk by the Histology Department at Covance.  Copper 
sulphate (0.5% w/v) solution was prepared by dissolving copper sulphate 
in 0.9% (w/v) sodium chloride.  Scott’s tap water consisted of 2% (w/v) 
magnesium sulphate 7H2O and 0.2% (w/v) sodium hydrogen carbonate in 
tap water.  Haematoxylin (0.3% w/v) was formulated in 25% (v/v) 
ethanediol (ethan-1,2-diol), 2% (v/v) glacial acetic acid, 0.02% (w/v) 
sodium iodate and 3.5% (w/v) aluminium sulphate in deionised water.  
Eosin (1% w/v) was formulated in 95% industrial methylated spirits (IMS). 
2.4.2 Sectioning 
5 micron sections of spinal cord from each animal were sectioned at 
50 micron intervals using a cryostat, sections were placed on 
aminopropyltriethoxysilane (APES) coated slides.  Slides were stored 
frozen (nominally -70ºC) prior to staining. 
 
APES solution was formulated at a concentration of 2% v/v in acetone.  
Clean slides were immersed in the APES solution for 5 minutes and then 
allowed to drain, but not dry.  The slides were washed in running tap water 
and allowed to air dry overnight.  APES is a section adhesive and is used 
when there is an increased risk of the tissue section lifting from the slide 
during drying or staining, CNS tissue being prone to this.  APES is a 
polyvalent cationic polymer which gives the coated slide a weak positive 
charge.  Section binding occurs by ionic interaction between the charged 
slide and the negatively charged functional groups (eg carboxyl, hydroxyl) 
within the tissue section. 
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2.4.3 Determination of IgM 
Rat spinal cord slides were removed from the freezer and allowed to air 
dry for at least 2 hours.  Slides were then placed in approximately 200 mL 
of acetone for 10 minutes to fix the sections and left overnight at room 
temperature to air dry. 
 
The following day the slides were washed with Dulbecco’s buffer for 
10 minutes.  Slides were blocked for endogenous enzyme, using 750 µL of 
hydrogen peroxide in 200 mL methanol (0.1125%) for 30 minutes.  Slides 
were then washed with running tap water for 10 minutes and returned to 
Dulbecco’s buffer.  Slides were placed in slide holders and washed with 
Dulbecco’s buffer for 10 minutes.  Slides were serum blocked by adding at 
least 100 µL of 20% normal mouse serum in Dulbecco’s buffer for 
30 minutes.  The slides were then washed with Dulbecco’s buffer for 
10 minutes.  At least 200 µL of the primary antibody, mouse anti-rat 
IgM:HRP in Dulbecco’s buffer at a dilution of 1:100, was added to each 
slide, with the exception of the spleen and spinal cord negative controls to 
which at least 200 µL of Dulbecco’s buffer was added.  The slides were 
placed in the fridge (nominally 2 to 8º) overnight.   
 
The following day the slides were removed from the fridge and washed 
with Dulbecco’s buffer for 10 minutes.  The slides were removed from the 
slide holders and placed in Dulbecco’s buffer.  Slides were placed in the 
chromogen DAB for 10 minutes.  DAB was prepared immediately prior to 
use by adding 0.5 g of DAB to 1 L of buffer containing 1 mL of 30% 
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hydrogen peroxide solution.  Once removed from DAB the slides were 
washed in running tap water for 5 minutes.  The slides were then placed in 
the chromogen enhancer, copper sulphate for 5 minutes, following which 
the slides were washed in running tap water for 5 minutes.  The slides 
were counter-stained with haematoxylin for 1 minute, rinsed briefly in tap 
water and placed in Scott’s tap water for 1 minute and finally briefly rinsed 
in tap water. 
2.4.4 Determination of IgG 
Rat spinal cord slides were removed from the freezer and allowed to air 
dry for at least 2 hours.  Slides were then placed in approximately 200 mL 
of acetone for 10 minutes to fix the sections and left overnight at room 
temperature to air dry. 
 
The following day the slides were washed with Dulbecco’s buffer for 
10 minutes.  Slides were blocked for endogenous enzyme, using 750 µL of 
hydrogen peroxide in 200 mL methanol (0.1125%) for 30 minutes.  Slides 
were then washed with running tap water for 10 minutes and returned to 
Dulbecco’s buffer.  Slides were placed in slide holders and washed with 
Dulbecco’s buffer for 10 minutes.  Slides were serum blocked by adding at 
least 100 µL of 20% normal sheep serum in Dulbecco’s buffer for 
30 minutes.  The slides were then washed with Dulbecco’s buffer for 
10 minutes.  At least 200 µL of the primary antibody, sheep anti-rat 
IgG:HRP in Dulbecco’s buffer at a dilution of 1:800 was added to each 
slide, with the exception of the spleen and spinal cord negative controls to 
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which at least 200 µL of Dulbecco’s buffer was added.  The slides were 
placed in the fridge (nominally 2 to 8º) overnight. 
 
The following day the slides were removed from the fridge and washed 
with Dulbecco’s buffer for 10 minutes.  The slides were removed from the 
slide holders and placed in Dulbecco’s buffer.  Slides were placed in the 
chromogen DAB for 10 minutes.  DAB was prepared immediately prior to 
use.  Once removed from DAB the slides were washed in running tap 
water for 5 minutes.  The slides were then placed in the chromogen 
enhancer, copper sulphate for 5 minutes, following which the slides were 
washed in running tap water for 5 minutes.  The slides were counter-
stained with haematoxylin for 1 minute, rinsed briefly in tap water and 
placed in Scott’s tap water for 1 minute and finally briefly rinsed in tap 
water. 
2.4.5 Determination of C3 
Rat spinal cord slides were removed from the freezer and allowed to air 
dry for at least 2 hours.  Slides were then placed in approximately 200 mL 
of acetone for 10 minutes to fix the sections and left overnight at room 
temperature to air dry. 
 
The following day the slides were washed with Dulbecco’s buffer for 
10 minutes.  Slides were blocked for endogenous enzyme, using 750 µL of 
hydrogen peroxide in 200 mL methanol (0.1125%) for 30 minutes.  Slides 
were then washed with running tap water for 10 minutes and returned to 
Dulbecco’s buffer.  Slides were placed in slide holders and washed with 
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Dulbecco’s buffer for 10 minutes.  Slides were serum blocked by adding at 
least 100 µL of 20% normal donkey serum in Dulbecco’s buffer for 
30 minutes.  The slides were then washed with Dulbecco’s buffer for 
10 minutes.  Slides were blocked with avidin for 15 minutes, washed with 
Dulbecco’s buffer for 10 minutes and then blocked with biotin by 
incubating the slides for 15 minutes.  Slides were washed with Dulbecco’s 
buffer.  At least 200 µL of the primary antibody, sheep anti-rat complement 
C3 in Dulbecco’s buffer at a dilution of 1:1000, was added to each slide, 
with the exception of the liver and spinal cord negative controls to which at 
least 200 µL of Dulbecco’s buffer was added.  The slides were placed in 
the fridge (nominally 2 to 8º) overnight.   
 
The following day the slides were removed from the fridge and washed 
with Dulbecco’s buffer for 10 minutes.  Slides were incubated for 
60 minutes with at least 100 µL of the secondary antibody, 1:200 dilution 
of donkey anti-sheep Igs.  The slides were washed with Dulbecco’s buffer 
for 10 minutes.  Binding was visualised using at least 100 µL of 
streptavidin-biotin for 45 minutes.  Streptavidin-biotin was prepared in 
Dulbecco’s buffer at least 30 minutes prior to use and was mixed 
thoroughly. Streptavidin-biotin kit Instructions were followed to ensure that 
there was an excess of biotin present in order to fully saturate the 
streptavidin so to prevent non-specific binding.  The slides were washed 
with Dulbecco’s buffer for 10 minutes.  The slides were removed from the 
slide holders and placed in Dulbecco’s buffer.  Slides were placed in the 
chromogen DAB for 10 minutes.  DAB was prepared immediately prior to 
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use.  Once removed from DAB the slides were washed in running tap 
water for 5 minutes.  The slides were then placed in the chromogen 
enhancer, copper sulphate for 5 minutes, following which the slides were 
washed in running tap water for 5 minutes.  The slides were counter-
stained with haematoxylin for 1 minute, rinsed briefly in tap water and 
placed in Scott’s tap water for 1 minute and finally briefly rinsed in tap 
water. 
2.4.6 Determination of B cells 
Rat spinal cord slides were removed from the freezer and allowed to air 
dry for at least 2 hours.  Slides were then placed in approximately 200 mL 
of acetone for 10 minutes to fix the sections and left overnight at room 
temperature to air dry. 
 
The following day the slides were washed with Dulbecco’s buffer for 
10 minutes.  Slides were blocked for endogenous enzyme, using 750 µL of 
hydrogen peroxide in 200 mL methanol (0.1125%) for 30 minutes.  Slides 
were then washed with running tap water for 10 minutes and returned to 
Dulbecco’s buffer.  Slides were placed in slide holders and washed with 
Dulbecco’s buffer for 10 minutes.  Slides were serum blocked by adding at 
least 100 µL of 20% normal rabbit serum in Dulbecco’s buffer for 
30 minutes.  The slides were then washed with Dulbecco’s buffer for 
10 minutes.  Slides were blocked with avidin for 15 minutes, washed with 
Dulbecco’s buffer for 10 minutes and then blocked with biotin by 
incubating the slides for 15 minutes.  Slides were washed with Dulbecco’s 
buffer.  At least 200 µL of the primary antibody, mouse anti-rat B cells in 
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Dulbecco’s buffer at a dilution of 1:80, was added to each slide, with the 
exception of the liver and spleen cord negative controls to which at least 
200 µL of Dulbecco’s buffer was added.  The slides were placed in the 
fridge (nominally 2 to 8º) overnight.   
 
The following day the slides were removed from the fridge and washed 
with Dulbecco’s buffer for 10 minutes.  Slides were incubated for 
60 minutes with at least 100 µL of the secondary antibody, 1:500 dilution 
of rabbit anti-mouse Igs.  The slides were washed with Dulbecco’s buffer 
for 10 minutes.  Binding was visualised using at least 100 µL of 
streptavidin-biotin for 45 minutes.  Streptavidin-biotin was prepared at 
least 30 minutes prior to use and was mixed thoroughly.  The slides were 
washed with Dulbecco’s buffer for 10 minutes.  The slides were removed 
from the slide holders and placed in Dulbecco’s buffer.  Slides were placed 
in the chromogen DAB for 10 minutes.  DAB was prepared immediately 
prior to use.  Once removed from DAB the slides were washed in running 
tap water for 5 minutes.  The slides were then placed in the chromogen 
enhancer, copper sulphate for 5 minutes, following which the slides were 
washed in running tap water for 5 minutes.  The slides were counter-
stained with haematoxylin for 1 minute, rinsed briefly in tap water and 
placed in Scott’s tap water for 1 minute and finally briefly rinsed in tap 
water. 
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2.4.7 Final preparation of IgM, IgG, C3 and B cell slides 
Slides were placed in five changes of IMS, followed by three changes of 
xylene.  Cover-slips were mounted using DPX.  Slides were allowed to dry 
prior to viewing. 
2.4.8 Validation of immuno-staining techniques 
Each of the above was validated using various dilutions of the primary 
antibody. 
 
IgG: various dilutions (1:400, 1:800, 1:1600, 1:3200, 1:6400, 1:12800) of 
sheep anti-rat IgG:HRP were used on sections of rat spleen.  Spleen was 
used as this tissue has a high IgG content.  Dilutions of 1:400 and 1:12800 
were added to spinal cord sections from an untreated rat.  In addition, a 
section of spleen and spinal cord were included as negative controls, i.e. 
Dulbecco’s buffer was added in place of the primary antibody.  On the 
basis of the results obtained a dilution of 1:800 was used for subsequent 
staining (figure 5). 
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Figure 5  IgG staining (1:800 dilution) using sheep anti-rat IgG:HRP and counter stained 
with haematoxylin, under light microscopy (x 20 objective).  The arrows point to areas of 
positive IgG staining on a spleen section taken from an untreated rat. 
 100µm 
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IgM: various dilutions (1:12.5, 1:25, 1:50, 1:100, 1:200, 1:400, 1:800, 
1:1600, 1:3200, 1:6400, 1:12800) of mouse anti-rat IgM:HRP were used 
on sections of rat spleen.  Spleen was used as this tissue has a high IgM 
content.  Dilutions of 1:200, 1:400 and 1:12800 were added to spinal cord 
sections from an untreated animal.  In addition, a section of spleen and 
spinal cord were included as negative controls, i.e. Dulbecco’s buffer was 
added in place of the primary antibody.  On the basis of the results 
obtained a dilution of 1:100 was used for subsequent staining (figure 6). 
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Figure 6  IgM staining (1:100 dilution) using mouse anti-rat IgM:HRP and counter stained 
with haematoxylin, under light microscopy (x 20 objective).  The arrows point to area of 
positive IgM staining on a spleen section taken from an untreated rat. 
 
 100µm 
 
 
  108 
B cells, various dilutions (1:10, 1:20, 1:40, 1:80, 1:100, 1:200, 1:400, 
1:800, 1:1600, 1:3200) of mouse anti-rat B cells were used on sections of 
rat liver.  Liver was used as this has a high B cell content. Dilutions of 
1:10, 1:80, 1:100 and 1:3200 were added to spinal cord sections from an 
untreated animal.  In addition a section of liver and spinal cord were 
included as negative controls, i.e. Dulbecco’s buffer was added in place of 
the primary antibody.  On the basis of the results obtained a dilution of 
1:80 was used for subsequent staining (figure 7). 
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Figure 7  B cell (1:80) staining using mouse anti-rat B cells and counter stained with 
haematoxylin, under light microscopy (x 20 objective).  The arrow points to an area of 
positive B cell staining on a liver section taken from an untreated rat. 
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C3: various dilutions (1:400, 1:800, 1:1600, 1:3200, 1:6400, 1:12800) of 
sheep anti-rat complement C3 were used on sections of rat spleen.  
Spleen was used as this tissue has a high C3 content.  Dilutions of 1:400 
and 1:12800 were added to spinal cord sections from an untreated animal.  
In addition a section of spleen and spinal cord were included as negative 
controls, i.e. Dulbecco’s buffer was added in place of the primary antibody.  
On the basis of the results obtained a dilution of 1:1000 was used for 
subsequent staining (figure 8). 
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Figure 8  C3 staining (1:1000 dilution) using sheep anti-rat complement C3 and 
counterstained with haematoxylin, under light microscopy (x 20 objective).  The above 
shows C3 staining on a spleen section taken from an untreated rat. 
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The dilution of primary antibody selected in each case was one that 
provided good specific staining with minimal non-specific background 
staining.  
2.4.9 DAPI (4’,6-diamidino-2-phenylindole) staining 
Due to the limited amount of CSF available from the rat EAE model, it was 
considered necessary to find an alternative method for the detection of 
anti-DNA antibodies.  DAPI is a fluorescent dye that binds selectively to 
DNA and forms strongly fluorescent DNA-DAPI complexes with high 
specificity.  Based on this information, the possibility of developing a probe 
which could act as a specific target for anti-ds or -ssDNA antibodies was 
investigated.  At the time of writing the only references with regards to the 
use of DAPI in the detection of anti-ss or dsDNA antibodies refer to 
demonstrating their presence in fluids or cell cultures and not in tissue.  
From the information available [Roche Diagnostics] a preliminary and 
novel technique was developed with the intention of creating a DNA probe 
for the detection of anti-ssDNA and anti-dsDNA antibodies in situ.  If 
successful, this method would not only be able to demonstrate the 
presence of such antibodies, but would also show their actual location 
within the tissue.  The latter being of particular interest in this project due 
to the possible pathological role of these antibodies in MS.  The theory 
behind this method was that if DAPI was allowed to bind to ssDNA or 
dsDNA, when incubated with sections of tissue any anti-ds or -ssDNA 
antibodies present would bind to the probes and could then be visualised 
using fluorescence.   
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DAPI was formulated in deionised water at a stock concentration of 
1 mg/mL.  For the staining procedure, DAPI was diluted from the stock 
concentration, using methanol to give a concentration of 2 µg/mL.  When 
combined with ssDNA or dsDNA a final concentration of 1 µg/mL of DAPI 
and 1 µg/mL DNA was obtained.  DAPI and DNA were thoroughly mixed 
and incubated at room temperature in the dark for 1 hour prior to use. 
 
Lewis rat spinal cord sections were prepared from an untreated rat and 
from a rat killed at the time of peak EAE.  Sections were fixed in 
approximately 200 mL of acetone for 10 minutes following at least 2 hours 
of air-drying and were then left overnight to air dry.   
 
The following day, spinal cord sections were washed with Dulbecco’s 
buffer for 10 minutes prior to staining.  At least 200 µL of the appropriate 
stain was added to each section as follows: 
 
• Spinal cord from an untreated rat – DAPI alone 
• Spinal cord from an untreated rat – DAPI bound to ssDNA 
• Spinal cord from an untreated rat – DAPI bound to dsDNA 
 
The above sections were included in order to determine if DAPI alone or 
as a DNA probe could cause unspecific staining, which would obscure any 
positive staining.  
 
• Spinal cord from a rat sampled at peak EAE - DAPI alone 
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The above section was included to determine if DAPI alone could caused 
specific staining, which could lead to the presence of false positives.  
 
• Spinal cord from a rat sampled at peak EAE – DAPI bound to ssDNA 
• Spinal cord from a rat sampled at peak EAE – DAPI bound to dsDNA 
 
The above sections were included as potential positive controls.  Spinal 
cord from a rat sampled at peak was used, as based on previous work 
(IgG, IgM, B cell and C3 determination) this appeared to be the most likely 
time when anti-DNA antibodies would be present. 
 
The slides were incubated at room temperature in the dark for 1 hour and 
then washed with Dulbecco’s buffer for 10 minutes.  The sections were 
embedded in Dako fluorescent mounting medium and allowed to dry.  The 
slides were stored cool (nominally 2-8°C) overnight.  Slides were read 
using a fluorescent microscope (Leica DMLB).  A Jenopik ProgRes C14 
camera was also used.  DAPI has a peak excitation wavelength of 340 nm 
and an emission maximum at a wavelength of 488 nm.  However, when 
bound to dsDNA the excitation peak occurs at a longer wavelength of 
approximately 360 nm.  In this project fluorescence was visualised under 
green light for reasons discussed later on. 
 
Following the initial work performed using DAPI probes, further work was 
conducted in order to refine the staining procedure and to gain confidence 
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in the results obtained.  The following summarises the key changes to the 
method detailed above. 
 
In addition to incubating ds and ssDNA with DAPI for 1 hour at room 
temperature in the dark, the mixture was also incubated for 1 hour in the 
dark under cool conditions.  Various incubation times with tissue sections 
(1, 4 and 24 hours) were examined both at room temperature and under 
refrigerated conditions.  DAPI concentrations of 1, 10, 100 and 1000 
µg/mL were used and a DNA concentration of 10 µg/mL was also 
assessed. 
 
The optimal conditions were found to be DAPI/DNA at 1 µg/mL (1:1 ratio), 
when allowed to incubate for 1 hour at room temperature in the dark.  The 
incubation time with tissue sections was optimal when stored overnight 
refrigerated and in the dark. 
 
In order to further increase the chance of detecting anti-dsDNA antibodies, 
rat spinal cord sections taken at the time of onset EAE were used.  It was 
thought that by the time EAE had reached a peak, fewer anti-dsDNA 
antibodies may remain in the tissue.  Whereas at the time of onset, when 
the disease is active, it is reasonable to think that the antibodies would be 
most prevalent.  Onset samples were found to be no better than those 
taken at the time of peak EAE. 
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In order to minimise non-specific staining due to unbound DAPI in the 
probe mixture, a spin column was used to ‘clean–up’ the probe.  The 
DAPI/DNA mixture was allowed to incubate for 1 hour at room temperature 
in the dark.  The spin column 1000 (batch number 87H0612, Sigma) was 
inverted several times in order to suspend the matrix uniformly.  The 
column was held upright and the seal broken.  The column was placed in 
a 2 mL tube with the cap removed and centrifuged for 5 minutes at 700 g 
(1970 rpm).  The collection tube was disposed of and the spin column was 
placed in a new 2 mL tube.  A 70 µL DAPI/DNA sample was placed into 
the centre of the matrix bed’s flat surface and the column was centrifuged 
for 5 minutes at 700 g.  The spin column was disposed of leaving the 
purified sample in the bottom of the collection tube.  A 50% recovery was 
assumed (based on the technical information supplied by Sigma) and 
based on this the purified sample was re-suspended in Dulbecco’s buffer 
to provide a concentration of 10 µg/mL.   
 
In order to investigate and substantiate potential positive staining, a dual 
staining technique was used.  Serial sections of spinal cord obtained from 
a Lewis rat sampled at onset of EAE were stained for IgG, B cell or 
endothelium.  A second set of sections was stained as before, but followed 
by dsDNA/DAPI probe and a third set was first stained with dsDNA/DAPI 
probe, followed by IgG, B cell or endothelium.  Sections were also stained 
with dsDNA/DAPI probe followed by H & E in order to visualise the 
morphology of the sections. 
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2.4.10 Alexa Fluor 647 staining 
Due to an absence of a convincing positive response, the DAPI stain was 
replaced with Alexa Fluor 647.  The Alexa Fluor 647 kit was used to 
prepare dsDNA probes as follows. 
 
One vial of DNase I was spun at 2100 rpm for 3 minutes to deposit the 
solid in the bottom of the tube.  100 µL of chilled DNase I storage buffer 
was added to the vial of DNase I to provide a concentration of 1 µg/µL and 
was stored frozen at nominally -20º prior to use. 
 
The ULS reagent stock solution was prepared by adding 100 µL of 50% 
DMSO to the ULS reagent.  The mixture was vortexed and stored cool 
(nominally 2 to 8ºC). 
 
In order to obtain fragments of DNA (1 µg) of approximately 100 to 1000 
base pairs in length the manufactures DNase protocol was followed.  1 µL 
of DNase stock (1 mg/mL) was diluted with 49 µL of 1x DNase I reaction 
buffer (20 µL of 10x DNase I reaction buffer in 180 µL of nuclease-free 
water, kept on ice).  3 µL of the DNase stock solution (1:50 dilution) was 
diluted with 1x DNase I reaction buffer to give a 1:1650 dilution.   
 
1 mg/mL dsDNA was diluted with TE buffer to give a 100 µg/mL solution.  
The tube was flicked to mix and left on ice prior to use.   
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The following was added to a microtube; 9.5 µL nuclease-free water, 2.5 
µL of 10x DNase I reaction buffer, 10 µL of 0.1 mg/mL sample DNA in TE 
buffer (10 mM Tris, 1 mM EDTA, pH 8), 3 µL DNase I working solution 
(1:1650).  The mixture was allowed to incubate to 10 minutes at 37ºC after 
which the reaction was stopped by plunging the mixture into wet ice.  The 
mixture was stored frozen prior to use. 
 
To prepare the probe, DNA was precipitated by adding 2.5 µL of 3M 
sodium acetate, pH 5.2 (batch 112K8928, Sigma) and 50 µL of absolute 
ethanol (batch 11K3657, Aldrich) to 25 µL of DNA (1 µg).  The mixture was 
frozen at -70ºC for 30 minutes and then centrifuged for 15 minutes at 
12000 rpm.  The resulting pellet was washed with 70% ethanol and 
allowed to air dry.  The pellet was re-suspended in 20 µL of the labelling 
buffer.  The DNA was denatured at 95ºC for 5 minutes and snap-cooled on 
wet ice.  The mixture was centrifuged briefly at 2100 rpm for 3 minutes to 
redeposit the sample to the bottom of the tube.  5 µL of ULS labelling 
reagent stock was added to the denatured DNA.  The mixture was 
incubated at 80ºC for 15 minutes and the reaction stopped by plunging 
into an ice bath.  The mixture was centrifuged briefly at 2100 rpm for 
3 minutes to redeposit the sample to the bottom of the tube.   
 
Purification of the probe was performed using a QIAquick spin PCR 
purification kit.  24 mL of ethanol was added to PE buffer, 500 µL of which 
was then added to 100 µL of DNA sample.  The spin column was placed in 
a 2 mL tube and the DNA sample placed in the spin column and 
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centrifuged at 13000 rpm for 45 seconds.  The flow was discarded and the 
column replaced.  3 mL of buffer PE was added to the spin column which 
was then centrifuged for 45 seconds.  The flow was discarded, the spin 
column replaced in the tube and was then centrifuged for 1 minute.  The 
spin column was placed in a clean 1.5 mL microcentrifuge tube.  DNA was 
eluted by adding 120 µL of buffer EB to the centre of the membrane.  After 
being left to stand for 1 minute, the mixture was centrifuged for 1 minute.  
An appropriate volume of Dulbecco’s buffer was added to the ULS/DNA 
probe mixture in order to obtain the required concentration for use.   
 
Alexa Fluor 647 has an excitation wavelength of 647 nm and an emission 
wavelength of 665 nm.  As such tissue sections incubated with the Alexa 
Fluor/dsDNA probe were viewed under red light (wavelength 
approximately 650 nm). 
 
Following four Alexa Fluor probe preparations and in the absence of 
positive staining, the quality of the probe preparation was questioned.  
Probe preparation was subsequently prepared by a contact at United 
Leeds Teaching Hospital. 
2.5 Method Validation of the Alexa Fluor Probe for Use in Anti-
dsDNA Antibody Demonstration in Biozzi (ABH) Mouse CNS 
2.5.1 Materials 
Plasmid dsDNA, 1 mg/mL (lot 5) was supplied by Bayou Biolabs, USA.  
Alexa Fluor 647 was supplied by Molecular probes Europe BV, The 
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Netherlands.  Alexa Fluor/dsDNA probes were prepared at United Leeds 
Teaching Hospital. 
2.5.2 Sectioning 
5 micron sections of Biozzi (ABH) mouse spinal cord were sectioned at 50 
micron intervals using a cryostat.  Sections were placed on APES coated 
slides.  Slides were stored frozen (nominally -70ºC) prior to staining. 
2.5.3 Determination of anti-dsDNA antibodies using Alexa 
Fluor/dsDNA probes 
Six spinal cord sections from Biozzi (ABH) mice (three from each mouse) 
which had been killed at peak EAE during a second episode of the clinical 
signs were removed from the freezer and allowed to air dry overnight. 
 
The following day the sections were placed in acetone for 10 minutes and 
then allowed to air dry for approximately 30 minutes.  The slides were 
washed with Dulbecco’s buffer for 10 minutes and then placed in slide 
holders and washed again for 10 minutes with Dulbecco’s buffer.  At least 
100 µL of Alexa Fluor/dsDNA was added to four of the spinal cord sections 
(two from each mouse).  The remaining two sections were incubated with 
Dulbecco’s buffer only and served as negative controls.  The slides were 
placed in the refrigerator, protected from light and were allowed to 
incubate for approximately 4 hours.  The slides were removed from the 
fridge and washed for 10 minutes with Dulbecco’s buffer.  The slides were 
removed from the slide holders and mounted using Dako immuno-
fluorescence mounting medium and allowed to dry.  
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Biozzi (ABH) mouse and Lewis rat brain sections, and Lewis rat spinal 
cord sections were also stained in this way. 
2.5.4 Dual staining with Alexa Fluor/dsDNA probe and H & E 
In order to investigate the apparent auto-fluorescence seen in spinal cord 
sections taken from Biozzi (ABH) mice exhibiting EAE, dual staining with 
the dsDNA probe and H & E was performed.  For this purposes spinal 
cord sections were stained as follows. 
 
1. Serial sections taken from an untreated Biozzi (ABH) mouse:- 
• 2 x spinal cord – Dulbecco’s buffer 
• 2 x spinal cord – H & E 
• 2 x spinal cord – Alexa Fluor/dsDNA probe 
 
The sections above were stained in order to see if auto-fluorescence could 
be seen in the spinal cord of untreated mice.  These sections were 
compared with the negative control Dulbecco’s buffer stained sections.  
The H & E sections were included for morphological purposes. 
 
2. Serial sections taken from a Biozzi (ABH) mouse sampled at peak EAE 
during the second episode of clinical signs:- 
• 2 x spinal cord - Alexa Fluor/dsDNA probe 
• 2 x spinal cord - H & E 
• 2 x spinal cord - Alexa Fluor/dsDNA probe followed by H & E 
• 2 x spinal cord - H & E followed by Alexa Fluor/dsDNA probe 
 
Various combinations of H & E and Alexa Fluor/ds DNA probe were used 
in order to identify and correlate areas of fluorescence.   
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The most successful method of dual staining was found to be staining the 
sections initially with the dsDNA probe and then looking for areas of 
fluorescence under the microscope.  Once fluorescence had been 
detected the co-ordinates of this were recorded and the sections re-
stained with H & E for (approximately 1 minute).  The slide was then re-
aligned with co-ordinates and examined.   
2.6 Immuno-histological Staining of Human Tissue 
2.6.1 Introduction 
In order to investigate the ability of Alexa Fluor/dsDNA probes to detect 
anti-dsDNA antibodies it was necessary to obtain human brain and spinal 
cord from an individual who had multiple sclerosis at the time of their 
death.  Although the detection of anti-dsDNA antibodies in these tissue 
sections could not be guaranteed, published literature [Williamson et al. 
(2001)] supports the presence of these antibodies around active plaques 
in multiple sclerosis.  This is in contrast to rat and mouse EAE models for 
which no such literature could be found referencing anti-dsDNA antibodies 
in situ.  A request was made to the Multiple Sclerosis Tissue Bank for 
sections taken from the brain and spinal cord which were exhibiting plaque 
activity at the time of death.  Sections obtained from the Tissue Bank had 
been cut from a cerebral tissue block, a couple of these sections were 
stained with LFB (Luxol fast blue)/MHC class II, which revealed the 
presence of a large lesion with immune activity on the lesion edge.  Luxol 
fast blue is a stain used to demonstrate demyelination and can also 
enable phagocytic macrophages containing myelin basic protein to be 
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visualised.  MHC class II staining was used to demonstrate MHC class II 
molecule expression.  In addition, sections of human spinal cord taken 
from a patient with MS were supplied.  Information provided by the Tissue 
Bank indicated that staining of the spinal cord block had been found to be 
less clear.  Although there appeared to be an area of myelin pallor 
(depleted myelin) that corresponded to an elevated MHC class II 
expression, the lesion was not easily identified.  
2.6.2 Materials 
Fifteen brain and spinal cord flash frozen sections were supplied by the 
UK MS Tissue Bank, on dry ice.  Sections were taken from a 51 year old 
male who had been suffering from multiple sclerosis for approximately 
10 years.  The classification of MS was secondary progressive multiple 
sclerosis, which is a steadily progressive form of the disease which may 
follow many years of relapsing/remitting MS.  In general, secondary 
progressive multiple sclerosis is associated with lower levels of 
inflammatory lesion formation than that seen in relapsing/remitting MS.  
The cause of death was sclerosis and bronchopneumonia.  His mother 
also had MS. 
 
Plasmid dsDNA, 1 mg/mL (lot 5) was supplied by Bayou Biolabs, USA.  
Alexa Fluor 647 was supplied by Molecular probes Europe BV, The 
Netherlands.  Monoclonal mouse anti-human plasma cell (Clone VS38c), 
batch 00005455, supplied by DakoCytomation.  Albumin bovine serum 
(batch 103K1363) supplied by Sigma, UK.  Hydrogen peroxide (batch 
123K3250) supplied by Sigma, UK.  Rabbit serum (batch R0511) supplied 
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by Vector Laboratories Inc., USA.  Rabbit anti-mouse Immunoglobulins – 
biotinylated (batch 00015064) supplied by Dako, Denmark.  StreptABC 
Complex/HRP (batch 00012270) supplied by Dako, Denmark.  
Avidin/Biotin (batch R0527) supplied by Vector Laboratories Inc, USA.  
Alexa Fluor/dsDNA probes were prepared at United Leeds Teaching 
Hospital. 
2.6.3 Sectioning 
5 micron sections of human tonsil were sectioned at 50 micron intervals 
using a cryostat, sections were and placed on APES coated slides.  Slides 
were stored frozen (nominally -70ºC) prior to staining. 
2.6.4 Determination of plasma cells - validation 
Due to the elusive anti-dsDNA antibodies, the presence of plasma cells in 
human CNS tissue sections was investigated.  The presence of such cells 
would indicate that immune activity was occurring and that it should be 
possible to detect anti-dsDNA antibodies in the serial sections taken if 
present. 
 
Human tonsil and spleen sections were removed from the freezer and 
allowed to air dry overnight.  Tonsil and spleen were used to validate 
plasma cell demonstration as such cells reside in abundance in these 
organs. 
 
The following day, the slides were placed in approximately 200 mL of 
acetone for 10 minutes to fix the sections and for approximately 1 hour at 
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room temperature to air dry.  The slides were then washed with 
Dulbecco’s buffer for 10 minutes.  Slides were blocked for endogenous 
enzyme, using 750 µL of hydrogen peroxide in 200 mL methanol 
(0.1125%) for 30 minutes.  Slides were then washed with running tap 
water for 10 minutes and returned to Dulbecco’s buffer for washing with 
Dulbecco’s buffer for 10 minutes.  Slides were serum blocked by adding at 
least 100 µL of 1:5 rabbit serum in Dulbecco’s buffer for 20 minutes.  The 
slides were then washed with Dulbecco’s buffer for 10 minutes.  100 µL of 
avidin was added for 15 minutes, the slides were washed with Dulbecco’s 
buffer for 10 minutes and Biotin (to prevent avidin non-specific binding) 
was added for a further 15 minutes.  Following washing with Dulbecco’s 
buffer for 10 minutes, at least 200 µL of the primary antibody, monoclonal 
mouse anti-human plasma cell in 2% bovine serum albumin at dilutions of 
1:25, 1:50, 1:100, 1:200, 1:400, 1:800, 1:1600, were added to each slide 
as appropriate.  One section of tonsil and spleen remained as negative 
controls and as such had at least 200 µL of 2% bovine serum albumin 
added to them.  The slides were left at room temperature for 
approximately 90 minutes.  The slides were washed with Dulbecco’s buffer 
for 10 minutes.  At least 100 µL of StreptABCComplex/HRP was added for 
approximately 45 minutes after which the slides were washed for 
10 minutes with Dulbecco’s buffer.  The slides were removed from the 
slide holders and placed in Dulbecco’s buffer.  Slides were placed in the 
chromogen DAB for 10 minutes.  DAB was prepared immediately prior to 
use by adding 0.5 g of DAB to 1 litre of buffer containing 1 mL of 30% 
hydrogen peroxide solution.  Once removed from DAB the slides were 
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washed in running tap water for 5 minutes.  The slides were then placed in 
the chromogen enhancer, copper sulphate for 5 minutes, following which 
the slides were washed in running tap water for 5 minutes.  The slides 
were counter-stained with haematoxylin for 1 minute, rinsed briefly in tap 
water and placed in Scott’s tap water for 1 minute and finally briefly rinsed 
in tap water. 
2.6.5 Validation of plasma cell determination 
Plasma cell determination was validated using various dilutions of the 
primary antibody.  Dilutions (1:25, 1:50, 1:100, 1:200, 1:400, 1:800, 
1:1600) of monoclonal mouse anti-human plasma cell (Clone VS38c) were 
used on sections of human tonsil.  In addition, a section of tonsil and 
spleen were included as negative controls, i.e. 2% bovine serum albumin 
was added in place of the primary antibody.   
 
On the basis of the results obtained a dilution of 1:80 was considered 
appropriate for subsequent staining (figures 9 and 10).  This staining 
method was never used on any other tissue sections due to the 
subsequent positive staining of anti-dsDNA antibody and the limited 
number of human tissue samples available. 
  127 
 
Figure 9  Plasma cell staining (1:80 dilution) using monoclonal mouse anti-human 
plasma cell and counter stained with haematoxylin, under light microscopy (x 20 
objective).  The arrows point to areas of positive staining on a human tonsil section. 
 
 
 
 
 
 
 
 
 
 
 
Figure 10  Plasma cell staining (1:80 dilution) using monoclonal mouse anti-human 
plasma cell and counter stained with haematoxylin, under light microscopy (x 
20 objective).  The arrows point to areas of positive staining on a human spleen section. 
 100µm 
 
 
 100µm 
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2.6.6 Determination of anti-dsDNA antibodies using Alexa 
Fluor/dsDNA probes 
Sections of MS human brain and spinal cord were allowed to air dry 
overnight. 
 
The following day the sections were placed in acetone for 10 minutes and 
then allowed to air-dry for approximately 30 minutes.  The slides were 
washed with Dulbecco’s buffer for 10 minutes and then placed in slide 
holders and washed again for 10 minutes with Dulbecco’s buffer.  At least 
100 µL of undiluted probe was added to each slide, with the exception of 
one brain and one spinal cord section to which Dulbecco’s buffer was 
added, these sections served as negative controls.  The slides were 
placed in the refrigerator, protected from light for approximately 4 hours.  
Slides were removed from the fridge and washed for 10 minutes with 
Dulbecco’s buffer.  The slides were removed from the slide holders and 
mounted using Dako immuno-fluorescence mounting medium and allowed 
to dry.  
 
The Alexa Fluor probe was used undiluted due to lack of staining when 
diluted. 
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3 CHAPTER 3: RESULTS 
3.1 Clinical signs of EAE in the Lewis rat– in vivo phase 
Following inoculation with the encephalitogenic agent, the majority of 
animals displayed signs of EAE, some animals however displayed signs to 
a greater severity than others.  This led to the animals being categorised 
into two groups, successful and unsuccessful.  Animals deemed to be 
successful displayed an anticipated EAE response at the time of sampling 
as follows; 
 
• Onset – animals achieving a score of 1 (slightly limp tail) by Day 10. 
• Peak – animals achieving a score of 3 or more by Day 10. 
• Plateau – animals achieving a score of at least 6. 
• Remission – animals achieving a score of at least 6. 
• Relapse (Day 34) - animals achieving a score of at least 6. 
 
The term peak relates to the approximate time at which the inflammatory 
response was expected to have reached peak activity.  It was considered 
important to sample the animals before the disease reached a plateau as 
at this time it was hypothesised that the inflammatory response could be 
coming to an end.  For this reason the score for clinical signs was seen to 
be higher in the plateau group compared to the peak sample group.  In 
general, histopathological evaluation found there to be a greater presence 
of inflammatory deposits in animals sampled at peak compared to those 
sampled at plateau. 
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Animals deemed unsuccessful displayed EAE signs to a lesser extent than 
that stated above or failed to exhibit signs.  The first occurrence of signs 
following inoculation was also delayed in some cases when compared to 
the successful animals. 
 
The times of sampling (CSF, blood, spinal cord and brain) were at; 
 
• Onset - the time at which the first signs were seen. 
• Peak - the time at which a substantially limp tail was observed. 
• Plateau - the time at which the same signs had been seen on at least 
two consecutive occasions. 
• Remission - at the time when the animals had fully recovered. 
• Relapse - which for the Lewis rat was Day 34 due to relapse not 
occurring in this particular model of EAE.  
 
Although relapse was not anticipated in the Lewis rat EAE model, this 
sample time-point was included to assess any potential histopathological 
changes in the absence of EAE clinical signs. 
 
Figures 11a and 11b show the difference between group mean total EAE 
scores at the time of sampling for successful and unsuccessful animals, 
respectively.  The differences in EAE development were as follows; 
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• Although animals in the onset group had the same total score, the 
unsuccessful animals were slower in developing the signs; Day 11 
compared to Day 9 and 10 for successful animals.   
• At peak a maximum score 3 or 7 was exhibited by successful animals 
compared to scores of 0, 1 or 2 for unsuccessful rats. 
• At plateau a maximum EAE score of 6 or 7 was exhibited by 
successful animals compared to scores of 1 or 2 for unsuccessful rats.   
• At remission and relapse (Day 34), successful rats had maximum EAE 
scores of 6 or 7 compared to 1 or 2 for unsuccessful rats. 
 
Thirty-nine out of 40 rats immunised with CNS material in the presence of 
an adjuvant (carbonyl iron), displayed signs of EAE to some extent.  All 16 
control (carbonyl iron) rats and four untreated rats appeared normal 
throughout the study. 
3.1.1 Onset EAE group 
All eight rats in the onset group were killed on the appearance of a slightly 
limp tail (EAE score of 1).  EAE was first apparent in one rat on Day 9, with 
all rats killed and sampled by Day 11.  For the data analysis, the four rats 
that exhibited signs by Day 10 were treated as successful as they 
matched the selection criteria, whereas the four rats not showing signs 
until Day 11 were classed as unsuccessful in EAE development.   
 
Although the time difference between the development of successful and 
unsuccessful signs was negligible, a decision was made at the time to 
distinguish between these two groups of animals to see if there was any 
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difference histopathologically.  The problem with sampling this group of 
animals was that there was no way of knowing that if left alone, what the 
maximum severity score would be.  That is, whether the animals were truly 
successful or unsuccessful.  Results from this study showed there to be no 
correlation between the time to EAE onset and the successfulness or 
unsuccessfulness of the animals to develop EAE clinical signs. 
3.1.2 Peak EAE group 
Seven out of eight rats in this group displayed signs of EAE to some 
extent.  Rats in the peak EAE sampling group were killed on the first day 
that they exhibited a substantially limp tail.  Only five rats in this group 
were classed as successful, with four of these rats having an EAE score of 
3 (substantially limp tail) and one having a maximum score of 7 (ataxia 
and a substantially limp tail).  EAE was first seen in two rats on Day 8 with 
all successful animals killed and sampled by Day 10.  There were three 
unsuccessful rats in this group, two of which had a moderately limp tail as 
a maximum sign; one rat failed to show any indication of EAE. 
3.1.3 Plateau EAE group 
All eight rats in the plateau group exhibited signs of EAE.  Five out of eight 
rats were killed after achieving a maximum score of at least 6, with the 
majority of these animals exhibiting a substantially limp tail and ataxia for 
two consecutive days.  EAE was first apparent in one rat on Day 9, with a 
plateau occurring between Day 12 and Day 16.  The remaining rats in this 
group exhibited slight signs of EAE with a score of no more than 2 
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(moderately limp tail), these rats were treated as unsuccessful in 
developing EAE.  
3.1.4 Remission EAE group 
All rats (including those deemed unsuccessful) in the remission group 
displayed signs of EAE to some extent in this study and when killed had 
an EAE score of 0 (normal).  The first signs of EAE were initially seen in 
four rats on Day 10, with three out of the eight rats exhibiting marked signs 
of EAE (at least a score of 6) on Day 15 or 16.  These three rats were 
regarded as successful.  The five unsuccessful rats displayed slight EAE 
signs with scores of no more than 2 (moderately limp tail).  The majority of 
animals appeared normal on Day 18 and by Day 20 all rats had been 
killed and sampled. 
3.1.5 Relapse EAE group (Day 34) 
As anticipated, rats in this study did not show any indication of relapse and 
as such were killed and sampled on Day 34.  All rats in this group 
developed EAE, with three out of the eight rats having a peak score of at 
least 6, as such these rats were treated as successfully developing EAE.  
All other rats in this group had a peak score of 2.  EAE was first apparent 
in all but one rat on Day 10, peak EAE was observed on Day 15 or 16, and 
all but two rats appeared normal by Day 22.  At the time of kill (Day 34) 
two rats had an EAE score of 1 (slightly limp tail) all other rats appeared 
normal. 
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Figure 11a  
  
 
Figure 11b  
 
Figure 11  Bar graphs showing (a) Group mean total EAE scores in successful rats at the 
time of sampling for animals immunised with CNS material.  (b) Group mean total EAE 
scores in unsuccessful rats at the time of sampling for animals immunised with CNS 
material.  EAE signs were absent in all control (carbonyl iron) animals.  
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3.2 Detection of anti-ss and -dsDNA antibodies in Lewis rat CSF and 
sera using ELISA 
Cerebrospinal fluid and sera samples obtained from Lewis rats used in the 
EAE model, killed and sampled at EAE onset, peak, plateau, remission or 
‘relapse’ were analysed using an ELISA at a dilution of 1:50 and where 
volumes permitted, undiluted.   
 
The results are summarised in Tables 4 and 5. 
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Group Samples taken 
at EAE point 
Group mean OD (±se) using an ELISA for  
anti-dsDNA antibody 
CSF Sera 
1:50 Undiluted 1:50 Undiluted 
 Untreated 0.00
(1) 
±0.000 
0.11(2) 
±0.021 
0.00(4) 
±0.000 
0.12(4) 
±0.019 
Part II 
(peak) Untreated Not tested Test failed 
Not 
tested Not tested 
2a Onset 0.01
(7) 
±0.008 
0.11(5) 
±0.009 
0.00(8)†† 
±0.000 
0.11(8)** 
±0.004 
2e Peak Not tested Test failed Not tested Not tested 
2b Plateau 0.01
(8) 
±0.007 
0.26(4) 
±0.053 
0.01(8) 
±0.006 
0.12(6) 
±0.015 
2c Remission 0.00
(6) 
±0.000 
0.12(5) 
±0.026 
0.02(5) 
±0.013 
0.13(8) 
±0.029 
2d Relapse 0.01
(4) 
±0.005 
0.16(6)† 
±0.047 
0.02(5) 
±0.015 
0.11(7) 
±0.009 
3a Carbonyl control 
– onset 
0.00(2) 
±0.000 
0.14(2) 
±0.035 
0.00(2) 
±0.000 
0.08(4) 
±0.002 
3e Carbonyl control 
– peak Not tested Test failed 
Not 
tested Not tested 
3b Carbonyl control 
– plateau 
0.00(2) 
±0.000 
0.20(2) 
±0.099 
0.02(4) 
±0.010 
0.06(3) 
±0.024 
3c Carbonyl control 
– remission 
0.00(3) 
±0.000 
0.10(2) 
±0.001 
0.00(4) 
±0.000 
0.10(4) 
±0.006 
3d Carbonyl control 
- relapse 
0.00(4) 
±0.000 
0.10(1) 
±0.000 
0.00(3) 
±0.001 
0.11(4) 
±0.006 
Table 4  Group mean OD values (±se) using an anti-dsDNA antibody ELISA. 
The numbers in parentheses indicate the number of samples analysed.  
Group means exclude samples with a CV >25%.  † not calculable due to only one value.  
†† not calculable due to ‘perfect’ data. 
Statistical significance of difference from the associated carbonyl group using Wilcoxon 
two sample test: **P<0.01. 
  137 
 
Group Samples taken 
at EAE point 
Group mean OD (±se) using an ELISA for  
anti-ssDNA antibody 
CSF Sera 
1:50 Undiluted 1:50 Undiluted 
 
Untreated 
All 
samples 
>25% CV 
No sample Test failed 
0.13(1) 
±0.000 
Part II 
(peak) Untreated Not tested Not tested 
Not 
tested Not tested 
2a Onset 0.49
(2) 
±0.102 No sample 
Test 
failed 
0.13(1) † 
±0.000 
2e Peak Not tested Not tested Not tested Not tested 
2b Plateau 0.11
(1) † 
±0.000 No sample 
Test 
failed 
0.21(4) † 
±0.049 
2c Remission 0.66
(2) † 
±0.149 No sample 
Test 
failed 
0.19(3) † 
±0.057 
2d Relapse 0.67
(2) 
±0.094 No sample 
Test 
failed 
0.16(4) † 
±0.014 
3a Carbonyl control 
– onset 
0.29(2) 
±0.124 No sample 
Test 
failed 
0.12(3) 
±0.026 
3e Carbonyl control 
– peak Not tested Not tested 
Not 
tested Not tested 
3b Carbonyl control 
– plateau 
0.09(2) 
±0.006 No sample 
Test 
failed 
0.15(1) 
±0.000 
3c Carbonyl control 
– remission 
0.11(1) 
±0.000 No sample 
Test 
failed 
All samples 
>25% CV 
3d Carbonyl control 
- relapse 
0.10(4) 
±0.011 No sample 
Test 
failed 
All samples 
>25% CV 
Table 5  Group mean OD values (±se) using an anti-ssDNA antibody ELISA.  
The numbers in parentheses indict the number of samples analysed.   
Group means exclude samples with a CV >25%.  † not calculable due to only one value 
Statistical significance of difference from the associated carbonyl group using Wilcoxon 
two sample test: P>0.05.   
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3.2.1 Detection of anti-dsDNA antibodies in Lewis rat CSF 
No anti-dsDNA antibodies were detected in diluted CSF samples from 
untreated, EAE or carbonyl control animals.  CSF samples diluted by 1:50 
and analysed in duplicate, were found to have an OD range of 0.00 to 
0.01.   
 
In order to confirm these results, where sufficient volumes of CSF allowed, 
undiluted CSF samples were analysed.  Duplicate analysis was not 
possible due to insufficient quantities available.   
 
The analysis of single samples of undiluted CSF was found to have an OD 
range of 0.11 to 0.26.  Although the highest OD values were found in 
samples taken from rats sampled at the plateau of EAE, the results show 
the presence of anti-dsDNA antibody at extremely low levels and not 
significantly different from the associated carbonyl control group.  In 
addition, the OD range for the carbonyl control groups was comparable to 
that of the EAE groups with an OD range of 0.10 to 0.20.  The OD for 
untreated animal samples was 0.11. 
3.2.2 Detection of anti-dsDNA antibodies in Lewis rat sera 
No anti-dsDNA antibodies were detected in diluted sera samples.  When 
analysed in duplicate, diluted sera from untreated, EAE and carbonyl 
control animals were found to have an OD range of 0.00 to 0.02.   
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In order to confirm these results, undiluted sera samples were analysed in 
duplicate.  The OD obtained for these samples ranged between 0.11 and 
0.13 for EAE rats.  When compared to the associated carbonyl group, anti-
dsDNA antibodies in undiluted sera taken from animals at the time of 
onset of EAE was found to be statistically significantly (P<0.01) increased.  
However, the OD at onset (0.11) was comparable to that of the untreated 
group of animals (OD 0.12) and as such is not considered to be 
biologically significant.  An OD range of 0.06 to 0.11 was obtained for the 
carbonyl groups.   
 
Undiluted CSF and sera obtained from Lewis rats in Part II of the rat EAE 
model, i.e. those sampled at peak EAE, were analysed separately.  For 
reasons unknown, the standard response curve failed the acceptance 
criteria on the basis that a number of the calibration standards failed to be 
within 25% of the nominal concentrations.  As such the results obtained 
were considered to be invalid.  Due to insufficient quantities of CSF it was 
not possible to re-run the dsDNA assay or to perform the ssDNA analysis.   
 
This problem (insufficient volumes of CSF) highlighted the need for finding 
an alternative method for detecting anti-dsDNA antibodies. 
3.2.3 Detection of anti-ssDNA antibodies in Lewis rat CSF 
In contrast to the anti-dsDNA antibody assay, the anti-ssDNA antibody 
ELISA of CSF (1:50) indicated that this antibody was present in the CSF of 
all EAE animals, with an OD range of 0.11 to 0.67.  In general, a markedly 
lower OD was obtained for CSF samples from the control animals 
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(carbonyl iron-treated) with a range of 0.09 to 0.29.  It was not possible to 
confirm these results using undiluted CSF, due to insufficient quantities 
available.  All samples from untreated animals had a sample CV value of 
>25% and as such there were no meaningful results available for this 
group. 
3.2.4 Detection of anti-ssDNA antibodies in Lewis rat sera 
The OD range for undiluted sera from EAE rats was 0.13 to 0.21, with the 
highest value occurring at plateau.  Carbonyl OD for undiluted samples 
was 0.12 to 0.15. 
 
The response curve obtained for diluted sera samples (1:50) was 
considered to be unacceptable and of no value in this study for the 
following reasons.  The lowest dilution of the response curve (1:40000) 
had an OD of 0.973, this being abnormally high.  For the first set of 
reference standards the 1:250 dilution was lower than found previously 
(OD of 0.536).  The intermediate (1:2000) and low (1:10000) dilutions of 
the reference standards at the end of the plate were higher than expected, 
with OD values of 0.951 and 0.896, respectively.  As such the results for 
diluted sera analysed for anti-ssDNA antibodies are not discussed. 
 
Although statistical analysis was performed on the ELISA data sets, this 
analysis is considered to be of little value due to the limited data available.  
However, when the data is presented graphically (figures 12-15) a distinct 
and opposing trend can be seen between anti-ssDNA and anti-dsDNA 
antibody levels in CSF.  At the time of onset, anti-ssDNA antibody levels 
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are markedly (5-fold) higher than anti-dsDNA antibody levels, however by 
the time clinical signs have reached a plateau, anti-ssDNA antibody levels 
have fallen sharply below the levels of anti-dsDNA antibodies, which at 
this time-point show a 3-fold increase.  By the time of remission, both 
antibody types have returned to levels comparable to those seen at onset. 
 
Sera anti-ssDNA and anti-dsDNA antibody levels on the other hand 
appear to have remained relatively constant throughout the course of the 
disease process. 
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Figure 12  Anti-dsDNA antibody levels in undiluted sera and CSF from EAE or carbonyl 
control Lewis rats sampled at onset, plateau, remission or Day 34 (relapse). 
 
Figure 13  Anti-ssDNA antibody levels in sera (undiluted) and CSF (1:50 dilution) from 
EAE or carbonyl control Lewis rats sampled at onset, plateau, remission or Day 34 
(relapse). 
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Figure 14  Anti-ssDNA versus anti-dsDNA antibody levels in undiluted sera and CSF 
(1:50 dilution for anti-ssDNA antibodies) from EAE Lewis rats sampled at onset, plateau, 
remission or Day 34. 
Figure 15  Anti-ssDNA versus anti-dsDNA antibody levels in undiluted control sera and 
CSF (1:50 dilution for anti-ssDNA antibodies) from carbonyl control Lewis rats sampled at 
onset, plateau, remission or Day 34. 
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3.3 Histopathology 
Histological techniques were used to investigate the incidence of 
inflammatory deposits (C3, IgG, IgM and B cells) in sections taken from 
the central nervous system, in order to profile the disease process. 
 
IgG and IgM antibodies were evaluated to see if the incidence of one was 
different to the other at particular time-points during the disease process.  
IgG antibody was of particular interest as high affinity anti-dsDNA 
antibodies are likely to be of this class.  B cells were of interest with 
regards not only to their presence, but also to what they were secreting.  
C3 is important in the activation of the complement system and is 
important in the development of inflammation. 
 
The incidence of each parameter (C3, IgG, IgM or B cells) was evaluated 
by examining two separate sections of spinal cord from each animal.  
From each section ten random areas were selected, i.e. 20 separate areas 
scored per rat.  The presence distinct areas of positive staining was 
recorded (as a count) along with its location with regards to areas of 
perivascular cuffing.  For this purpose the sections were viewed under the 
x 20 objective.  The group mean was determined by adding the number of 
incidences of positive staining together and dividing by the total number of 
sections viewed for a particular group of animals (treatment / time-point / 
control / untreated / successful / unsuccessful).  
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3.3.1 C3 staining  
Figure 16 shows C3 immunostaining under light microscopy (x40 
objective).  The section was taken from a female Lewis rat that had been 
immunised with CNS material and killed at peak EAE. 
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Figure 16  C3 staining using sheep anti-rat complement C3 and counter stained with 
haematoxylin, under light microscopy (x 40 objective).  Arrows point to areas of positive 
C3 staining on a spinal cord section taken from a female Lewis rat that had been 
immunised with CNS material and killed at peak EAE. 
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Figures 17a-17c indicate that comparable total C3 staining was found at 
each time-point in spinal cord sections of animals showing EAE signs, 
animals failing to show acceptable signs of EAE and control animals.  
Minimal C3 was present in the spinal cord of untreated animals. 
 
Specific staining at non-perivascular cuffing sites was also similar between 
successful and unsuccessful animals, with the greatest C3 staining 
apparent for animals sampled at peak EAE.  In general, there was little 
difference in the incidence of C3 between the different time-point groups 
sampled, the exception being those sampled at peak EAE.  When 
unsuccessful and successful animals were compared to the carbonyl 
control groups using a Wilcoxon two sample test there was no statistically 
significant difference. 
 
C3 detection at the sites of perivascular cuffing in animals exhibiting EAE 
and to a lesser extent in those that failed to show comparable EAE signs, 
display a trend which increases from onset of EAE, reaching a maximum 
at peak EAE and diminishing thereafter.  C3 incidence was approximately 
twice as high in animals showing EAE signs than in those showing 
minimal signs.  C3 presence at perivascular cuffing sites in the control 
animals was found to be negligible in comparison.  When unsuccessful 
animals were compared to the associated carbonyl control animals using a 
Wilcoxon two sample test there was no statistically significant difference.  
When EAE successful animals were compared to the associated control 
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animals using the Wilcoxon two sample test, the increase in C3 was found 
to be statistically significant (P<0.001) at the time of peak EAE. 
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Figure 17a  
   
Figure 17b  
   
Figure 17c  
 
Figure 17  Bar graphs showing the group mean C3 incidence at the time of sampling as 
determined by counting distinct areas of positive staining from ten areas selected 
randomly from two separate sections of spinal cord per rat (i.e. 20 separate areas 
counted / rat).  (a) Successful EAE rats immunised with CNS material.  (b) Unsuccessful 
rats immunised with CNS material.  (c) Control (carbonyl iron) animals.  
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3.3.2 IgG staining 
Figure 18 shows IgG immunostaining under light microscopy (x 40 
objective).  The animal from which the section below was taken was a 
female Lewis rat that had been immunised with CNS material and killed at 
peak EAE. 
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Figure 18  IgG staining using sheep anti-rat IgG:HRP and counter stained with 
haematoxylin, under light microscopy (x 40 objective).  Arrows point to areas of positive 
IgG staining on a spinal cord section taken from a female Lewis rat that had been 
immunised with CNS material and killed at peak EAE. 
 50µm  
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Figures 19a-19c indicate that a relatively low incidence of IgG antibodies 
was present in the spinal cords of untreated animals.   
 
In general, total specific IgG staining and staining at non-perivascular 
cuffing sites were comparable for animals showing signs of EAE, those 
failing to exhibit acceptable EAE signs and control animals sampled at 
plateau, remission and ‘relapse’ (Day 34).  There was a marked increase 
in total IgG antibody incidence and the presence of IgG at non-
perivascular sites in animals successfully developing EAE when sampled 
at onset and peak EAE, compared to IgG levels found at other sampling 
times and in unsuccessful and control animals.  However, when 
unsuccessful and successful animals were compared to the carbonyl 
control groups using a Wilcoxon two sample test there was no statistically 
significant difference.   
 
IgG detection at perivascular sites was negligible in the spinal cord of 
control animals, with a slightly increased incidence in animals that 
exhibited minimal (unsuccessful) EAE signs.  Specific staining at 
perivascular sites in animals that successfully developed EAE signs had 
an increasing/decreasing trend in IgG antibody detection, with maximum 
IgG correlating with peak EAE.  When unsuccessful animals were 
compared to the associated carbonyl control animals using a Wilcoxon two 
sample test there was no statistically significant difference.  However when 
successful animals were compared to the associated carbonyl control 
animals using a Wilcoxon two sample test, the increase in IgG in the 
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spinal cord of animals sampled at peak EAE was found to be statistically 
significant (P<0.05).   
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Figure 19a 
 
 
  
Figure 19b 
   
Figure 19c 
Figure 19  Bar graphs showing the group mean IgG incidence at the time of sampling as 
determined by counting distinct areas of positive staining from ten areas selected 
randomly from two separate sections of spinal cord per rat (i.e. 20 separate areas 
counted / rat).  (a) Successful EAE rats immunised with CNS material.  (b) Unsuccessful 
rats immunised with CNS material.  (c) Control (carbonyl iron) animals. 
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3.3.3 IgM staining 
Figure 20 shows IgM immunostaining under light microscopy (x 40 
objective).  The animal from which the section below was taken was a 
female Lewis rat that had been immunised with CNS material and killed at 
the time of EAE onset. 
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Figure 20  IgM staining using mouse anti-rat IgM:HRP and counter stained with 
haematoxylin, under light microscopy (x 40 objective).  Arrows point to areas of positive 
IgM staining on a spinal cord section taken from a female Lewis rat that had been 
immunised with CNS material and killed at EAE onset. 
 
 
 50µm  
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Figures 21a-21c indicate that a negligible incidence of IgM antibodies was 
present in the spinal cords of untreated animals.   
 
Total specific IgM staining and staining at non-perivascular cuffing sites 
was in general, notably higher in animals that successfully developed EAE 
compared to those unsuccessful in EAE development and control animals.  
With regards to total IgM incidence and detection at non-perivascular sites 
in successful animals, the peak occurred at onset sampling.  When 
unsuccessful and successful animals were compared to the carbonyl 
control groups using a Wilcoxon two sample test there was no statistically 
significant difference. 
 
IgM antibody detection at perivascular sites was negligible in the spinal 
cord of control animals and in those that failed to exhibit acceptable EAE 
signs.  Specific staining at perivascular sites in animals successfully 
exhibiting EAE signs was negligible at onset, peak, remission and Day 34 
(relapse) sampling points with peak IgM incidence occurring at plateau 
EAE.  When unsuccessful and successful animals were compared to the 
carbonyl control groups using a Wilcoxon two sample test there was no 
statistically significant difference. 
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Figure 21a 
  
 
  
Figure 21b 
  
 
  
Figure 21c  
Figure 21  Bar graphs showing the group mean IgM incidence at the time of sampling as 
determined by counting distinct areas of positive staining from ten areas selected 
randomly from two separate sections of spinal cord per rat (i.e. 20 separate areas 
counted / rat).  (a) Successful EAE rats immunised with CNS material.  (b) Unsuccessful 
rats immunised with CNS material.  (c) Control (carbonyl iron) animals. 
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3.3.4 Perivascular cuffing 
Figure 22 shows an area of perivascular cuffing in the spinal cord of a 
female Lewis rat immunised with CNS material under light microscopy 
(x 40 objective).  This section was taken when EAE signs were at peak for 
this animal.  Perivascular cuffing is seen as a dense area of cell infiltration 
around a vessel within the spinal cord.   
 
Figure 23 shows a section of spinal cord from an untreated female Lewis 
rat under light microscopy (x 40 objective).   
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Figure 22  perivascular cuffing in the spinal cord of a female Lewis rat immunised with 
CNS material under light microscopy (x 40 objective).  This section was stained for C3 
using sheep anti-rat complement C3 and counter stained with haematoxylin.  This section 
has been taken when EAE signs were at peak for this animal.  The arrow points to an 
areas of perivascular cuffing as seen as a dense area of cell infiltration around a vessel 
within the spinal cord. 
 
Figure 23  A section of spinal cord from an untreated female Lewis rat under light 
microscopy (x 40 objective) counter stained with haematoxylin.   
 50µm  
 
 50µm  
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Figure 24 shows how the incidence of perivascular cuffing in the spinal 
cord of animals immunised with CNS material (with carbonyl iron) 
increases from onset of EAE signs, reaches maximal cuffing when EAE 
signs are at a plateau and then diminishes thereafter.  This trend can be 
clearly seen in both EAE successful and unsuccessful animals alike.  In 
general, the incidence of perivascular cuffing in the spinal cord of control 
animals remains comparable at all sample time-points. 
 
When compared using a Wilcoxon two sample test, the increased 
incidence of perivascular cuffing in EAE successful animals at onset, 
peak, plateau, remission and Day 34 was found to be statistically 
significant (P<0.01 (onset), P<0.001 (peak), P<0.05 (plateau), P<0.001 
(remission) and P<0.05 (Day 34)) when compared to the control animals.  
This was in contrast to EAE unsuccessful animals for which there was a 
statistically significant increase in perivascular cuffing when compared to 
the control animals at peak and plateau only (P<0.001 and P<0.01, 
respectively). 
3.3.5 Negative control group 
Comparisons were made to animals treated with carbonyl iron alone.  
Animals in this control group were treated exactly the same as the EAE 
animals with the exception that they did not receive CNS material along 
side the adjuvant (carbonyl iron).  The purpose of this group was to see if 
carbonyl iron alone had the potential to induce an EAE state and cause an 
inflammatory response within the CNS.  By comparing the EAE animals to 
this group any potential adjuvant effect was eliminated.  A small number of 
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untreated animals were included for reference purposes only and were not 
used for comparison.   
 
Untreated animals showed no clinical signs, negligible perivascular 
cuffing, no sign of IgM and minimal IgG, C3, B cell staining when 
compared to the carbonyl iron group and EAE positive animals. 
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Figure 24  Bar graphs showing the group mean perivascular cuffing incidence at the time 
of sampling as determined by counting distinct areas of the accumulation of inflammatory 
deposits from ten areas selected randomly from two separate sections of spinal cord per 
rat (i.e. 20 separate areas counted / rat) for successful EAE rats immunised with CNS 
material, unsuccessful rats immunised with CNS material and control (carbonyl iron) 
animals.  The individual counts from successful animals sampled at plateau ranged from 
1 to 36 and as such this mean is associated with a large standard deviation. 
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3.3.6 B cell staining 
Figure 25 shows B cell immunostaining under light microscopy (x 40 
objective).  The animal from which the section below was taken was a 
female Lewis rat that had been immunised with CNS material and killed at 
the time of EAE onset. 
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Figure 25  B cell staining using mouse anti-rat B cells and counter stained with 
haematoxylin, under light microscopy (x 40 objective).  Arrows point to areas of positive 
B cell staining on a spinal cord section taken from a female Lewis rat that had been 
immunised with CNS material and killed at EAE onset. 
 
 50µm  
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Figures 26a-26c indicate that B cells were not detected in the spinal cords 
of untreated animals.   
 
In general, total specific B cell staining was comparable between 
successful and unsuccessful rats sampled at peak, plateau, remission and 
Day 34 (relapse).  B cell incidence in animals successfully developing EAE 
sampled at onset was notably higher than B cell detection in unsuccessful 
animals at this time-point.  The highest total B cell incidence and presence 
at non-perivascular sites in control animals was observed at onset and 
was comparable to that seen in unsuccessful animals at this time-point.  
Minimal B cell staining was observed at all other time-points in the control 
group.  
 
When unsuccessful and successful animals were compared to the 
associated carbonyl control animals using a Wilcoxon two sample test 
there was no statistically significant difference. 
 
B cell detection at perivascular sites was negligible in the spinal cord of 
control animals.  A similar incidence was apparent at perivascular cuffing 
sites for successful and unsuccessful animals sampled at onset, plateau, 
remission and Day 34.  Peak B cell staining correlated with peak EAE 
activity, with a considerably higher detection level in animals successfully 
developing EAE.  When unsuccessful and successful animals were 
compared to the associated carbonyl control animals using a Wilcoxon two 
sample test, the increase in B cells in the spinal cord of animals sampled 
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at peak EAE was found to be statistically significant (P<0.05 and P<0.001, 
respectively). 
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Figure 26a  
  
 
  
Figure 26b 
  
 
  
Figure 26c 
Figure 26  Bar graphs showing the group mean B cell incidence at the time of sampling as 
determined by counting distinct areas of positive staining from ten areas selected 
randomly from two separate sections of spinal cord per rat (i.e. 20 separate areas 
counted / rat).  (a) Successful EAE rats immunised with CNS material.  (b) Unsuccessful 
rats immunised with CNS material.  (c) Control (carbonyl iron) animals. 
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3.3.7 DAPI staining  
Preliminary investigations into the feasibility of using DAPI labelled DNA to 
probe for the presence of anti-ssDNA and anti-dsDNA antibodies in situ 
were encouraging.  Sections of spinal cord from all successful EAE rats 
sampled at peak and plateau EAE (10 animals in total) in addition to 
untreated (4 animals) and associated carbonyl iron control animals 
(8 animals) were fixed in acetone, which in general showed better 
morphology than sections air-dried without fixation.  Staining was not 
apparent when the probes were applied to the spinal cord of untreated 
rats.  When applied to EAE rat spinal cord sections, the sections to which 
the ssDNA probe was added showed slight fluorescence, whereas the 
addition of the dsDNA probe produced slightly better results with regards 
to staining.   
 
Three main types of staining were observed following incubation with the 
DAPI/dsDNA probe; small discrete, circular areas of fluorescence (e.g. 
figure 34), fluorescence around the perimeter of a largish circular ‘cell’, 
with fluorescence gradually diminishing with increasing distance from the 
cell body (e.g. figure 27) and fluorescence around the perimeter of a cell 
(e.g. figure 30). 
 
These areas of positive staining were investigated in a number of ways.  
Fluorescence was observed under light in the green wavelength (510 nm) 
and compared to fluorescence under light in the red wavelength (650 nm) 
(figures 32-35).  This was purely done as a matter of interest rather than 
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being based on a scientific rationale.  In general there was little or no 
difference in fluorescence, with similar intensity and staining patterns 
observed under both wavelengths.  In addition to red and green 
wavelength light DAPI/dsDNA staining was initially observed under 
ultraviolet light, this being the wavelength recommended following DAPI 
staining for nuclei DNA (figures 36 and 37).  Under ultraviolet light, the 
intensity of the fluorescence seen as excess DAPI bound to nuclear DNA 
obscured any potential positive staining for anti-dsDNA antibodies.  Dual 
DAPI and H & E staining was also employed to further investigate areas of 
fluorescence. 
 
Although the area of staining seen in figure 27 was considered to be too 
large for any cell and as such is most likely an artefact of slide preparation, 
similar staining patterns were observed in a number of sections which 
were not considered to be artefacts.  Figure 28 shows a group of cellular 
structures for which fluorescence is radiating from the outer surfaces, such 
staining patterns show a similarity to that of Russell body cells (figure 29) 
[reference unavailable].  Russell bodies are small spherical 
intracytoplasmic hyaline bodies, which are common in plasma cells and 
are frequently seen in cases of chronic inflammation.  As inflammatory is a 
major occurrence in EAE this finding is certainly a possibility.   
 
  171 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27  DAPI/dsDNA probe staining (x 100 objective).  The above shows DAPI/dsDNA 
fluorescence on a spinal cord section taken from a female Lewis rat that had been 
immunised with CNS material and killed at peak EAE. 
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Figure 28  DAPI/dsDNA probe staining (x 100 objective).  The above shows DAPI/dsDNA 
fluorescence on a spinal cord section taken from a female Lewis rat that had been 
immunised with CNS material and killed at peak EAE. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29  Plasma cells forming Russell bodies.  
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Figures 30 - 33 show positive DAPI/dsDNA staining round the surface of 
B cells in rat (untreated) spleen sections as indicated by the arrows, which 
is suggestive of secretion of anti-dsDNA antibodies.  In normal animals it is 
not unusual to find low levels of anti-dsDNA antibodies.  These natural 
antibodies tend to be IgM and are non-pathogenic [Datta (1983)]. 
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Figure 30  DAPI/dsDNA probe staining as visualised under 650 nm wavelength of light, 
of a spleen section taken from an untreated rat (x 40 objective).  The white arrows point 
to positive staining around the surface of B cells. 
 
Figure 31  DAPI/dsDNA probe staining as visualised under under 650 nm wavelength of 
light, of a spleen section taken from an untreated rat (x 40 objective).  The white arrows 
point to positive staining around the surface of B cells. 
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Figure 32  DAPI/dsDNA probe staining as visualised under 650 nm wavelength of light, 
of a spleen section taken from an untreated rat (x 40 objective).  The white arrows point 
to positive staining around the surface of B cells. 
 
Figure 33  DAPI/dsDNA probe staining as visualised under 510 nm wavelength of light, 
of a spleen section taken from an untreated rat (x 40 objective).  The white arrow points 
to positive staining around the surface of B cells. 
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A similar pattern of staining can be seen in figures 34 and 35 which would 
suggest the presence of anti-dsDNA antibodies in this section of spinal 
cord taken from a rat displaying signs of peak EAE. 
 
In addition, the arrangement of the staining (indicated by the arrow) seen 
in this section is such that it appears to be on the outer edge of a 
structure, which could possible be a lesion.  This is typical of anti-dsDNA 
antibodies in MS [Williamson et al. (2001)]. 
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Figure 34  DAPI/dsDNA probe staining as visualised under 650 nm wavelength of light, 
of a spinal cord section taken from a rat showing peak EAE (x40 objective).  The arrow 
points to positive staining around an oval structure, possibly a lesion. 
 
Figure 35  DAPI/dsDNA probe as visualised under 510 nm wavelength of light, of a 
spinal cord section taken from a rat showing peak EAE (x 40 objective).  The arrow points 
to positive staining around an oval structure, possibly a lesion. 
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Figures 36 and 37 show DAPI/dsDNA probe staining of a section of spinal 
cord taken from a rat showing peak EAE signs.  The nuclear DNA can be 
seen in the centre of the blue stained cells as a pale blue fluorescent area.  
Figure 37 shows there to be an area of interest (indicated by the arrow) to 
the right of the section which has the appearance of a secretory B cell with 
reddish staining diffusing from its surface.  To the left of the section there 
is another very small area of red staining (indicated by the arrow) because 
of its small size any distinct pattern is prevented from being determined. 
 
  179 
 
 
Figure 36  DAPI/dsDNA staining of cell nuclei as visualised under UV light of a spinal 
cord section taken from a rat showing peak EAE (x 40 objective). 
 
 
Figure 37  DAPI/dsDNA staining of cell nuclei as visualised under UV light of a spinal 
cord section taken from a rat showing peak EAE, unknown magnification. 
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3.3.8 Anti-dsDNA antibody determination in the rats using Alexa 
Fluor/dsDNA probe 
Alexa Fluor/dsDNA probe on EAE rat brain sections was investigated.  
The apparent lack of fluorescence in human spinal cord and the 
successful detection in human brain sections suggested it would be a 
worthwhile exercise to examine the brains of rats killed at peak EAE.  In 
support of this, in MS patients, the lesions are more often found in the 
brain than in the spinal cord [MedHelp. Multiple Sclerosis Community].  
 
No positive staining was found in any of the sections of rat brain 
examined.  This may have been due to the sections taken not containing 
any active lesions.  Human brain sections examined in this project had 
been screened and selected specifically due to the presence of active 
lesions.  The sections taken from animals were randomly selected without 
any indication of a lesion being present. 
 
  181 
3.4 Clinical signs of EAE – in vivo phase – Biozzi (ABH) mouse 
(remitting/relapsing) 
Due to the limitations of the acute EAE model in the rat, in that the 
antibody response to subsequent disease flares was not possible to 
assess, attempts were made at developing a reliable relapsing-remitting 
EAE model in the mouse.  It was anticipated that with each EAE episode a 
greater antibody response would be produced, resulting in a higher 
incidence of anti-dsDNA antibodies in the CNS. 
 
There were in total eight attempts of getting the Biozzi (ABH) mouse EAE 
model to work.  
 
Part I: This method was based on published information [Liblau et al. 
(1997) and Heremans et al. (1999)] and modified based on previous 
experience with other immunological animal models, i.e. the collagen type 
II arthritis in the rat.  
 
Group housed female Biozzi (ABH) mice (approximately 6 weeks old) 
were injected with finely chopped Biozzi (ABH) mouse spinal cord in 
Freund’s adjuvant (FA).  The route of administration was intradermal into 
the base of the tail.  EAE signs were not detected in any animal. 
 
Part II: The lack of EAE signs in Part I, was thought to be due to poor 
preparation of the spinal cord.  For this phase of the validation, spinal cord 
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was homogenised, rather than finely chopped, to form a uniform and fine 
suspension. 
 
Group housed female Biozzi (ABH) mice (approximately 6 weeks old) 
were injected with homogenised Biozzi (ABH) mouse spinal cord in 
Freund’s adjuvant.  The route of administration was intradermal into the 
base of the tail.  EAE signs were seen in two out of eight mice with one of 
these animals displaying a completely limp tail.  Weight loss was also 
apparent for these mice at the time of the appearance of EAE signs.  
Signs were first apparent on Day 18 and had disappeared by Day 26.  
Neither animal relapsed.  Another mouse displayed a transient weight 
loss, but showed no conclusive sign of EAE. 
 
Part III: Due to limited success in Part II of the validation, it was 
considered necessary to change the EAE induction protocol.  Three 
different methods of induction were examined.  Spinal cord homogenised 
with carbonyl iron dosed intraperitoneally was assessed, this being the 
method of induction in the rat EAE model which was found to be 
successful.  The use of bovine and murine myelin basic protein has been 
documented in published literature [Asensio et al. (1999)] and as such 
were also considered worthy of investigation. 
 
Group housed female Biozzi (ABH) mice (approximately 6 weeks old) 
were given an intraperitoneal injection of homogenised Biozzi (ABH) 
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mouse spinal cord in carbonyl iron (100 mg/mL (1:1)) or an intradermal 
injection of bovine or murine MBP in FA at the base of the tail.   
 
EAE signs were seen in two out of six mice treated with murine MBP.  
Signs were first apparent on Day 20 and by Day 27 had completely 
disappeared.  Both animals exhibited a completely limp tail, neither 
showed any sign of relapse.   
 
EAE was not exhibited by any of the mice treated with bovine MBP or 
Biozzi (ABH) spinal cord in carbonyl iron. 
 
Part IV: Due to limited success it was considered appropriate to return to 
the original induction protocol.  However, in this phase of the study the 
animals were weighed daily to see if a cyclic decrease in bodyweight was 
present, even in the absence of EAE specific signs. 
 
Group housed female Biozzi (ABH) mice (approximately 5 weeks old) 
were injected with homogenised Biozzi (ABH) mouse spinal cord in 
Freund’s adjuvant.  The route of administration was intradermal into the 
base of the tail.  The animals were weighed daily to closely monitor 
bodyweights.  EAE signs (a completely limp tail) were seen in one out of 
ten mice.  Signs were first apparent on Day 21 and had gone by Day 24.  
There was no indication of a relapse. 
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A noteworthy observation was made with regards to all mice receiving the 
encephalitogenic agent, this being that from Day 78 all mice had hair loss 
around the whisker area.  There was no indication that scratching or 
excess grooming had taken place.  Although not related to this project, this 
finding is of some interest in that Alopecia Areata is caused by an 
autoimmune response.  Why this should occur following this particular 
immunisation protocol is not known. 
 
Part V: A possible cause of the lack of anticipated response in the 
previous validation attempts was thought possibly to be due to the 
encephalitogenic agent being too similar to ‘self’, i.e. Biozzi (ABH) spinal 
cord.  For the acute EAE study, rats are injected with guinea-pig spinal 
cord and successfully develop EAE signs.  In order to investigate this 
further, for this phase of the study CD-1 mouse and guinea-pig spinal cord 
were used.  
 
Group housed female Biozzi (ABH) mice (approximately 6 weeks old) 
were injected with homogenised CD-1 mouse or guinea pig spinal cord 
with Freund’s adjuvant intradermally into the base of the tail.  A slightly 
limp tail was seen for one out of five mice dosed with CD-1 mouse spinal 
cord.  Signs were first apparent on Day 17 and had disappeared by Day 
21.  There was no sign of relapse.   
 
EAE was not seen in mice treated with guinea-pig spinal cord. 
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Part VI: Following advice from a contact at St Bartholomew’s Hospital 
Medical College, London, validation was attempted using male Biozzi 
(ABH) mice.  Although female mice are in general more susceptible to 
EAE, success of inducing EAE in females can be varied due to fluctuating 
hormone levels.  The mice were housed individually to prevent in-house 
fighting, thus minimising the potential to increase stress hormone levels 
such as corticosteroids, which have the affect of inhibiting the required 
autoimmune response.  The animals used were considerably older than 
previously tested and were considered to be an optimum age for EAE 
induction.   
 
Individually housed male Biozzi (ABH) mice (approximately 10 weeks old) 
were injected with homogenised CD-1 mouse spinal cord and Freund’s 
adjuvant intradermally into the base of the tail. EAE signs were not 
detected in any animal. 
 
Part VII: Due to a failure of EAE induction, further advice was received 
which indicated that freeze dried spinal cord was preferable to 
homogenised material and also Freund’s adjuvant should be 
supplemented with mycobacterium.  Subcutaneous administration into 
each flank was suggested [Liblau et al. (1997) and Heremans et al. 
(1999)]. 
 
Individually housed male Biozzi (ABH) mice (approximately 12 weeks old) 
were injected with freeze dried CD-1 mouse spinal cord, Freund’s adjuvant 
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and Mycobacterium butyricum (heat killed) subcutaneously into the flank. 
EAE signs were not detected in any animal. 
 
Part VIII: A lack of EAE signs in mice in Part VII led to a final attempt at 
inducing EAE in the Biozzi (ABH) mouse.  For this phase intradermal 
injection into the base of the tail was used as before, but this time 
Mycobacteria were added to the Freund’s adjuvant. 
 
Individually housed male Biozzi (ABH) mice (approximately 10 weeks old) 
were injected with freeze dried CD-1 mouse spinal cord, Freund’s adjuvant 
and Mycobacterium butyricum (heat killed) intradermally into the base of 
the tail.  EAE signs were not detected in any animal. 
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3.5 Anti-dsDNA antibody determination in the mouse using Alexa 
Fluor/dsDNA probe 
Examination of Biozzi (ABH) mouse brains and spinal cords using Alexa 
Fluor/dsDNA probe produced no positive results (figure 38). 
 
Alexa Fluor/dsDNA probe staining of mouse CNS sections in general 
produced similar results to those seen with DAPI/dsDNA probe staining.  
Areas of fluorescence were seen and ranged from small discrete areas 
(figure 47) to larger B cell type structures similar to those seen in figure 42.  
Fluorescence was apparent in both EAE-treated and untreated mouse 
spinal cords alike. 
 
Areas of fluorescence were extensively investigated using dual staining 
methods (Alexa Fluor/dsDNA probe and H & E).  Dual staining in many 
cases showed there to be little correlation of fluorescent areas with cellular 
structures and as such was thought to be due to autofluorescence of the 
tissue or an artefact introduced during the preparation of the sections.  For 
example, the large fluorescence structure seen in figure 39 (indicated by 
the arrow), although initially promising, once stained with H & E  (figures 
40 and 41) appeared to be out of the plane of section, suggesting that this 
finding is most likely to be an artefact of the staining process.  
 50µm  
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Figure 38  The above shows negative Alex Fluor/dsDNA probe fluorescence as visualised 
under 650 nm wavelength of light, on a spinal cord section taken from a female Biozzi 
(ABH) mouse that was showing peak EAE signs at relapse (x 40 objective). 
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Figure 39  The above shows Alex Fluor/dsDNA probe fluorescence as visualised under 
650 nm wavelength of light on a spinal cord section taken from a female Biozzi (ABH) 
mouse that was showing peak EAE signs at relapse (x 40 objective). 
 
Figure 40  The above shows H & E staining on a serial section of a spinal cord as above, 
under (x 40 objective) 
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Figure 41  The above shows the composite of Alex Fluor/dsDNA probe and H & E on the 
same section of a spinal cord as shown in figure 40 (x 40 objective). 
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The fluorescent staining seen in figure 43 (indicated by the arrow) has that 
of a B cell appearance, however H & E and dual staining (figures 43 and 
44) show the structure to be out of plane and have little cellular 
characteristics.  The fluorescence seen was concluded to be a false 
positive. 
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Figure 42  The above shows Alexa Fluor/dsDNA staining of a brain section taken from a 
female Biozzi (ABH) mouse that was showing peak EAE signs at relapse (x 40 objective). 
Figure 43  The above shows H & E staining of a serial section of brain as that shown in 
the figure above (x 40 objective). 
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Figure 44  The above shows the composite of Alex Fluor/dsDNA probe and H & E on the 
same section of brain as shown in figure 43 (x 40 objective). 
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Figure 45 shows H & E staining of a section of spinal cord taken from a 
female Biozzi (ABH) mouse that was showing peak signs of EAE at 
relapse. 
 
Figure 46 shows the same section of spinal cord visualised under red 
wavelength light following incubation with Alexa Fluor alone.  The arrows 
indicate a number of discrete areas of slight fluorescence which from the 
pattern and size of the areas are comparable to nucleated cells, some of 
which appear to be forming sites of perivascular cuffing. 
 
Figure 47 shows the same section of spinal cord as above, following 
staining with the Alexa Fluor/dsDNA probe.  In this figure the areas of 
autofluorescence seen in figure 46 have disappeared.  There are however 
three areas of fluorescence as indicated by arrows which do stand out 
from the section.  These fluorescent areas due to their appearance size 
and location are thought unlikely to be true positives.  
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Figure 45  The above shows H & E staining of a spinal cord section taken from a female 
Biozzi (ABH) mouse, that was showing peak EAE signs at relapse (x 40 objective). 
 
 
Figure 46  The above shows Alexa Fluor dye staining (in the absence of dsDNA) on the 
same section a spinal cord section (x 40 objective). 
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Figure 47  The above shows Alexa Fluor/dsDNA probe staining on the same section a 
spinal cord section as shown in figures 45 and 46 (x 40 objective).  
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3.6 Determination of anti-dsDNA antibodies in human MS tissue 
using Alexa Fluor/dsDNA probe 
Due to this novel approach of detecting anti-dsDNA antibodies in situ it 
was extremely difficult to interpret whether the areas of fluorescence seen 
were false positives or true positives.  There was no published reference 
information available to use for comparison purposes.  In addition to this 
there was no indication from published literature to suggest that anti-
dsDNA antibodies are found in animal models of EAE in the same way 
that they appear in MS, i.e. located around the edge of active lesions 
(plaques).  A solution to this was to obtain human central nervous system 
tissue from a deceased MS patient via the MS Tissue Bank.  A request 
was made for sections of brain and spinal cord tissue, which had been 
found to be positive for active lesions.  The presence of active lesions 
being essential as this is where anti-dsDNA antibodies have been found to 
reside in MS.  
 
Immunohistological staining of human spinal cord sections revealed no 
areas of positive staining for anti-dsDNA antibody.  Brain sections 
however exhibited marked fluorescence, which was far more intense than 
that previously seen and when counter stained with H & E demonstrated 
good correlation with cellular bodies.  Figures 48, 50 and 52, are not only 
good examples of the fluorescence seen, but also show good correction 
with a cell structure.  It is possible that these areas of intense fluorescence 
are a result of autofluorescent pigment lipofuscin.   
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Figures 48 and 49 show the presence of anti-dsDNA antibodies (indicated 
by the arrows) on the outer edge of two separate areas.  The larger of the 
two areas appears to be a blood vessel.  The surrounding edge has a 
thick cellular wall, composed of endothelial cells.  The smaller area has a 
less defined surrounding edge with fewer cells present, in addition there 
appears to be a small number of cells within the centre of the area.  It is 
likely that this area is an active lesion.  
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Figure 48  The above shows Alexa Fluor/dsDNA probe fluorescence, as visualised under 
650 nm wavelength of light, on the brain tissue taken from a human MS patient (x 100 
objective).  The white arrows point to areas of positive staining, whereas the black arrows 
points to autofluorescence which is thought to result from lipofuscin. 
 
Figure 49  The above shows the composite of Alexa Fluor/dsDNA probe and H & E on 
the same section, same area of brain as above (x 100 objective).  Arrows points to 
possible areas of lipofusion. 
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Figure 50 appears to show the location of fluorescence to be on the outer 
edge of an oval structure.  H & E staining (figure 51) reveals the inner 
region of this structure to consist of what looks like to be a number of 
apoptic cells (indicated by the arrows).  This finding suggests that the 
structure is an MS lesion, rather than a hole in the section.  The absence 
of endothelial cells surrounding tis area rules out the possibility of this area 
being a blood vessel.  The relatively large orange/yellow fluorescence is 
once again thought to be a result of lipofuscin. 
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Figure 50  The above shows Alexa Fluor/dsDNA probe fluorescence, as visualised under 
650 nm wavelength of light, on human brain tissue of a MS patient (x 100 objective).  The 
white areas point to areas of positive staining, whereas the black arrow points to 
autofluorescence which is thought to result from lipofuscin 
 
Figure 51  The above shows the composite of Alexa Fluor/dsDNA probe and H & E on the 
same section of human brain as above (x 100 objective).  The arrows point to apoptotic 
cells. 
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Figures 52 and 53 show the presence of anti-dsDNA antibodies in what 
appears to be a collapsed blood vessel.  Endothelial cells can be seen in 
figure 53 with positive staining for anti-dsDNA antibodies within this area. 
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Figure 52  The above shows Alexa Fluor/dsDNA probe fluorescence, as visualised under 
650 nm wavelength of light, on human brain tissue of a MS patient (x 100 objective).  The 
white arrows point to areas of positive fluorescence. 
 
 
Figure 53  The above shows the composite of Alexa Fluor/dsDNA probe and H & E on the 
same section of human brain as above (x 100 objective).   
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4 CHAPTER 4: DISCUSSION 
The aim of this project was to further understand the role of anti-dsDNA 
antibodies in multiple sclerosis and to determine if their presence is 
associated with pathogenicity.   
 
Firstly and in order to do this, the validation of a number of methods for 
use in the detection of anti-DNA antibodies, IgG, IgM, C3 and B cells using 
the acute EAE model in the Lewis rat, relapsing/remitting EAE model in 
the Biozzi (ABH) mouse and in CNS tissue donated by an MS patient was 
performed.   
 
The Lewis rat is an EAE susceptible strain of rat [Lassmann (1986)].  It is 
known to be a reproducible, reliable animal model of multiple sclerosis and 
a model that is particularly useful for examining the inflammatory phase of 
the disease [Lassmann (1986)].  This model was therefore initially 
selected to profile the disease process by evaluating the incidence of IgG, 
IgM, C3 and B cells in the parenchyma of the central nervous system and 
their relationship with clinical signs.  Following inoculation with guinea pig 
whole spinal cord and the adjuvant carbonyl iron, the majority of animals 
displayed signs of EAE.  Some animals however displayed signs to a 
greater severity than others.  This led to the animals being categorised 
into two groups, successful and unsuccessful.  Animals deemed to be 
successful displayed a marked EAE response, which occurred at the 
anticipated time following inoculation.  Animals considered unsuccessful 
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displayed EAE signs to a lesser extent and in some cases such signs 
were absent.  The first occurrence of signs following inoculation was also 
delayed in some cases when compared to the successful animals.  The 
purpose of splitting the animals into these two groups was to see if the 
severity of clinical signs correlated with the incidence of specific 
histopathology parameters.  For comparison, two further groups of animals 
were included in this study.  The first of these groups was inoculated with 
adjuvant (carbonyl iron) alone, to rule out any potential effects caused by 
the adjuvant.  The second of these groups consisted of animals that had 
not been treated with anything; these animals were included for reference 
purposes.  In order to profile the progression of EAE, the animals were 
killed and sampled (blood, cerebrospinal fluid, brain, spinal cord) at five 
different stages during the disease process; onset, peak, plateau, 
remission and relapse (Day 34).  
 
The use of carbonyl iron as an adjuvant compared to the typically used 
Freund's adjuvant, is a novel approach in EAE induction and was originally 
described by Levine and Sowinski (1980 &1989).  It is an interesting 
adjuvant in that it has been found to induce signs of EAE when 
administered with an encephalitogenic agent in the Brown Norway rat, a 
strain of rat previously considered to be EAE resistant [Staykova et al. 
(2005)].  The Brown Norway rat has substantially higher nitric oxide levels 
upon immunisation with Freund’s complete adjuvant compared to the 
Lewis rat.  It is thought that administration of carbonyl iron may prevent the 
release of nitric oxide in Brown Norway, thus allowing for the induction of 
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EAE and if this is the case would suggest that high levels of NO have a 
protective effect against EAE [Staykova et al. (2005)]. 
 
In this study, although administration of carbonyl iron alone produced no 
clinical signs in rats, inflammatory infiltrates were present throughout the 
spinal cord.  The greatest difference in the incidence (frequency of areas 
of positive staining) of IgG, IgM, C3 and B cells between the carbonyl iron 
control and CNS-treated animals occurred at the sites of perivascular 
cuffing.  At these sites IgG, IgM, B cells and C3 were negligible in the 
carbonyl group compared to the incidence seen in the spinal cords of 
animals successfully developing EAE.  This finding alone suggests that 
the area of interest with regards to EAE pathology in the Lewis rat is at the 
perivascular cuffing sites.  To further support this theory, the results 
indicate that it is at such sites that a distinct correlation between the 
degree of inflammatory infiltrates and the severity of clinical signs can be 
seen in animals inoculated with CNS material.  Animals successful in EAE 
development had a higher incidence of inflammatory infiltrates compared 
to those animals displaying EAE signs to a lesser extent (unsuccessful) at 
these sites.   
 
Results show that perivascular cuffing in the carbonyl control animals 
remained at a low level throughout the study.  The incidence of 
perivascular cuffing was found to be greatest in successful EAE animals 
and slightly less in the unsuccessful EAE animals.  Incidence for both 
groups peaked at the time that EAE signs had peaked (unsuccessful 
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animals) or reached a plateau (successful animals), thus demonstrating a 
close correlation between PVC and EAE signs.  The incidence of PVC 
was seen to decline as EAE signs diminish. 
 
The correlation between inflammatory infiltrates and clinical signs is also 
true in multiple sclerosis, where in the majority of people active MS is 
associated with inflammatory infiltrates in the parenchyma of the central 
nervous system, whereas people in the inactive stage of the disease 
exhibit very little in the way of such a response [Khan et al. (2008].  In 
addition, active MS lesions have a plasma cell presence, which produce 
mainly IgG antibodies and to a much lesser extent IgM; PVC is also a well-
recognised feature of MS.  These characteristics are also the case in the 
Lewis rat EAE model as demonstrated in this project.  The similarities 
between MS and the acute EAE model in the Lewis rat supports the use of 
this animal model in MS research, in particular as a model for the 
discovery of novel drugs, which are intended to suppress or modify the 
inflammatory response.  This model however is not appropriate as a 
research tool if the area of interest is demyelination.    
 
Activation of complement in MS is thought to be a primary cause of 
demyelination, possibly as a consequence of prolonged damage indirectly 
caused by C3 activation resulting in a release of self-antigens e.g. DNA 
histones or MBP.  However, in the Lewis rat despite the presence of 
significant C3 activation, demyelination is not seen in this model [Antel et 
al. (2005)].  This would suggest that there are other mechanisms involved 
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in the demyelination process in addition to, or in the absence of 
complement.   
 
Activation of C3 results in the cleavage of the molecule to form C3b and 
C3a.  It is C3a that is responsible for causing vascular permeability, which 
in MS and EAE is key to allowing inflammatory infiltrates to pass through 
the blood brain barrier and thus potentially causing destruction within the 
CNS.  The release of C3a also triggers phagocyte and macrophage 
recruitment.  C3b tags the 'foreign' body so to increase the selectivity and 
efficiency of the inflammatory response.  Some studies have 
demonstrated that complement activation is necessary for the 
development of EAE and this has been supported by studies using C3aR-
deficient mice (mice deficient in the anaphylatoid receptor C3a).  These 
studies have found that by preventing C3, EAE symptoms can be 
alleviated or prevented [Boos et al. (2005)].  Other studies however have 
found that that C3 (and C4) are not involved in EAE for which the 
encephalitogenic agent is the immunodominant epitope of MOG, peptide 
35-55 [Calida et al. (2001)].   
 
The results obtained from the Lewis rat EAE model in this study suggest 
that overall C3 incidence has little or no role in the development of EAE 
clinical signs.  The overall incidence of C3 was comparable between 
animals successful in developing EAE and for those animals inoculated 
with carbonyl iron alone, which did not exhibit any EAE clinical signs.  The 
presence of C3 at sites of PVC however did show a close correlation with 
  209 
clinical signs, with there being negligible detection at PVC sites in the 
carbonyl iron control animals.  In addition, it appears as if the location of 
C3 is of greater importance than the overall magnitude of this molecule.  
C3 incidence at peak EAE was approximately 4-fold less at PVC sites than 
at non-PVC sites. 
 
In the EAE model in the Lewis rat the pathological role of C3 is likely to 
relate to its ability to increase vascular permeability, causing areas of 
localised accumulation of inflammatory infiltrates around blood vessels, 
that is, perivascular cuffing. 
 
The question is, what causes the increase in C3, which is seen within the 
parenchyma of the central nervous system.  Is it in response to 
autoantibodies or inflammation in response to the administration of 
carbonyl iron?  
 
In this study the peak incidence of IgG antibody, C3 and B cells at 
perivascular cuffing sites occurred one-step behind the first occurrence of 
marked EAE signs (peak).  That is, maximal infiltration was seen during 
the effector stage of the disease, at the time when the first marked signs of 
EAE (substantially limp tail) were seen.  This could be considered to be 
the time when the lesions were active, i.e. causing damage to the CNS.  
Following ‘peak’ EAE the incidence of these parameters decreased 
sharply.  This supports the hypothesis that the presence of at least one of 
the above parameters (IgG, C3, B cells) has a potential pathogenic role in 
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EAE.  The only parameter not following this trend was IgM, for which the 
incidence was relatively low at PVC sites at all time-points with the 
exception of the plateau time-point where levels sharply increased.  There 
are two possible reasons for this, the first being that following the active 
phase of the EAE episode IgG antibodies have disappeared and are 
replaced by non-pathogenic IgM antibodies ‘clearing-up’ following the 
peak inflammatory phase of EAE by opsonising apoptic cells and therefore 
reducing the risk of further tissue damage.    The second explanation is 
that their presence may be in response to an antigen which is different to 
the one initially driving the response.  It is possible that breakdown 
products released as a result of damage caused by the initial inflammatory 
attack have caused a secondary response.  Such breakdown products 
could include DNA and histones, which could form autoantigens leading to 
further destruction of the CNS.  If this is the case then subsequent attacks 
would result in increasing levels of these antibodies.  Studies have found 
that some IgM antibodies that are specific for CNS antigens potentiate 
remyelination [Warrington and Rodriguez (2007)].  It is also worth 
commenting on the peak incidence of IgM throughout the spinal cord 
parenchyma (i.e. not localised to PVC sites) which occurred at the time of 
EAE onset.  It is possible that this peak was in response to the 
encepahlitogenic agent/adjuvant being treated as an invading 
microorganism.  This may explain this early, un-localised effect. 
 
The incidence of B cells in sections of spinal cords obtained from animals 
successful in EAE development sampled at peak, was found to be notably 
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higher than the incidence of C3 and IgG antibodies at this time-point.  This 
increased presence may suggest a pathogenic role for B cells in this 
model.  Studies have suggested that B cell pathogenesis is through 
demyelination rather that its effects on inflammation [Svensson et al. 
(2002)], however, in the EAE model in the Lewis rat this is unlikely to be 
the case, as demyelination is not seen.  Alternatively, it may be that B cells 
have a role in limiting EAE duration.  Studies using B cell deficient mice 
have found that EAE in these animals is a long-term chronic disease 
compared to wild-type mice that, in a short period of time recover 
completely [Wolf et al. (1996)]. 
 
This study has shown there to be a correlation between leukocyte 
infiltration, perivascular cuffing and EAE severity.  These findings may be 
of some significance with regards to the following alternative hypothesis of 
MS pathogenesis [Reik (1980)].   
 
It has been found that vascular changes following various infections and 
some vaccinations are often associated with demyelination [Poser (1978)]; 
this is known as disseminated vasculomyelinopathy.  It has been proposed 
that in diseases of sudden onset, marked severity and short duration [Field 
(1975)] as in the EAE model in the Lewis rat, vascular changes may be 
more important than demyelination in the disease process. 
 
The hypothesis for disseminated vasculomyelinopathy assumes that 
following infection antibodies form and bind with the antigen, forming 
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circulating immune complexes.  If these complexes are of an appropriate 
size and contain the correct proportion of antigen to antibody they can 
cause the systemic liberation of vasoactive substances.  This results in an 
increase in vascular permeability with complexes becoming focally trapped 
in vessel walls, complement is activated and inflammatory cells 
accumulate releasing proteolytic enzymes thus causing tissue injury 
[Cochrane and Dixon (1978)].  If this is the case then demyelination may 
occur as a by-product of this event.   
 
This theory supports the possibility that demyelinating antibodies are not 
the key pathogenic agents in MS and that they are potentially a by-
product.  To support this further, it should not be overlooked that despite 
MS pathology focusing on perivenous lymphocytic infiltration and 
demyelination within the CNS white matter [Carpenter and Lampert 
(1972); Oppenheimer (1976)], there are many other pathological reactions 
occurring at all levels within the nervous system.  These range from 
perivascular cuffing, lymphocytic infiltrates and endothelial proliferation to 
vessel wall necrosis, fibrinoid degeneration, infiltration of neutrophils and 
eosinophils and perivascular haemorrhage [Carpenter and Lampert 
(1972); Oppenheimer (1976); Hart and Earle (1975); Miller et al. (1956); 
Reik (1980)] and occur in arterioles and capillaries as well as venules 
[Carpenter and Lampert (1972); Reik (1980)].  These occurrences are 
frequently more common in the cerebral cortex, basal ganglia and grey 
matter of the brain stem and spinal cord (in the centre) than in white 
matter [Carpenter and Lampert (1972); Hart and Earle (1975)].  It must 
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also be remembered that in addition to demyelination, axons are often 
substantially affected in MS and a clear differentiation between 
perivascular demyelination and necrosis, which can cause the same 
clinical symptoms, has not always been made [Hart and Earle (1975); Reik 
(1980)].   
 
It is possible that changes in vascular permeability and perivascular 
inflammation may alter the antigenicity of myelin or release antigens 
previously sequestered by the blood brain barrier.  The cell-mediated 
immune response could then maintain the damage initiated by the original 
vascular injury and this would explain the presence of antibodies to 
myelin.  In MS, the nervous system appears to be preferentially targeted 
by immune complex mediated vascular injury.  This may in part be 
explained by the fact that any resultant permeability is going to be more 
serious in the nervous system which is protected by the blood brain 
barrier, than in other organs where the vascular bed is already permeable 
[Reik (1980)]. 
 
If the above hypothesis proves to be correct, then this would go some way 
in explaining the increased incidence of IgG, B cells and C3 in regions of 
perivascular cuffing and the appearance of EAE signs in the absence of 
demyelination in the Lewis rat.  It would also provide a parallel with SLE 
where immuno-complexes are recognised as having a pathogenic role 
with anti-dsDNA antibodies being of major importance. 
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In addition to histopathology, serum and CSF samples collected from 
Lewis rats at each of the sample times (onset, peak, plateau, remission 
and relapse / Day 34) were analysed for the presence of anti-dsDNA and 
anti-ssDNA antibodies using an ELISA.  Limited CSF volume (approx. 
0.1 mL) was the main reason contributing to the incomplete data set in this 
study.   
 
Although the ELISA was the assay of choice for this study and one proven 
to be of sufficient sensitivity [Alnaqdy et al. (2007)], there are other assays 
available for anti-DNA antibody detection in CSF and sera.  Frequently 
used methods are telomeric DNA sequence recognition and binding 
[Salonen. (2002)], isoelectric focusing (IEF) and immunoblotting [Fortini et 
al. (2003)].  In the clinical setting, sufficiently large volumes of CSF can be 
obtained and as such volume is rarely a limiting factor.  Typical volumes 
required for analysis are 0.5-2.5 mL of CSF and approximately 1 mL of 
sera, depending on the tests to be performed. [Laboratory Corporation of 
America].  In the clinic these volumes are not only possible, but can also 
be obtained repeatedly if necessary.  In this study, 0.1 mL was the 
average volume of CSF collected and this was a terminal sample which 
meant that an insufficient or contaminated sample could not be replaced. 
 
Analysis of the data obtained in this study showed there to be a 
statistically significant increase in anti-dsDNA antibody in the sera from 
CNS immunised animals sampled at the time of disease onset when 
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compared to the associated carbonyl control group.  No other 
significances were observed.  
 
The ELISA data for sera samples showed that anti-dsDNA and anti-
ssDNA antibodies remained relatively constant at all sample time-points 
and this was true for both the carbonyl iron control animals and the EAE 
animals.  It is not surprising to find low levels of circulating anti-DNA 
antibodies in the sera and this is found to be the case in people. 
 
In contrast, the ELISA data for CSF samples showed a distinct trend, with 
a peak in anti-dsDNA antibodies at the plateau sample time-point and a 
trough at the same time-point for anti-ssDNA antibodies.  Although 
samples from both the controls and EAE animals follow the same trend for 
both antibodies, the greatest effect can be seen for the samples taken 
from the EAE animals.  The interesting point here is that at the time when 
EAE signs have reached a maximum, anti-ssDNA antibody levels are at 
their lowest level, whereas anti-dsDNA antibodies are at their highest 
level.  The decrease in anti-ssDNA antibodies at this time-point could be 
due to them binding to DNA from damaged tissue during the peak phase 
of the disease.  This is to be expected and is part of the clearing-up 
process whereby anti-ssDNA antibodies are forming immunocomplexes 
for disposal.  This drop in antibody level has also been reported by Stetler 
et al. (1985) during their research into the correlation of antibody 
production with delayed onset of Lupus-like disease in MRL +/+ mice. 
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As these results are reflective of a single acute EAE episode, a greater 
antibody response leading to an uncontrolled immune response was to be 
expected in a relapsing/remitting model of EAE.  In a relapsing/remitting 
EAE model it is thought that the controlled immune response as seen in 
cases of bacterial infection is compromised.  Under normal conditions IgM 
anti-ssDNA antibodies are produced and the switching to high affinity 
pathological anti-dsDNA antibodies is prevented.  However, if this block for 
some reason is removed, then these antibodies are produced, leading to 
their predominance in the CSF and contributing to an uncontrolled 
autoimmune state.  
 
Regardless of the results obtained, the differences in antibody levels were 
slight and the data too limited to reach any meaningful conclusions.  In 
addition, no CSF data was available for animals sampled at peak EAE. 
This was due to insufficient sample volumes obtained or the CSF 
becoming contaminated with blood during the collection procedure.  
 
It is possible that the low level of anti-dsDNA antibodies detected may be 
due to these antibodies being compartmentalised within the parenchyma 
and as such not free in CSF.  Alternatively it is likely that a single episode 
of EAE is not sufficient to produce a marked antibody response.  This 
response would be much increased with each subsequent episode or in a 
model of chronic progressive EAE.  This has been found to be the case in 
a Russian study [Ershova et al. (2003)] of MS patients where an 
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association between increased anti-dsDNA antibody titre and the level of 
disability was observed. 
 
In this project anti-DNA antibody levels in cerebrospinal fluid from the 
Lewis rat were found to peak with the plateau phase of the disease and 
decline in remission.  As successive phases of relapse and remission 
result in successive rounds of antibody selection this finding suggested 
that in order to investigate these antibodies a relapsing model of EAE was 
required.  The evidence for the importance of a relapsing/remitting model 
comes from the experience in SLE where the relapsing/remitting phase of 
the disease leads to multiple rounds of antigen selection [Ehrenstein et al. 
(1993)].  Given that MS is a relapsing and remitting disease the same may 
occur in MS.   
 
In addition to finding a relapsing/remitting EAE model, the issues relating 
to insufficient volumes of CSF placed a greater emphasis on developing a 
technique which would enable anti-dsDNA antibodies not only to be 
detected, but also their position within the central nervous system to be 
visualised.  In the early stages of disease, the generation of 
autoantibodies that are the result of multiple rounds of antigen stimulation 
may be difficult to detect, as such detection of the presence of anti-dsDNA 
antibody secreting cells was considered to be an alternative approach 
[Borg et al. (1990)]. 
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Methods often used for the detection of anti-DNA antibodies are the 
microtitre plate assay [Mouratou et al. (2002)], enzyme-linked 
immunosorbent assay (distinguishing IgG and IgM anti-ssDNA and anti-
dsDNA), Crithidia luciliae, a nitrocellulose filter assay, the Amersham kit, 
and the radioimmunoassay  [Isenberg et al. (1987)].  Literature searches 
revealed no documented method for the detection of anti-DNA antibodies 
in situ, as such the probes developed for use in this project are considered 
to be a novel approach for visualising anti-dsDNA antibodies.   
 
It was hypothesised that if DAPI was allowed to bind to dsDNA the 
resulting mixture could be used as an anti-dsDNA antibody probe.  The 
DAPI/dsDNA probe was incubated with sections of rat spinal cord, with a 
view that if anti-dsDNA antibodies were present then binding would occur 
resulting in positive fluorescence.   
 
DAPI has a peak excitation wavelength of 340 nm and an emission 
maximum at a wavelength of 488 nm.  However, when bound to dsDNA 
the excitation peak occurs at a longer wavelength of approximately 
360 nm.  In this project DAPI was initially bound to dsDNA and once 
incubated with tissue sections was potentially further bound to anti-dsDNA 
antibodies.  Although not documented, the possibility of this effect further 
increasing the excitation wavelength was considered.  When viewed under 
the recommended ultraviolet light, marked fluorescence was observed 
(figure 36).  The intensity of this effect, which was most likely the result of 
free DAPI binding to nucleic acids was so great that the detection of anti-
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dsDNA antibodies was thought to be unlikely.  A decision was taken to 
view the tissues sections, once incubated with the DAPI/dsDNA probe 
under a much longer wavelength of light in order to visualise a more subtle 
effect.  Visualisation subsequently took place under green light 
(wavelength of approximately 510 nm).  Patterns of fluorescence were 
seen under this light which where thought to relate to positive staining 
(figures 28, 33 and 35).  Based on these results the DAPI/dsDNA probe 
sections were viewed under green light.  For interests sake and based on 
no particular scientific rationale sections were also viewed under red light.  
Aschar-Sobbi et al. (2008) developed a protocol for the detection of the 
signalling molecule polyphosphate (poly-P) whereby the optimal excitation 
wavelength for the DAPI-ploy-P complexes was found to be 550 nm 
(within the green light range).  By using this longer wavelength 
fluorescence from free DAPI and DAPI/DNA was minimal, thus allowing for 
the visualisation of poly-P. 
 
Although the ELISA for the detection of anti-dsDNA and anti-ssDNA 
antibodies was found to be inconclusive, initial investigations using the 
DAPI/dsDNA probe suggested the presence of anti-dsDNA antibodies in 
the spinal cord of rats in this model. 
 
The DAPI/dsDNA probe produced a number of potentially positive results 
when incubated with Lewis rat spinal cord sections.  Based on the disease 
profiling results, spinal cords taken from successful animals at peak EAE 
were used, this being the time when IgG antibodies were at their greatest 
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incidence.  Potentially positive staining was found in a number of sections.  
Some of these were concluded to be artefacts, either because the area of 
positive staining was too large to be any cell type or because they were 
out of the plane of the tissue section.  The most encouraging positive 
staining had the appearance of a number of relatively large cells clustered 
together with positive DAPI staining surrounding each cell (figure 28).  
Following a literature search a similar picture (figure29) was found that 
showed plasma cells containing Russell bodies [reference not available].  
Although scales are not available for either figure, the figures are very 
similar in appearance and the association of Russell bodies with chronic 
inflammation would not put them out of place in this model [Kopito & Sitia 
(2000); Pelc et al. (1981); Tsunoda et al. (2005)].   
 
Russell bodies are thought to be an accumulation of condensed 
immunoglobulins in the endoplasmic reticulum cisternae probably resulting 
from a disturbed secretion [Pahl & Baeuerle (1997) and Kopito & Sitia 
(2000)].  Although they can be found in many cell types, they frequently 
occur in plasma cells and may develop as a response of the cell trying 
unsuccessfully to get rid of somatically mutated stable unsecretory 
molecules [Pahl & Baeuerle (1997) and Kopito & Sitia (2000)].  The 
retention of immunoglobulins in Russell bodies suggests that the 
mechanism of protein transport in those cells affected is incompetent 
resulting in the accumulation in dilated endoplasmic reticulum cisternae of 
proteins that are neither degraded nor secreted [Pahl & Baeuerle (1997) 
and Kopito & Sitia (2000)].  The accumulation of immunoglobulins may be 
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so great that it results in the endoplasmic reticulum overload response 
which results in the induction of cytokines followed by inflammation and 
apoptosis [Pahl & Baeuerle (1997) and Kopito & Sitia (2000)].  Russell 
bodies may be pathogenic with regards to inflammation and apoptosis or 
protective by maintaining the secretory pathways [Valetti et al. (1991)].  If 
indeed the structures seen in figure 28 are plasma cells containing Russell 
bodies their presence with regard to pathogenicity is unknown, other than 
inflammation being a primary characteristic of EAE and Russell bodies 
being associated with such events. 
 
The results from the Lewis rat and DAPI/dsDNA probe experiments were 
encouraging, but improvements to the methods used were considered to 
be necessary if conclusive results were to be obtained.  Two approaches 
were taken.  The first was to refine the probe used for the detection of anti-
dsDNA antibodies and the second was to use an EAE animal model for 
which the disease process was closer to that seen in people; this being a 
relapsing/remitting form of EAE for which demyelination is a characteristic.  
The DAPI/dsDNA probe was replaced by an Alexa Fluor/dsDNA probe.  
The principal was the same, just the fluorescence agent differing and the 
light under which the tissue sections were examined (red light).  The Alexa 
Fluor/dsDNA probe was initially tested in Lewis rat spinal cord sections 
with little success and testing was stopped until spinal cord from a 
relapsing/remitting model of EAE was available.  
 
  222 
The Biozzi (ABH) mouse was selected as the species of choice for the 
relapsing/remitting EAE model.  This mouse is a frequently used strain for 
this type of testing and is well documented in published literature.  Many 
immunological animal models can be difficult to establish to such an extent 
that reproducible, reliable results are obtained.  This was certainly found to 
be the case in this project.  Eight consecutive attempts over a period of 
21 months were made to validate a reliable and reproducible EAE model 
in the Biozzi (ABH) mouse.  The differences in the protocols used revolved 
around the route of administration of the encephalitogenic agent 
(intradermal injection into the base of the tail, intraperitoneal administration 
and subcutaneously into the flank), sex of the animals (males or females), 
the encephalitogenic agent (mouse spinal cord, guinea-pig spinal cord, 
bovine MBP or murine MBP) and the adjuvant used (FCA, FCA plus 
Mycobaterium butyricum or carbonyl iron). 
 
None of the protocols used proved to be successful, despite being used as 
standard models for EAE [Liblau et al. (1997), Heremans et al. (1999) and 
Asensio et al. (1999)].  EAE signs were only seen in 3/18 female mice 
following inoculation by the intradermal route into the base of the tail with 
homogenised Biozzi (ABH) mouse spinal cord, 2/6 female mice inoculated 
intradermally into the base of the tail with murine MBP and 1/5 female 
mice inoculated intradermally into the base of the tail with homogenised 
CD-1 mouse spinal cord.  None of the animals that initially showed EAE 
signs relapsed following remission.   
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The results suggest that females mice are more prone to EAE and this is 
supported by Baker et al. who found that EAE susceptibility in Biozzi 
(ABH) mice was increased by a major locus in chromosome 7 [Baker et al. 
(1995); Sinha et al. (2008)] and also that females tend to have a stronger 
Th-1 mediated immune response [Sinha et al. (2008)].  With some 
refinement, intradermal administration into the base of the tail of spinal 
cord homogenate using FCA/FIA has the potential to induce EAE in the 
Biozzi (ABH) mouse.   
 
The reasons as to why so few animals responded and the complete 
absence of relapse may be due to a number of factors.  Group housing of 
the animals may increase stress levels.  This is likely to have affected 
males more than females due to an increase in bullying of cage mates 
seen in male mice as they get older.  Stress causes the release of 
corticosteroids [Joéls & van Riel (2004)], which has immunosuppressant 
properties and potentially the ability to prevent EAE.  However, individually 
housing animals in this project did not cause any of the animals to develop 
EAE.  Another possibility is interference from hormones in female animals.  
Studies [Kim et al. (1999)] have shown oestrogen to have a protected role 
against EAE development.  Teuscher et al. (2004) investigated the effect 
of gender, age and season on EAE susceptibility in mice.  They found that 
clinically, the chance of developing EAE signs increased by 4% for each 
increasing week of age and that there was a 90% increase in the chance 
of developing EAE when immunised in the summer time compared to the 
spring and winter months (February – May).  In this study the age of the 
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animals ranged between 5 – 12 weeks of age at the time of immunisation, 
with there being no effect on EAE susceptibility.  Immunisation took place 
of a period of 21 months at various times in the year and did not appear to 
increase/decrease EAE susceptibility.  Finally, it is possible that the Biozzi 
(ABH) mice were not strictly antibody high.  Antibody high (ABH) Biozzi 
mice elicit high antibody titre response following immunisation with an 
encephalitogenic agent and have a high susceptibility to EAE compared to 
antibody low mice for which EAE susceptibility is much reduced [Baker et 
al. (1990)].  The difference in antigenic response is thought in part to be 
attributed to genetic difference in macrophage activity.  Interestingly, 
antibody high and low Biozzi mice respond differently to parasitic infection 
but this is not related to the degree of antibody titre elicited [Male et al. 
(2006)]. 
 
In the interests of moving this project forward and to limit the number of 
animals being used, spinal cord and brains were sourced from a lab which 
has a proven record of the EAE relapsing/remitting Biozzi (ABH) mouse 
model.  Alexa Fluor/dsDNA staining was performed on the spinal cord and 
brains of mice which had been killed and sampled during a second 
episode of EAE.  Although slight positive staining did occur on a section of 
spinal cord, dual staining techniques using Alexa fluor/dsDNA and H & E 
indicated that the staining observed was an artefact of the slide 
preparation procedure.  A limitation of being the recipient of donated 
mouse tissue was the lack of control with regards to the time at which the 
animals were sampled.  Instructions were given to sample the animals at 
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the time of peak EAE, as soon as the animals exhibited a completely limp 
tail during the second EAE episode.  However, as histological signs return 
to normal soon after peak, any delay in sampling, even by a day would 
make detecting lesions more unlikely. 
 
The lack of a positive control was a problem throughout this project and in 
its absence lengthy investigations were performed on areas of positive 
staining in order to determine if they were true positives.  In addition to this 
there was no literature available that suggested that anti-dsDNA 
antibodies are present in the animal models used.  The next step was to 
obtain human tissue from a human who had suffered from MS.  Such 
tissue was obtained from the MS Tissue Bank.  A request was made for 
sections of spinal cord and brain which had active lesions.  Active lesions 
were important as anti-dsDNA antibodies are known to be present on the 
outer edge of such lesions [Williamson et al. (2001)].  Such sections were 
thought to be the best chance of seeing positive staining which would 
prove that the probes work in situ. 
 
Brain and spinal cord sections were examined for the presence of active 
lesions by the MS Tissue Bank prior to dispatch, using Luxol fast 
blue/MHC class II.  The presence of a large lesion with immune activity on 
the lesion edge was found in the sections of brain tissue, but less clear 
staining was found for the sections of spinal cord.  The human tissue 
samples were donated by a patient suffering from chronic MS.  The patient 
was suffering mild symptoms approximately 10 years prior to his death 
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from the disease.  The disease took on a chronic progressive form which 
would have led to raised antibody titres, which probably played a 
significant pathological role during the late stages of the disease. 
 
Alexa Fluor/dsDNA probes incubated with spinal cord tissue from the MS 
patient failed to produce positive staining.  This was not unexpected, as 
information provided by the Tissue Bank indicated that staining of the 
spinal cord block had been found to be less clear compared to that of the 
brain sections.  Although there appeared to be an area of myelin pallor 
(depleted myelin) that corresponded to an elevated MHC class II 
expression, the lesion was not easily identified.  Positive staining in the 
sections of brain tissue however, was not only present, but was found in 
the anticipated locations.  Anti-dsDNA antibody demonstration was seen 
on the perimeter of lesions and within blood vessels. 
 
In addition to the positive fluorescence seen in the sections of tissue 
shown in Figures 48 – 51 and to a lesser extent, figures 52 - 53, are areas 
of bright yellow/orange fluorescence.  These areas are thought likely to be 
autofluorescence resulting from lipofuscin.  Lipofuscin is an 
autofluorescent pigment that accumulates in the cytoplasm of many cell 
types including those of the CNS [Schnell et al. (1999)].  It is composed of 
lipid-containing residues of lysosomal digestion in addition to sugars and 
metals such as mercury, aluminium, iron, copper and zinc and is thought 
to result from the oxidation of unsaturated fatty acids [Double et al. 
(2008)].  The presence of lipofuscin can indicate that there has been 
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damage to the membrane, mitochondria and/or lysosomes [Double et al. 
(2008)].  Although its presence is common in the aging animal it is also 
associated with diseases such as Alzheimer’s, Parkinson’s and amyotropic 
lateral sclerosis [Allaire et al. (2002)].  Within the sections examined, such 
fluorescence was only observed in the vicinity of pathological changes i.e. 
around active lesions and within perivascular cuffing regions.  Whether 
such damage as indictated by lipofuscin is a by-product of the disease 
process, due to normal aging or directly involved in the pathogenicity of 
the disease is unknown.  One comment to make with regard to this 
hypothesis is that the proposed areas of lipofuscin are largely based on 
H & E staining (figures 49, 51 and 53).  Lipofuscin fluoresces yellow when 
excited at a wavelength of approximately 350 nm [Mochizuki et al. (1995) 
and Goldgefter et al. (1980)], figures 48, 50 and 52 are under red light of 
the wavelength of 650 nm and as such further investigation is required 
before these areas of staining can be concluded as lipofuscin. 
 
The two different locations of anti-dsDNA antibodies raise the question of 
different pathogenic roles, or possibly pathogenicity being dependent on 
location.  We know that the extent of perivascular cuffing is closely related 
to clinical signs and that within these areas there is a high incidence of 
IgG.  In SLE it is thought that anti-dsDNA antibodies cause damage to 
blood vessels due to the deposition of immune complexes and fixation of 
complement leading to necrosis.  It is possible that this is also true in MS, 
but as this is occurring in the central nervous system these seemingly 
small effects can cause significant disability.  The research in this project 
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supports this as anti-dsDNA antibodies and C3 were found to present in 
and around vessels.  In the EAE Lewis rat model it is likely that that this is 
the primary cause of disability and this may also be true in the early stages 
of MS.  If this is the case then SLE research into the deposition of immune 
complexes could be applied to MS research.   
 
The potential pathogenicity of anti-dsDNA antibodies on the leading edge 
of lesions is more difficult to explain.  What appears to be clear is that they 
are only present on the edge of active lesions, which suggests some 
involvement with lesion development; whether or not this involvement is 
pathological or not remains to be determined.  It is likely that their 
presence around lesions is likely to have a different role than that when 
they are found in and around blood vessels.  DNA antibodies could be 
binding to oligodendrocytes which are trying to remyelinate the lesion.  
SLE studies in mice have found that anti-dsDNA antibodies can attach to 
the glomerular basement and cause damage [Han (1998)] and such 
antibodies from SLE patients have been found to bind to the surface of 
ogliodendroctes [Williamson et al (2001)].  Anti-dsDNA antibodies could be 
bordering lesions due to ‘harmless’ attachment to ogliodendrocytes or 
binding could be having a pathological effect on such cells eg inducing 
apoptosis or fixing complement, therefore potentially increasing the lesion 
area.  Alternatively anti-dsDNA antibodies could be picking up apoptic 
cells that are present around the leading edge of the lesion.   
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When the positive staining of human tissue is compared to that obtained 
from animal tissue a similar pattern can be seen.  Figure 34, a section of 
spinal cord from a Lewis rat sampled at peak EAE is a particularly good 
example of this.  This section shows intermittent areas of fluorescence 
creating an oval shape (‘lesion’) very similar to that seen in figure 48 
(human brain section).  This correlation suggests that anti-dsDNA 
antibodies are present within the CNS of EAE Lewis rats and based on the 
staining pattern seen is likely to have a comparable role in disease 
pathology.  It is also reasonable to hypothesise that in a relapse/remitting 
model or chronic model of EAE such findings would be more pronounced.  
To fully confirm this, a vast number of sections of CNS tissue would need 
to be stained and examined as the locations of lesions are not easily 
found. 
 
Throughout this project it is recognised that the inclusion of controls for 
some aspects of the work performed was far from adequate.  Although this 
thesis is lacking in the relevant photographs of control sections from the 
EAE Lewis rat, used to profile the inflammatory phase of EAE, this phase 
of the study did include adequate controls. Rather than photographic 
representation of such sections, the data has been presented graphically 
and textually.  A number of control sections were included during the DNA 
probe investigations, but insufficient photographs were taken and in 
addition such sections were also not adequately, if at all, described.  For 
the human tissue, controls were very limited and this was largely due to 
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the restricted number of sections available.  Future work including 
sufficient controls is needed in order to substantiate these initial findings. 
 
This research has clearly profiled the inflammatory phase of EAE in the 
Lewis rat and confirmed its similarities with MS.  A novel and relatively 
simple method for the detection of anti-dsDNA antibodies in situ has been 
developed and by using this method the presence of anti-dsDNA 
antibodies have been found to reside in two different locations; within 
vessels and on the outer edge of active lesions, the latter being reported 
by Williamson et al. (2001).   
 
The implication of this research with regard to anti-dsDNA antibodies 
potentially having similar pathogenicity to that seen in SLE, may be in the 
way in which researchers think about new therapies for multiple sclerosis.  
Currently the standard treatment for MS is to minimise pain, reduce the 
number of relapses and slow the disease progression [Andersson & 
Goodkin (1996)].  Treatments typically involve the use of 
glucocorticosteriods and corticotrophin to reduce the intensity and duration 
of disability associated with acute relapse [Andersson & Goodkin (1996)].  
Diazepam and baclofen may be used to reduce spasticity [Andersson & 
Goodkin (1996)].  Amantidine hydrochloride and pemoline may be used to 
counteract fatigue and pain may be controlled by the use of non-steroidal 
anti-inflammatory agents and tricyclic anti-depressants [Andersson & 
Goodkin (1996)].  More recently the use of drugs targeted towards 
cytokines has been used.  For example, copaxone, a MHC class II 
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modulator that has the ability to lower IL-2 levels and is thought to have a 
protective effect against demyelination [Ge et al. (2000)] and interferons 
(interferon beta-1a) such as Avonex and Rebif [Charatan (2000)] have be 
used successfully to treat symptoms of MS.  Natalizumab, a monoclonal 
antibody which has immunosuppressant properties has also been used in 
MS treatment [Kappos et al. (2007)].  None of these treatments directly 
target anti-dsDNA antibodies.  It is possible and something being 
considered by some researches that SLE treatments which target anti-
dsDNA antibodies may also be affective in MS.  Examples of drugs used 
in SLE which may be beneficial to MS patients by targeting anti-dsDNA 
antibody secretion are rituximab, LJP394 and IVIg. 
 
Rituximab is used in the treatment of SLE.  It is an antibody directed 
against CD20 which is expressed on B cells [Sah and Liu (2008)].  By 
eliminating B cells this can prevent the generation and expansion of 
autoreactive antibody secreting cells [Sah and Liu (2008)].  This treatment 
has been found to be successful in SLE patients and in some cases has 
been shown to decrease anti-dsDNA antibody titres.  Rituximab is being 
trialled in MS patients and so far the results have shown promise as a 
treatment for relapsing/remitting MS [Hauser et al. (2008)]  
 
LJP394 is a complex of four oligonucleotides which have a strong avidity 
for anti-dsDNA antibodies [Sah and Liu (2008)].  It has been found to 
decrease anti-dsDNA antibody levels, decrease the number of renal flares 
in SLE patients and reduced the need for corticosteroid treatment.  It has 
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also been found to increase the time between flares [Sah and Liu (2008)].  
No information could be found as to whether LJP394 has been trialled in 
MS patients. 
 
Intravenous immunoglobulins are used to eliminate individual IgGs in 
direct proportion to their concentration.  This treatment has been found to 
be successful in SLE and MS patients alike and is often administered 
when corticosteroid treatment has failed.  A drawback of this treatment is 
that it has a limited duration in its action against pathogenic 
immunoglobulins [Sah and Liu (2008)]. 
4.1 Future work 
In order to investigate the findings in the project further brain and spinal 
cord sections containing active lesions from deceased MS patients are 
required.  Ideally these sections should be matched for age, sex and type 
of MS.  This is not an easy task for many reasons.  The MS tissue bank 
has a limited number of donations.  It is unlikely that tissue is available 
from people who were in the early stages of the disease or having the 
relapsing-remitting type of MS at the time of death.  The majority of tissue 
donations are from people suffering from chronic progressive MS, which in 
some way has contributed to their death.  The time involved in selecting 
sections on the basis of active lesion presence is considerable.  Tissue 
from patients living with MS is not an option, so correlations between 
disease severity/disability and histopathology can not be easily made.  In 
view of these limitations, the availability of an animal model of relapsing-
remitting and chronic progressive EAE for which demyelination and the 
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presence of anti-dsDNA antibodies are characteristics would enable 
researchers to investigate the locational pathogenicity of anti-dsDNA 
antibodies in more detail. 
 
The results from this project have shown that it may be possible to detect 
anti-dsDNA antibodies in EAE models.  However, a more thorough 
investigation using a much greater number of controls is required before 
this finding is conclusive.  The presence of anti-DNA antibodies in CSF is 
worthy of further investigation, in particular with regard to obtaining a 
greater number of samples.  Due to the limited volumes of CSF that can 
be obtained from rodents, this work would be best performed using a rat 
model of EAE.  Additional immunohistology is required in order to confirm 
the positive fluorescence seen using both DAPI and Alexa Fluor/DNA 
probes.  Dual staining could be used to identify the isotype of the 
antibodies.  If they are found to be of the IgM class then it is likely that 
their role is not pathogenic, if they are of the IgG then this would put them 
back in the picture as potential pathogenic agents in this disease.  
Pharmacological studies using drugs known to target anti-dsDNA 
antibodies could be used to further investigate the potential of appropriate 
SLE drugs to modify the progression and severity of EAE and ultimately 
MS.  
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5 CHAPTER 5: CONCLUSION 
This research has clearly profiled the inflammatory phase of EAE and 
confirmed its similarities with MS.  A novel and relatively simple method for 
the detection of anti-dsDNA antibodies in situ has been developed and by 
using this method of anti-dsDNA antibody visualisation the results 
obtained have been found to support those reported by Williamson et al. 
(2001).  Finally and most importantly, anti-dsDNA antibodies have been 
found in two different locations, which opens up the possibility that 
pathogenicity may be location dependent. 
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